var title_f5_16_5376="Nonproliferative diabetic retinopathy";
var content_f5_16_5376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonproliferative diabetic retinopathy: Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color fundus photograph of nonproliferative diabetic retinopathy showing reintal hemorrhages, yellow lipid exudates, and dull white cotton wool spots (nerve fiber layer infarcts).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5376=[""].join("\n");
var outline_f5_16_5376=null;
var title_f5_16_5377="Malignant mesothelioma Surgical";
var content_f5_16_5377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 322px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFCAOUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VHWgigdaWmAmM0lOxwefwptIBwI7ipY2g2yeZG5YpiMq+ArZHJGDkY3DHHJBzxgw095C6RqQuI12jCgEjJPJHU89Tk4wOgAp3ELlAeV/WjMf9z9TXZ/CTw34d8U+KE03xRrNxpcUy7bbyYwTPMTgJuPCn0yOegwSK6v4wfCaz8Lae2seFrnUrzSo5UinW8g+aIOPkkWVQEkjZlYbgAASoy2c0c0W+W+u/X/L+vUtUpOPMtkeRZj/ALn6mlJjH8AP4mosUEGi5FiUGPps/EmgmP8AuD8zUQUnpWxLpkP9iQXELTfbssZYjgjYDgMO4I7g5PIPSqTTdupUacpXt01Mz5Ouzj6mgGP/AJ5j8z/jUWDSjI6EjipuTYkHlnjZ+pozFn7g/M1FjNGPei4WJSYs/c/Wk/deh/Oo8GlCmjmCxKPK/ufmTSfuj/CfzpgXr0PHftSbT60cwWJQIe6n8DShYfRvzqHBpQOBjrT5wsS7IvRvzpQkXHDfnURHPGcdgTTgp9aTmOw8JD6N+dL5cPo//fX/ANamhHO7AJwMk46Dpn+VKFOeTUuQ7DZo0WIFRznGSar1ZnBEP/Ah/Wq1CEFFFFMBRS0g60GmgDHBNBxxjPSlCswYgEhRk4HQdP6ilKnbuHTOKAEBBPzg4x247cUlK2c/NnI9aSgB8ZOeMj3HavrPwBc2nxl8N6/p2pLNYXFxaIzvbzFoY5GO1SY1KliGh8zad2QeXr5d8M6HqHiTW7bSdFtxc6hcFhFEZFQHapY/MxAGACeT2r7a+DfhKy0Tw3otpZQTvFPbm8e6dQ0bzEDhuQyk5BCkAbeMlgSeTFu3LyJOd7pP8X8v+G6ndg+ZRqO9otW/r5Jnj1t+zJqTa7LDfeILf+zOQk9tau8+/KgbomICrySWDMMLjvXW+DP2dbbw7qcWpajqtprcK5RoJNLZlXPBIBcgnt8y4GcgggV9Jwp5UA3bd+MsQMAnvXkPjD4x6XaNc2WkwPf3gh328qNiORtzIdmDvkAIb5oty5BBZQGK9FOckkqm/kv6/wAvJXaOeFk7xW3p+pjXPw/03VrqW31nwXpUdnDL5n2mN4beMRKCMkxbZOOu0sOuSSAoqvJ8GvhpHqUEmm61caXOv7xVs9ajyM8hhvDHgHg56etcV4h1LWPFbt9qv5xotgBmbR7tZhAMl5AyRbY55dpywhf91ETnzG68Hq+qNPo15c2sQtdOutQkt41mcXFqFCfPKG2fvJOT+88vzQNpDbtxbaMK0lo00+65l2b3/wA3ttpfpq1qc5czjb00v99zvdW+AnhwWcstl4gkkzOGN5KypbomeUzGjoCem4sMEj5ea5HV/wBnjxOLRLnwzeaZr0TSFNkFwsTqOxO8hfYgNkelc9q+sx6FNpl3pV632oxvJFPa3KxiJXAGwGL5lXliwLLIckMig5butB+KXiyO0tR4UTV9XW2hSK8ae2W6UyMxA2suHReML5jEkD2wZqe3TbiozS8rN/d+v4sJrD1I2jpLu9vw/wAjwvXdJ1TQ9Rew1yyurK9iABhuYyjAdiAe3oehrPya+uNO+KWjeKNNW2+IeiWKi3by0uZYo7uBXI+Y7GXzIcYAJAcZBz2Fcj410zw5qFg+jaRoekxJf3EkllqtqmXWdS2URo0xJEwAwoJUbuxG0ZyqRVk4yTfS3631+XXTUVLL6lVtRt9/9fofOu7ijdTpopIZXimRo5EJVlYYKkdiKjqjhH7jx7Um6kpccZosAoal30wjBwetFKwErSswUMzEKMKCcgDOcD05JpRIAahpaLIZMHFOWQetQDp70o/WjlGSztmHHuP61WqaT/V/jUNO1hMKKKKBBS0lKetNAFLkgHk88GnyIVSMkoQy5G0gkckc478d+2PaoqAF7UUlLRcDufg7FY3fja20/UZltk1GGWyiui2BbyOpCvjaSf7oA28sPmAzn9ENOjWGxgiRFRERVVVGAABgYGTjjHGTX5haRefYNTtrrYz+TIJNquUJwc8MOQfevub9nTx8fGHhO5S4hu430lo7Yz3BLLImwkHefvOAp3Z6ZX1rJ83tFpp/X9f8Obp81Hlvs9vWxc+MniS2P2bwyrzubhllvEtXZZHhX5miDKQVLAZIBLMiuFBPT5X8QeIZ5YZorOa3FqEWUfYos5hwQSRsXC56Cbc4Ux4OAGPpXxs123fWLifT1juINQaG4uPtyzCG9hSUiJCoCqIRgOk4YB97LuI348TSYW+k3lm07eYoCOqFo2lJZQyujFTJtIDBQvVstnGR003BR739Pl/kl39dCorJKxrWEMmnaJBcQ2bT380UQtHimeKVW84GORASH27vl+UAcA7s8Vn6tNfwarfQS3klrdR27x3ggmy8srlvNiYkq2zJIdfmC4Oc4zUN7BbaVo1/py3VnqWpXhgGYIIZEhQKsh2yk+YJATsYIoBII3tjFUNO0S71K4S2tLdPPGQ8e1w6Dj5mGOQOvyg4Gc4rdVebRK/9fdbv0f3tw4Sm7oueFobvU9UtrW1gvLmKJWwtvaLNLlgVG0HBC8jBY4Xk4J4O/wCL9T0xLPT9H054JNJtz+7S1STy3fODMC8Y8xj9zzCu44I2qNtcrLa3lpYL9tv4YEcb4bfzWlaXaSpKBdwHcAkgHnBxmpZLd0trZFuJNUEiGGO3iYjymcjaMDvkDjG1j0LDJqueSXvfdf0/y/LbrLS6Fu31YbNLjvY4lgWSS4miJV7V+yA28QVkYlcHcxLZHAA5r2Wu3drOdkt41m7rJcQowj2MDyY1XiIj+EjHHGMEip9KXUdSspNJYwyy2M73X9m3KJGWbgOqtuWVpCVC+WvJHIIIqLV/C9xa29xdSzWFnLAI2WxW482UhhnhlBXIPJRmEgXnDDmom41I8r/NX/r8X5mtOc4NShc6z4leEbPUdHHibwwGMMEMf2q2+zrCGgwFS6iVXcFeiyAHKOckDdgeR9K9f+FPiPU7WQ6TYsYjva9sPNUbZGHyywlWOHRxkEAjBBPrXNfFTwbP4c1ma+tYIk0K+uHNmUlVjFkK/kuoJZGUOo+bqOQSOa53Ga+Pfv8A1/VvO5piIqf76PXf1/yZwtFFJUnILRSUtACgc80dTRQKBi0o60lKKBjn/wBV+NQ1NJ/qvxqGkJhRRRQIKWkpaaADQMYOc+1FJSAKKKKAHDrX2T8FdYg0X4Qpe272On6W99tjnd/38Qkcp5kyKDuJfbGuei4Y/KK+NhjA9a9el8X2EXwr0vwppd+JAY999HHabWmeVy8gbcMMY1VVV+TnkEDGD52/r+v61W9B68lr3sL8SdfvrrWZIbeFra1gRLdbdoykMNxGR5ojQgLFtfapKBc+VuPDHODpugavqeq3GjeTZXepX84V7+S6ScdGlZhOrFcEByzAnOGBwQao6dY7dOtrieZfIO4OBIGeMKR1QHKg7uM9cNjpXqdr4Q1C1+F9/r/i28u7fTpYVGlafFbhk5bCzSKcbWcHaJD84Vj2wDzqrZyS6a+d9/x3a7dT344GNOlTnUfxfrvtr5WXn2Z414gaKPVXgS5t7+OLbGLtUcidVAAPzAMBjgZAPArR0m0m1hbhItYmN7LGiJZSbjJe4cfu42xtDAZIQnk4UbicVXkmlvbGK1SOON45HK5iAY78dwu4/dCgMTjPG3nPSx/De7i1e3tLl7qUskYvBBYSTTW8r5xEIwcOeFPJAYEkA4rphrH8df8AhzzsTh3Um5LW+2ljHsdM+z3sena1c/2fDGTE10xS9htXkBG140J8snbgkZdSM4zxWvoHgee+jisr6WxSCS6lUX6QvdjfHHu2oYQWcSKCRkhfkfHzV6N4Y+Gtxqel6OPiBq2pabJAF+wackCLdIobDeWigyrkk7cKRkFiBwa07vSvD/hawv47vUbGweV42CXumw/aGTPzN5hZpixbYW8zZ3Kr2NqtFvl/K+j7PbW2vp8jP6nyJTqbdvL8tOuunU5KG4Fzoj22jadPqNtqVzHLd2Ft5zXqMiABrdwXCwqflDysxBJwikNnJu9HMLCGyupbmS+uRZP5tlLczWgSQ+WkMhRZI8Zw4CI7E/LGynFdL4g8ZamNNhm034g6LqMliiyWwltGEzseHEeULxk8L94ZA6R9+AWfXvEMT3Mely6iGXN1HbW58qRd/JZFxg7gMtHtUkDPPJ2jGcVeV3fre/6X17ab6re+btOVlp5FqyllsNQs9QhvZvMtLmKaL5hKijfsJb/loiMnygEHkkMFr3b4+fD4eJtHjOnYN7AoNkrXKwxLkruVy3yknoPu4J5OOB4ivhbVNN2y3thdaZ5cQkEerKtuB1UbBuEjHPcDtyGGTX2P4RtrXUPD9pO8XmM9ugdZAOu0Z4HHPtxisqz1UVa/ppp3Wj6+V+jNJtQjzy1WzPzk1GyudOvrizvoJILq3kaKWJxhkYHBB981XXrxj8a9C+PmiwaB8XfE1jZxrHbfaFuI0VQFUSoshAA4ABbAFefCszz2tdBpGDg0U4kjK5O3PTNJSEJS0lLQMKcv6U0U7vQMdL/q/wAahqaT/Vj61DQJhRRRQIKcT09qbS0wDtRRRSADz2xSUUtACVq+GrO8v9btLfTbc3N0W3JGCBwoLFiTwAACSTwACTxSeGtC1HxLrlnpGi2zXOoXb7IolIGcAkkk8AAAkk9AK9g+GHh2ex8R69pEulbIYLdo7m9vrBW+zBJN+JlbITzVTaFBznaVYDcS2ko80tjpwtF1Jpp2tY3vh34Zn0/wudfv9LtvsU0bPaPfQh4FjKsrTXGMkRAD5UA3yPjaVXJqGeaW6umvLe6aYSStcahqN5DumlMbjLzKRs2qCgSEZRBtGCSTXruveDNS1nwbcf8ACS6uYJF1GfUzBuzb2gSMpDbJxjy0CgllUndk7TkmuF0jwVqeuhXvr7ULbQJWj+xWkUEZv9UVgS8rfP8Ausjo75IT05z51SDk+VPT1172016Xsk7762XL9NhsZTinXqaz2S3SX3W/rsZPgbwDD8QNf1OeKKS18L+awmmgj8q4eQrjyVBBQcgSMqqQowAc8V61rq2fgPwzpUDeJBpcI2WFvd6jEHMaqp2pBFuCIy4yZZAevJIwBx3j7xongjwtFpFlc2ttf3NtLb2lhpe/7NY25JTesgG9pd3zeYRtYo6gZBY+O6JoWm+IbO41LWNc0zTNQ83E17e6uFeeLH8FsA8juc9QUXAAVeCTpJc+jdl0btdvv227O1n1Vzza05ynz3sr272/r7vXc6hPEugahN9tvLDX7vTbeVftV9f68XGz5gqBIFVi5+cjB3AHLfJnHDaj4ktLvUMrouhJBDDvgWFI4Zgi52kzEnzJgOPmWTf1+Y4NdfpcfgbS7+O+jkn1+WHGII7BYbCIuQoEs11uYoST8+3rkjbxXRaB8WtL8MRXNvpXgyxj0zY8FxHaXalZTkkEyNDlwRuABY5HNbxqKLtfbTTRWXlp56pNfgTPDOavD3nvd/8AB/BmP4Z8U6dNZ+fe3/jW2itZGk+y6UjfZrIgYLq0sjSNGd251I5JOVAwK0tYm8HNDNq0n2TWYSwtDPMPKmdSch5AkaGOVQoIwFZlGC5xtq3qfxN8JzXEaW3gqylgj2JHLaX72RlQgHEoESI2xtoYOzKOSNwyal0vx/ZahK0U+g2elJnbA9tHDOyhDnEVw6eWFHYBSoxgDmnWnzKzbt10jf8ADX53ffdl4aLhK7gr+f8Amnv5mfZeE9GvLUXVtDdaVPLGZEh1i3d4SThRJHMnlyryeCwZOcEGvYPgzcX1kjaHfT2dwtuu2Ca1kV0ePkgDacAj6Dg5ArxXU4dOnvDdvrd1qNqm6UwySzqt5HnadxG/yCDxiTrkfKgIx1/wc1y1g8UiX7LamyfbFDMsiP8AZVPOwFTwAWOcALyeBSk3GMXJ3XT0/wDJVbvpe++ptjP3sZ6Wvr1+W5z37W3ge/C6f4shjeSGGIWd8dozCC5MTEjqMsY9x/uqMnNfMnQ1+lXxI0m01vwVq9hqMfmWk1uyyDjIH94Z7qcMD2KivzXmQpIyHqpKnHtTp2gvZrov6+4+fabjz93/AJf5jWxwRSGkpQCVJAJA6n0rUgf5jNEkWECqxYHaAcnA5brjjpnA59TTKTtS0gClXqKQU7oaBjpP9WPrUNSv9z8aioEwooooEFLRTnGGIHSmgG0lOBKkEHBHIIqzplhc6nf21lYwvPdXMqwwxJ1d2ICqPckinZt2QFUCuo8M+CdT8RaBrerafNYCPSYTcTW8twFmeNRlmRPQDnJxnoMnivrTw38I4fCvwb1nSjYWur61cwPcT77dXWS42EKicb9qAsFIIYlnZdu4Y8U+GPh611bSpNA1i4uNMtjdNJfiJdiXtvCkpMjS4ZmdJGRfLwiYXu5ysyaWkXr57b+vT/Lub0qLnZ20enz/AK/U7P4B+GrfwX4Mm8Y6zLFZz30BlFzNGW+y2IbA2jj55Xxj/ZXjqaj+HniaHxf8XL+8guW03T3tHaCznjeeW4ENsbePeykneFeRuDu+YrluMU/FOvab4n8S6jY6vb3Vj4btNtppsEMMn2SO7t1ISG6287V3IjJErDLDa4GS3rvwm+G+n+GLzUtRk0u5skmhNnGLi5EjzRE/M+xAAiuFjO1ssrbxgcE8vspNOrVdr7LW1unpff79TujVpx0h0X9W72/HdLe/SqiS6Jb2fitYHE1v9sy0ALWwUEv5kZBAVRsG4/eJIKrwK8E8bfGd5IdVt/Ceiw2lneSSwnVEdme5TayfMNoYHBRgA4K4GcjIPo3xb07UbjwonhvSXtjql5BbWt9PdXIiURLny4BIxGZJXGNo6gMTjIJ8c8J+C9Zu9Pn077DLJpdvcNFeCWPyWtbwK6mSAySxxll4WQBududrKq5xoQlOPNUeivpfb1/4burOyOxRTuuj13svu89LeiasefNPBfW0fnzXJvkEUCAvuTylG3czu2cgYAXAUAkjHSp9SsZ9JmWOT7C10fuvazJcxoFH3VKlkY8gnkkegNew6F8IJF0tn8aagPssUbTRtpW0/ZATl5Jbhl2FAFz5fzk/wgc5xdQ8b+DNG1bWx4P8N2WpxXsMMJuNRR2SQglpC8LHDbmKkbfLwVB6DnaSUFyt6+S9eu39W6M641PeUKcbr1/r+rnA6VoUE9heSXFxOLmKMNGkVtvVGJw3nSsQIwBgnrwR71pT3es2NtDpt7qRsFsib+2SblZ5Nww8bpkSk4+R3JXAwGwcHFsT9ovrUX9xFFYrIADcmRokQH7vybpMdsrk+9eg/wDCR3M1oxsNRsrXS9KZzYwxWs0q2jA/ujHMU3jzCWALEcg715rGUko6/wBf5+X5nc4ycuWK/wCB87f19yKfhXxLoGoPcw+JrTSjPPI9/LqMcQtroCMcQx+WioC/baR82S2eBVe9k0e9u7iO31TWLnTpuLWJ7ZJGtixbMbx+d1UBf3gyM5ynArYg8S33ia6tbXV7zTpdNhk8y1h1aCIZLFR5URijjHzNwSzBMcuvAJ6G4t7pLfVEt1OkySk20jabZ2N1Z7CSHileJC6sckbGznA46EJ1JXTT19L/AP2y+5Jb+Zy8rh7k/d+dl8u5wHhZtSj1F7W2ngumWMiCEX5jDTNgKEIXy88/ecBWGQHViDXe/DYw+IvEL28hNvrnn5u4wu8TLgLIGjfAbhWxxxkli5ANchZ+GINMaKXUkuUgkZV8yK4SPzPkLKkT4YEEFeXA9wOTXqXwuvdNuvG9kZ5odPu7BQlpI1sha8jZBG8ZnTaHwyj5WTcrZ+Zt1XRqc0nFaei/O/4Po9SMwpujDn3v5/5fke+3NtE9i0DDEITaRjI2jtjuMV+cHxQ02XSfiJ4ksp7Y2zR6hMVixgBGYshHsVII9iK/RfSdVh1T7SkPDwvtILAkqfutx0zg8e1fG/7Xmh2+lfEGwu7aHyxf2W92GMOyMVH4hdo+gFbwnGcozhqndf1+J8y4ygpQno1Z/wBfeeDUUpFFbmIlFL1A6DH60UAFOzSDFA6igaHy5KD61DUr/wCr/GoqBMKKKKBCjqKec+tMHUU/PBJFUgBVyRX01+yZ4HtvtEnjW7u7ec2qvbW9tDvMtvM2Q7SdAD5X3cbgRKTwVr5lVsNmvpT9lH4inT9QTwhc2fmQXUjy2sluuJPNYpvEijhwFXdvOCqow5GAIqSlGN46FQV5JM+qPD7301i02pwi3mkkdlhB+5HnCA++0DPvmua0zwloj+LPEF/Y2hiW9lRr4pKyiW4jAKMoH3Su5iWBBLEn1rr5bxIi6sGLqhcqoz0xwPc54rBuL1PDXh9GZCdRumPkWjMC0k7gkRDBwcHgnPYknqa85zjFKCd4r4r7v/gt/idlJylJygrSeyXT/hu4uieCvD2hWy2mh6RZ2cMcnnL+637XJUkqWzg/Ihz6qvoK1rhQ1oJrCbdIpLpiQbZW5AVj6ZP51xC6P4vm0rU4f7RuLMQI6W/lMjS3jbGDNkgeXufkHIwMdOtUdW03XB8D4v7FeWy12ws/MRbXBMjRk7tpw24sA2GGclsjrTc6tWTUo6tPdvuttNPu1srmssOox5nUTs0u+6b1/rQp/Faw8P8AiqfQrHULvVbbULS5NxDp4nNmLl2G1TIzDO0EBfMTJAZgvLV5/qvxC1nwxq1xbatp+j2mslpyRbWlyfsrbvldEeRYyshBZjGfmIG8Zbj0nwh4wsL74WaHrHxBeGFGiDs15DvWcB2COQQcv+7STgdweM15P8WfElv8Q/Fht4rvTdNsNOMdpbLq8rWsk7ylHMxQrvMfER6cLluNwxdKVouMm9HZ3srbb2tr2vq9GtDakoX5LNJ9bvX07+lvUn02fUvid4VfWPFslxe6do8039pRWWoG1doRHvQi2x5bAHOGLKx5HOAa8g8a+IrXWby2+w6fb2GkW0SxWkMMCRySR4GJJivDSsACeSB09SfTvAHg+z0q5mbxDH4hTxJayXED6fp0cE5wqbl3wOGaRHwxVtrRn5TuU1xnhXwhY+IfFs+nao8ulzBwsemgG3muMnA+/uMXyjeSd3U+orRaLlemutr/AI936XOyEYwm3B+n3fcclfy2QnWTSUvUtGwf9KCFlbGdu5Thh3BIH04ybCBLm4SRZ23PhnZ0SNYyepG3hV6c8fhXpnxN8BaP4WsS2lWNjFIEa3mE2r+arMCANiEK7XZDCQgAKq4G05qPwJcWeg+GXMaWY1jWrlbWM3bBbaW0UfOyyMyoD5gG5W3DgDHNTVUea1/ut+m3nsjuwmJbhzSW3n/S8zP8G+F9Q11Gn03T7m40+NXWeV5FMRC9QDwc4JGFPzEj0r1Twr4RuNMvhdWket6TvwfO06CWcR2+MxxMJYw0mD22OOfmC4BpLj4iC209jK1tpGUAkXRWS9NsmMGaQExpAdxG3hsnkqeDS6LqeiyyQHTZdT11sRzefqfi1YGTeB8gRHALEj5lI69+RWF4WT2T7u113+GS/G6drPoKdSpWurfivnu0vT+kdD4h8HRS20FxHqOsWt7apJsmt9ryXJdmba6kKJD0O37wHGSOnjtvczWPiH7FqGozyLLc+YiL5sKidCoT9yflEp4+XG4DBDjHHtdj4lv7i0CX9hNBbSzvaTytPhoSFJ27ZH5BB+8eOnXtUvbOw1fU9Ph23UaXbJaqmnOkmRE2YnnRh5g8s7sSq2AchsjglDEUppw5bSt/XS9vLto9NTnq06tJL2mqTXVd/wA+vc9G8Kw3CiWe4tUtpGZo2QEMWC42Nu6nIyx3ZbLV4b+2rpUcvhvw9qoP722vWtsAD7syFsnv1h4+pr2rxFqM0BsFtLxFgFyY7mRArySFV+5gdCTwTjgDtXCftN6Hc+IvhJdvDCEl08jUtpccCPIbp1GxnP4CtIV4wTinomtd73dv+H/RHhVoTm1Udvev+H9flc+EzSU8jLYUE56DHNR16DOMWikFLSAWlpKmuvI89vsnmmHAx5uN2cc5xx1z+FAyOT7g+tRVLJ9wfWoqBMKKKKBCjrSmkHWl47VSAB1rsvhZZateeLrJtC1a10a9tyJ0vrm4EKQjcEzk8uSWC7ADu3EYxmuMrpfDsdjLoWoho4ZdWjuIJYUmBCmALKJeQRwCYmPfC56BqTXMuXuVG19T748Ra41rq+jWFkh/tHUf3szyRMY4YIQWlLYyAedoXPUiua8PazoMd9ca9d6kNd8Tyb0gjVvltwQQsMYPyxkhQGbjJznqa4j4QfEK/muLq61fUb0+Hllc2P21ozcSSKjvLHIw2kM4IlVdu3ClQ/yENv8Ajzwm8Op6trlnqENh4fmK3rR2ShWuXMQyS3TBK546kk9c141Z1KV+VpSv66Nbrt1vo3q77nu4KNCr7sno1unvr8O19raJ9Nz157u7nsbO5sYopGd0aWMyjCIfv4IyGYcgdAa82tNV8VXlgHs76W/tsxZfRo4FKLJKpdg0hY5jXzE8vZnAUkjNcT8NfitFZm3tNSlaxVclDdZH2hWc4IHQenXIr16TTss+seEY7K6tL9jPcQLMYfNcgBpY3XpIQADnGcckc5ijJzfvwvPqr2vtqtfLVNPp6ClQWH5qWmr0bS6X0d9nbb8Tw7x/4otLGx1nT9Ws9cPiNBItrNqFv9uRZBj5CEVIleRWAEse5lRhkggLXA6b4xvNCtLKLVJNH1fRJkRYbY7JPIRHXzoTbShnjYmUruwCQm8b1Ar6I1LX7vw7DFpzwT2VvawNd3DX18Zrkruy/lsTtkAL8HcT2AGAK858a+I7Xw14u/4Ruy8BJrEcwic6lNaNdz3rSAMHjPAZM4UAP1Ujjmu3D4pSbp06crx6f5L3bfn96Iq4V0uWpXqWT2+0rddnp027+Rb0rwpP4leM+D/FGrfZbTY1vPqlokv2CQcGKOeRllBwoJVV2AHnkiuR8ZReMfC9/Mb4QQSXN611b39oykCQbFaRJA3mlHBVCshwScAcDHV+LdY8OaLa6Qt7/ZeiXkc4tns4Y47ie0jkIdZ5oyxKMvIaMu+0Ywea5nxN4gmk1a5h19o7fTLe2BtZNPktHjEVwfLkmihZQZll2hgmVZFO8ZyDURm56Stpp20XktH6K79L6+g3Sg/3crp9Gteq32fy283vyNpqjaJNq2l31tZ6naXAML+dY/LcyLu8tyzKrghnYFshzjqQBXf6R4r8Ox+HxpkGl2H9sTCK2vZtU02JIMRnJLRrgO8ahtg3c55JNedx2U8MaGw1jTdQsZpjmwW6ZCRGcr5kLkNhgOMdOmc4rpIdA+wT5fwxDez3tujqomkkjgY5JVNp5J4JUtnjg1bnOOzflZ3X5r/gep1LD0aiV0vPZM6dfFvhSx0i10nRdOvdenmZVjP2Vo4rm8JADyQ7l3nAUbSdo/hHJNYc+mS6tcX412cRqkCzPG2kC2S3dG2vhUIAIyFOUZ2AwBj5q7uLwXeamJr7xNoNssyQBP8AiTtCTIAf9V5YIYMi5YhSzMeN3QVtWHw9066uUFpaa7fQToRIdZhZVXCFSP3hEnQ/KuOCMluKcY1Kl5Ru/ut9yVl967GU61Gjpz/r+O2vbY5Twn4HudMc2qiKZJXeWxma3W1lZo/mKhnAYBsN8pyBjOSCVr0fwgz6B4/nXUESeTxFEHinUoJLfyULeVJEo/dptJwQzAsCTtLAVh+HNC1/R9X/AOK1l0/VpWjMsjI4DttChQuVCqqqBuyRnJ2qxNegeH9Bgt86jJ9ibzlZLT7LF5axW74IjUADJPrgfQc1Mac6dRuLTV+6069Pu27+TOLF4yniaKjLTTtu/J32/D56LntDubjU/FOqadaRRx2Ng0kBup40V766fDTn5cEbVKjA56ZJxisn9p/xhD4V+Gs2m2zhb/WI2sLeMAECLAEzH2CHbn1celddq1hZad4z8P30GjNJJHHJaieNNxiUoTzz7Yz1+avnj9rlr25TwdPfQTGdYLjzpkhK26l2BSMN08wBTkZ7CiFKPM6dnr19LP8AryXc4cXecI1Vtbbrq2v0v87bHzjvZHDRsVKnIIOCKjpWHPNIevFd55YlKKO/pRQAU4Yx702lFAySbZ5abM5x82emcnp7Yx+tQVI/3BUdAmFFFFAgpaB1FLTQCVPY3H2S9t7gwxTiKRZDFMCUkwc7WAIyD0PPSoKSgDubbxhBMNKGsi8v2tI1QSTGNygEjP5QDKd8WfLO1mGCHwQGxXrPwm+MZg0iLwx4msG1aF2MOnoyEuFwxVZc53JuKhduSoBzwBn5ur1n4SeJrGHTdU0zVRo73MiRGyOqIQkhUt+7aXpHtDM6k9SNpyCAMqqvHX9P16f8PudWFcedKUrf18jt/wBoTTruY2niKy027h0d4hA7zQ+W8chxhWU/Nt6AMQMk+4J5z4C+JtfsvGdnbabcywacjG61QEnyBax8yOy8hTjhSMZYgd69P0hdO1GK40XxLFNqWtXN49lrVpesFkeMGFI5oth3MEEYYOARtSZjjAFeofD7wb4OtNPntfDltELG3uWjuICNzTTRMV3zMcmTBBZQflG7IGenFFU+X2cl7zel/v8ALbslrpay1Xr4qcoNSTvC1n1+Xz6N2/Q27+z0bx54Tk0/VFjmhuI/nXKiSElcB1JztYBshh618k/EjTfiD8KLuTTYvEWrt4fnWRLW4W4PkyIwG4FTkK/8j04bNe/fFrwM99ptw3hsC51EMZvsv2jy3WMDBEeMcZ6g8c9q4T4W+JrPxWlv4H8bxl763ZhplxeJuaORcH7PKr5DEAcZzkDHUCop1ne1WKaWl9/689td7K7MXhqcqfNTl7r8tY/jt+mqu0eD/DpNbt9csJvDDeVrckhihkUIcCRfLwd4KjIY8n17VevvCOsxz3sVrb2t3/Z7uJxayhgFT5S49VOOvevfPDemX/hrx4mgajpluI78SC7lWPzk1KEnjg4CleBxj3HSk8W+DfDkV9eR2dvIGt5RE9jalnkAKAMyE5L7fvEc965sRmMubmUettv8n/XzPo8Fl+FoJUJN3lFNSjZp62+Xl+NnoeGsfCTeFFd5/EL+JmXCLsT7ImGxtJJ+7g9eoIxiuj8G6hqNmkNnpYgsbe4lGYorkS3M0qgJu2lSzrli3lKASM4Pesrwd4EjuvGNnYanawzaVe3MkVtez332VJhC4LhTyWyGVSMZGTjkVow+GJfLvZTpejxWlnqjxjzdSnlktwOipAMPJG33gAu9iO2K9WEFKzvf7l+qPKeIqRc4zXXtddrbeXkfQ/wg8S3GqGRNastM3QB4ItStZI2jmMZw23oyqQcgEY6j2HrQAHQYr430r4X6t4njtL7wzFpsSJG8ckkYlSMNywJ80sfn3YKrwrdu9e+/DfxLfab8NrV/G32qLWLZ5bd1lUNJcFX2qY8ffyCoz65z60Q5qWl7r72vLd+dtd9PTzMbS9rJSivedlZf1/l3R1viHWNC0Bku9Ye1tjJlfPkQcY5+Y4yB0/HFeea/8X/Iu5rWzsXt5llUxC7Rkkli2Fvu4+VmKlV3YBypPWvIfinqlvrGtvqdmNStYzfoG2Kt1brhTv3AnKTAg5iI5GccYNcw+pXbXN7Y6fHex290ht5LMtvkMO8uqoScgAqCQfmy23niuZe3q6zdvJaabb9f68retQy7DU4pzvOVuuy+6+229meof8LNOm+LLfU7AyGG4iRp7KS585p8jCJg/cZfmG9c8ghuK9uurPQviB4Smt5o4r3TL1dk8LN/ECCVbafldWA5HIIB+vypY3ljqGnx6NthSGCVL2eRIVE+0KRITIcEfMvKggBXGASCK7L4f/Eb/hG5VuI2im0+6Zy+nJuFwBvIUjKgPIeAgUDcODgrV0uag7w1XVWt80v03fbvnmWGp1VeC5ZL8fJ/p+Om3k/x1+Ed18OdQhurSaW80C7kMcE8g/eRSYz5UmOCcAkEdcHgYryY1+jmtWHhz4r+BZIg/wBu0m8GN8fySxup7bhlJFbsR6gjBNfBvxN8G3ngTxhe6JesZVjxJb3GwoLiFuUcA/kQM4YMMnFd91NcyPmWmtGcpSkY7Y70UUhBSjrSUooGOcnywO2aiqWT/Vj61FQJhRRRQIUdacSCBxj39aZTjTQCUlLSUAFOViM4ptL2pAdh4X8bXmm3th/aEs1za2z4SQHNzbRlHjYQSE7kwrlgudu4KccV778LPiULGC90u61ee+uIp2ubC7EWVvGcEhHHDI7/ADZVsjec5r5Sq7aXc8TRmGVo5Im3xOvUHII5+oH0rnxGHjXhyt+n9f19+p3YTGKjdTV4v+v6+7Zn3xpOveCrDxbqN1H9gi8RXW0ag8NwHeNkJVlYE/LhlIIUcjaTnNcV8XPAVp4nv28QeBLu2fWo4hdtFaXCiSTZ910AOVcHow7jB61lN4R8E/FK30zxRY6o+hXeomO3ukgiUwfbSg3Q4YDbJnAz0b5cZJrndZ0XxT8GNXtry1urae1lmzFcCNf3xVTmNl+8oIbkDjpjkV59SnWhG/PzL0s/T5/P1R7eEpUa0rwk1JrRPZpfjp5Xt2Ov+Evjs+P9QtF164ij8QaS8JibaFM6s2yVwnGN64R0GQr7WGASBr6n8RtI13xQ/h/WPD+oWSW88yDU4ZW8+0ZQQJAFXcvABPJA75AqhL4d0fVNNi+JOgaa1veaijT3sLNhHYfK8QwCyl3HDDAzy3HFeq+DNY+0aRp1zeJMgvY18qa6QJNuOf3Uv+2MYzwG+tZwpr2rV7Rlrtf5O/T/AIK6EuSoQ5pRblG6VnZxte60363Xz1uz5+8ZWVtrfiW403XdNvjqdsYYJ9U02NWg1NJ2H2eU8YjlJyRztdlIJx0reJzc+Bddtre7trbVNl0rQZhmjiYoVUmB87o7ogBmIYquBjOePRfjt4Lh1jxRoGqNcWFrZeVLaXZvkc2sjL80SSbPu9ZCHPC7fcA+MaJ4lgZNS0S/1cjTJr+Hfq4gE/mpCGEL+VI4YKxXlkAAAxgA16sKXLGzvp1/4bW3rfyertjDESqtN7Pp8/01t/lY9A/tzQ9EtZb3UZriaC3Y6gumX8sdoZbiaXbiSADc8gQljN93gnb3rl/H+oapq/jPVYPB97eahBc2cd3ejSGaa2c+WiuiunLr8igu5BLKRiq2p+HtJ1XXdO8uz1vUTf2xSG5tJxCuqus3zzxmRmwwi3KEYjJ28Dvm2FtBofnwX+qeNvD+pRXb3d9BFEIPKsHUxJJ5Y2qz7vLDOOMMcAkVn7NO8m016NflG3ztr07O51JU5LlXe12rdNr6fhfuxfFGsXkWnWNr41k1aPWLM+a8GpWZWWdi4OUnTDLtUYVnLHrjGcDndXE1kYboQ3VuJYVlzLdAujEK3mJsY/LuKEFueTwTyPUfDlpp8Vj5l7eQeJ9QtoHglhu7mZG0tNwZiLaQB2XoWZckMoxxnPJ/EbX9Kt7hdJ0LVr65aAhZUiEM1nHGAflhmCLJIV3E5I+XJA9aIxVtfu3+Wi6ea/E6VUnGooq1npfbovmtf+H2MXwvpiTSXtxrkti+jRtELuP7QFmEsn+rJYglcOBuB4xuPJFdDc3OmT2+o2cemPLeW829ru/uw7Q4CosKEAMThV64OEJ7E1wWi3Bhv1msgZ5Et5PMWfBEisNhRATy2GyvVgSSOQK66XxJErNZWFlodlbMZIPkhEi+Sw+dJJH+d+VB4AIPAOTirjNWXRen5ttP8lbybHOjK76u/wDX9f8ADHoPwT8bppfiS3hvby5nttUWOG5mvrlS8lyxyjxR/eKDJQt/u55GK7D9p74anxh4WXVNItTLr2lhnjWNAXuYScvF6kjl1HPIYAZavGLnxTFpumm401dHs9SlcxNbxac9xcKjNjfJM/yoD8pCL8wOMYNevfAb4jX3iSSbwrqQmvJ7aBpoNSBySikDL5PJDMMH86fM6UvdjdP03+XR9++tt7eRi8Pz3mnqt15f8BfgfEx/SivSv2hfCa+Efihqdvb2629hegX1qiY2qjk7goAAChw4A7ACvNO9bJ31PKegtO6n9KbS0wHSf6sZ65qKpX+4PrUVAmFFFFAhR1pSKbS9qaAKSlHWkoAkdGjYCRWViA2COxGQfyINR04knkkmm0gXmFeh/C/wdpniC61C/wBbuL+PQNPHz/Yo1NxM21n2jPyooVHYsfQDqwx55Xofgi6t4tNfRdRuYrOz1Avi9VT5lvdBQ0auBy0ZKxggjgkkdDlS20dv68zpwtOM5+8tP6sej6X4+0SXxFZ+F7e3ntvAb2I0ZoJwFeQMci8cDgSByGB6gc8E1H8R9F+IsmnxHVftmvaNo5uTHchtxSKNgjPJJgFmJBwDlwFyc1ynijRrc6Hps5utKtNRli4sopGeZ33bWcKAV5cf3v4cAcV7Jp/ihr7w9oOq+Hb+6TxbMY9NeAstxZ6xcxxISlwDhY5CBxICGwepA4y9h795a+u9/wCu9l6HqVK3skvZbrrp816/pYyP2avHNxY6jHo19uGlak7RxM5yBdcZHqu4EA5AGele7W8lpBrT+Gr65SYyxiQRzAs0qkn/AL4wRwepIzXhPjHSdO8VW+o+KvDkl34b8SRuLa+tG2GM3kZ3IsxHQuQNkgwjEJ3JruA2peNfh5pV+POsfEraWLnTL2KRVme7VWV4gwAGJAuWQ8gluDgEcOKw8ac1bv1vp3Xo3Zddb33aVe0+sL2nVrdW3Wz+Wt+y81c0fiVqtnbeGxoWp3Im07W9QOjpqazCVbZiuUE4Pfcu0j0BJ9/N774hafouoCPWdNuNM1C2X+zr+Kz021Z5WRf9YJWXag38bACNpBHPRvhzxLa6yb3wB8XtKm0qXUlVVvpx5RknUkJKxPyiXjBkHD4APoeibRNZsZtH8OeMNXFlDaXPki6a1R7fxHalcLFIzfKkwUeWA5/iBBJANbUHKnpzONt/Tvazurf5N9rp1qdnDlv18/O/3babJ2XXxqL+1vHOqXs8+swCeaYXP2eacQs0pIjUQrwC+BwB0A5r2H4328OleCV0rUxZy3Mc0cem3ur3Bub644VpHRgP3YVjg7iV4x1Ir53u0u7TUJrEafLaxrLLGsN7ETNAjHjcxGVKKo+bHHJrSefTmtrPUJLi3u9QszHDLpV0Jp1ulDlmkWQHG04yV44b15qlTcJP+n+a/qx0yqc9mo2S12et7afLX5PY7vTPF1zeaVZXd/aeH9T1JJILqXUtQhc3UccD+WC7bQshQsOVYsBjcDzXnviqxs28Sai/hfzbjSxcvFA+/e7EjO5cD7pwSueSOOoNWo9N1jWLMw2mnXkmkAzana2lrC5hjXOJWiZjlVXG04zkjuRWJpk9rBPAbi1mlgVX8xIrhojNw23J7bWIPvjHGaq9lbp/X9fd5FwpVIq7ir+X9f19w3SIr2aVTp0FxJc2wa4WSFGcxhcfvDgfLt4OT3NdXpOlXcd1cS+I7jTrY3dubgPfyebKXY5DpGmSXI3AK2BluccVh6jearDpyJd3l05kMxmRn2hZZCpbay8NuUISCTjJ471o6fPoNnYStexXck4jZrcQ7St3P5r4kmJ6RgDGwctipjKMXdr8/wBNf6+ZrFVXFp6W9fy0NPS9RtNNLPby6ZcIhXMeqrKxuTuLZCjgRqSARnkqSDmtHwh4t/4Qnx5purQXsVxDIBDfCO1MUfku/wC8Vc8ttIVww7gDoTXP27vHax3E9+kN1M3lLDO7RyWiHDLIFC7fJZdo49scYotfsc+oW7w2jWt9cTMsEdiUEYTnrHKdwXBxliF2jnkV1ppxa2/r7l93T7+atTdRWk7r+vU9Y/bP0pb7w/4Z8R2kkMltDPJas6nJkEyiSNgRwVHlv3/iFfKBr6v8JaFeeOvh14k8P3N60uiWkkK2n2V1neVlbzsRbioViqlApwB5gz92vlnUriK6vZpre2S1hc/JAhJCL0AyeScdSep5qacnKN3+G3r/AF/k34GKoewm4Xv/AF/lYrUo5NJSirOYV/uD61HUjfcH1qOgTCiiigQUtFFMB7t5spY7VLNngYAz/So6WnMBgEcHuP60gGUUUtAHXeAvC39vNNdSTQGK3migFp5mya4eQORsyNu1BGzuWKgKOuTXc+EIbxtd0651jTYrq2mhlaC7uYVRoXdcxyTSKMu4R02juzqOtc38H9PtNQ1Vn1CKGGy024h1C7v7jdJHFbruR4TCP9YZXkiXH+zjoTX0Bosul+CfD9mI1YxWcU0i2uqQsrpaz7Jl3OMKXzEDnkhiflCqK5sRUUGv6/H/AIa/Q9rLqTlC9tP+G/ry9WeAeIpQ9wz3V3ftIMW2BCVVVVtghAP3NseSPXK8Zyau+JLWJPC/hfXYJUs7yZGDG0l3T74n2xyMAeBsjkwcBlIIPykGtf4on7B4w1VxI839qWSXziH50cuSAJTxlcLncCPvDpk1yNzNZ2uqQy2lmr6coIkF9tV7l9oDMdv3cEnbjlRyOTXoe7yX6P8Aq99F9/8Aw2NWLu0tT1DQfElr411BL62+ynxeq+VqNjNL9ltPEsCnjBBAjuOAQDxuwR6VteIdX1/wJPc694euJbO0vboQHSp7MJFZzBVcxzruKpKVZXDLjeMsepFeA3lzLHEtujAWscxe3DMAYWOCeerD2Oeleo2fxZN9Fdw+LPDltdpqTCHVLi2UxGaIYMexBjMq4LKxJABIAwa5qy9r7s9bdf67bJ728zWh+6ei0e6tp/X9emSfiHq15r1jqGtiz1EwSMXS4tEKzq+S4ZejA57AdBX0PbtcaZ4b0f8A4R7QBqnhbW4MT6G9yrtZ55UxGQkbWG4FGwA20AqTivnR9KtX8C3uraaGeJr9UAmhLywwj5lZZwQox3UKW75xmvUfgTqt3r9xq8usahOriYtqE2VUPBPHtPHAQmRFYuuORmvOnTUbOF/xXzVvmr+qPWrrmj73Trr6pL52a7PybueIfB8Pjy+dvC9p4n0jUbG32Qx6vYvFCgUDFv5+47So3BQ2V5xnvXN/Dn4SW3jnTXki8S2VjeQnm1gTzLiLLkEzIcFTwcDJ+oFfRepahe6FoItLcxRSXRNpps9xK1zbrM4Ih3MT5hVmCjbhj83BIGK8W8dRaf4c8aWGseKLCztb3UbQSXmlxxebEzj5JPLdGBXJG5XPKk5PSr5/dU0tt72/Da6+Vv0ywtapWcqPPbT3W0ne3Tsn5/e9iXXPhjF4Xsp/7W8SazDo1hMbSIT2UktsY5AZOGibeiHlXYAAMTwRzXC/En4ZX3h63GtWMX2rQXY7HhbcsQI+X5hwUwQVYcNxnBJFddb/ABv1K31O2t7K2jsdNso2Z01S/muZbllzhDMASu7PHBGVGeK1tI8Y+Rr/ANt8VanKI79IlazsmjK2UQIbZJApZXiZGwzAhvvjaDiok4R96Ol/NffbfT09WdNCeJc/ZVVdpbWs+9lZfO2q8m3Y+b5UDmOF7opbpGZRtyyRM2A3y/3sdTj+EVu2c1sIJbiCewsZUuGjW1hMsklyGj245BCRYLjd1y30I6Hxl4ZudK1pYItOuLjRL4S3dtDCfMic+WSTDIjZmEQKnIwWC5KjmsXQElvdNl0u3tkVbeFp5DbqxM6qHk82Q7wpYKSuD1DcAsMHqjPlWq/y+8zdJud4vTv/AJq/9baouprFxJePrNrY21rI7gxQx7pUgOw/ugjHdgYQgYKjHBwMVq23iG6j1Ca6tPJLamIWZ5rdZd0isdzv5gwVOyQ7U+Vcgfw1X0Wy1a800azEHilkmWzGo5Y5TaY/LZcYVNuU3DuNpxkkb0Xhuw0uzsU1/W9Nvp0VooYTfsy22SWKqsa5YZ3DAYDdgjIbkbS1T9Nfy+X/AA+h2KVkoS66fL+rf1v23wFvZ7Txtc6e5jlhuLaSVQtr5GdrgpOVPKqwbaM857cCvAPjr4fl8O/FXxDbupEF1cNfW7CMorRTHzAFHopYpxxlDX0R8B7Wyh8aRlrmCW5exk2MwXzZUYq+GAJKlOF2sSQB78ZP7aWk2R0nw/q0Tqt7DdSWZRVB3Iy+YST/ALLA4H/TQ1dOUVdN6t/jZfefNZpH99bd2/V/ofKGOKKKWtjywb7v40ypZAQuCCCDggioqBMKKKKBBS0lKaYAcUlKOvNB60gEpaSlFAHefBS0vbr4g6W1nBJPDFPG86B2VGw6lA+AcjzAhxg9M9sj7S+Ivh281bwYyrBbTzW0guZI5U+a4VQQ6AnO0unynOcZ46Cvnr9jmbSovE+p/bLZ21EiJbWcciMMsgbI7E8AH3NfXmuW73ei39vFMIJJYJEWXbu8slSA2O+OtckoKrOeuq0/C/8AX4np063sI0uVb63fray8tPvv5HxB4j0zUJ9T8PppVqbzUv7LEl1bvKB5zQvMHiGCAwwCAoJYhOOa8+gDxgE2Ll5AZ0dJS22LOQ2Op2kZw3XuK9e+NelWlrpOh3tkZI5LeKSxiQsySwlJ3eK4ABwSyZ6jI3A8GuDj0qD+z7S+1mfRLZtQiV4GSUokSR/uypjiBAkkC53MOPmJ+ZgR10Zx5bO33r+vkdGNU1UckrL+tTIhktGtbv7FdtaRERxzW0pEjTDG442r/fBPtkdeTUVtEDy5njd4i6GBw0agAgv3PGMEdaprLE+nWbRRlXj3xOZJcLuAyrLyCvHUDvjucVrPrN5aXxuY45IL7zftDXMkm6dHIKlWk6hOfut3605L5/1939bPUKNVuKv/AF/XyNzwtrL6OdQM1r9osbyERMjOQhAwcMvQnOD1B9PSoYNQu9F1i4v9KEVvPCWeNYAZYQrD7jK2QY8MQQc8nnmq3hYabaarKmvQTQxhGSRk4kgk/hZUOAxDDkE9DWuL6OHRdPu30TT59Plae38/y9ss/wAys8bkHKupI2uoBAbHIrmnR6/evPv03+Z6tGrCa9lJav8Ar8PwMzxBq1xf2d5dXes6usU/2ee1tbhzMJ5Yx5ZLuGGx0UHacHIwPemLqMniK3/s+W3ubjWmnkvptYa6mufMj8sZVo8YGMcuBnjniuwTSoNX+H+qJZ2EkelreNcWFxPaSmcOo+dHmVPKdNg6ZUhhwpzmvPtDv7vRZL2S0uZYJp7c2+5O8bn5xn0I7ikpKKTlH9P6/ryOVYT95zQdl/wNV6di5IkkWjSu8TTKW8k3aruhcA5UoxAZTkHrjiun8H6lptrotzCNON3fy5F9ZzRhlniU7hPbyL80cyAkHqCrbucEBPDWuWk13ctqlvcXFleQrBqMVuFMgVdoEsQb5d2BjnpkkY4IqNMfCHiWz1TSr+TUdMYg29xau0DvF0IVxkwyAEoRyRkjlW5xjad9Lfp/X9bnq1nOnytO7Xyvbrf+mvMbodprerrcaLbalZxRApPHYXN+sSzlg2GiYkJuVdxJ3L1xyTivQfAPgd9Ktob2+8L2uvQG4aCd5bxC7ZIBe3jLCORVXjLMTvbAxtrjNZ0LwtImp3Om6ncalaQbo5SkItcTsDhghVsL0G3jJBIIHS34d8eeJtI8PR21nqMVzpa28UMyNZxiKwuVyI0RiPmlKIHLgD5i2ckZqouKg+WPz1T9dXr/AF1WvNV9pOcYp3UvX5p21+9b/MteNby/1CWz0e7tbyweBvJ03R0smtY4I5cq45AaSTcYx1bO1ySRk1P4U0LXJtUgns7Z9AgsY4pZrwWLRtuztBSNsl5GZ9gwByeQO3Y2HxjutX8OTWmp3It7y3s41guUCm9numDBnhwmxE/hOcMFbgkmtHS7u6N5BpPjCaCe605x5lreR+cysCQJAx/1m/ccL1LHnkA1nKrHs0vNp7+S38rtPyNqXtYwfOkvT8X+P3vXz6T4JeCoNI12/vYPmWBQnmyAeZI7DJIVcrGvfZkkbjk8jHKftm2Q/wCEP0W5jjkCLqjKzjAXc8RPPOSTs4IGAAckcZ+gPDdilnokSR71abMzlsBtz8nPvzj8K+U/2u/GVtq2rWXhqxNu8elSea8sU4kLs6Y24HC7cEEE55HTvtCLjKN15/18t/kfMYyu69WUlstP69WfOJopSOaTFdZwiuSVySSSetR1I/3B9ajoJYUUUUCClNAOCDxx60lMBSMd80ZpKUYzz0pAJS0cUlAHqPwG1eTR/Ed7cQRSSTRW3mq6siJGFIJZ3ZhtGdo43E5wFOa+vfAnizWde0ywu9StLdNOv0MsF9GSqHMhSKMqx3Mzgby21QA4Xbnmvib4SDSn8Y20HiCawj0ycrDOL6R40KtIuSHXhWX74LfL8uDXrfiT4naNpo8N6Pos+oasmlWktqZhamB40YoVaNg2/eY1Kl1KnB3K3zVlKgnPnV7v+tbfPp6HoU61OVFQnbS/r3/r12Z6l+0H4Tkv9C/tjTYLZ7fTYpGvgpJmkgAUjA4VvLbMm1uu0DPJr5hk8I65PfXUY0u4vIpJFDS6fatOpOeTCUG3gZ4zgjjmvSNf+NNx4k8D634Ytkv5Na1WcW0V0SgLW5Yja4jUAyMoClUXDBjjB4Pk94+p6dZ2mq2Vw1hJcXLmFbOSWJoigUkKMgAKzAZ65B7c1r7Ob95L+v6/4ILHpQ9nJ37f1/X5nZeAvhH4u1LULea0gtrWGJluEubhklEYOR/qxu/ecZ2ZyCMEA4rpb34OeLvD6y6jZ2pDW5wk8cplmz90uqqpLBwTlTnAznmuy+EPxN0e88SX/wDwmt7ZWGuzRrKsyOLfTZEVVPmA5w1wWL5Zh/DhTxg+96Z4g0zVLkJYX0c+YlkHlhtrK2drK2MNwD0qalSFN8s3Z+qNaGLUU/ZwvHrvf79vwPgnVLOe1u38yMxmAC3kM6lHDhQAdowwx05yMDkZNb/hk2o8LatpOqXMMloG/tC3ktQzPbyKPLDMAv8Aq5Nwyo5GAe2D9j+KfBfhnxIWl1zT7WWZMAXP+qlTHT94CDXN6X8FvBlnd3k0dpNOJ0eF4ZbksgVgMj1zwDnNTKavyprX7zshjcP8bbTXS39fofLMWqeI/Culh9O1YCK+haIxJN5jW7xtjDRnmJ+Tg4wVY4PUDBvbeymFq1jJvBij8yMxlMTY/eR5ySR6Nx14Ar658SfA3wvqtuV0+3fSrhQAs0MhcHHZlbOc+vWuA1P9njVLZml0nVra7dwAwmUxE+hB5wR2Nc06U4rRfcerQxuDqO/Pa/Rq346r8TxTSLbTbDWtLfVZ2u9Lnt/NuhbwuWUEHMa5K7mBwCQceucEV0ni/U5tZ1C/8PxvZf2bdXLahp5iiGE3oSEjCA4LjaNox8wGa9vb4E213Z2M011DbaiET7XHHFvtZmGc7V+UoCcZAIB/Gufn+AmtxapLPZ3OilTKJY5FDwGDDhwIkVSEIIx1PHFN05K3b+vn/X3tYvCTdlUXz0/4H4niena7fDxRARb28Ect2BIgtAEcyModHQD5lOPu9j0wa7i10bS9R0/Up/Dmp2EOi2s8d7cx3Nvv1JY43IZI41D4iy3yb8kZIYkZrs/EPwI1+9hbVINVhm1w3CXBjlO1JD1YkhcK24AjHbqSRmtfQfh3430ppL2HVYbDVpGaZ7pIYZ3uJJT+88xmA5XjaPmU+inmi0oWf3/1/XZre2M8RRne1RaP+a35dPPWx4d4Q8P3firUriHT1hgE6uw3TlAoZjgA4O4AjgYAJ7jANfUnhfQbC11CxiivJ9QvobdLT7ZcnMyIindtbHBcseQTgE4OSaafBk9pLf3VilhHJdRiafDPtinP+uaJcEhTtU4Oc44xmrfgYXOn21xqviIrYwsVtbY3bCNkgUAIu3jBLbjk5Jyo4wK4puXtbSXu9W+3Xrb+u5niq8a1Fzpy20t1bf8AWy+Z3+MLheOMD2rxXW/gHod/4av9LOu6kPMma7jklWFhDcH/AJaEKilgeRtLY+ZiME5r2nCuAwwwI49DSSKCCDjB68V6NTmXvxS8v69bHy8KsoJxT0Z+Y/iXQ7/w7rV5pOsW72t/aOY5Ym7HqCPVSCCCOCCCKy+K+tf2y/Ckc2j6R4nhT/SbWX7BOQMloXyyZPba4Yf9tPavktlwa0pVPaRv1W4mra9xJMbB9aiqWQYQfWoq0IYUUUUCClNJS0wEpT9MUlFIAooooAXNPaaRmDM7FgAoOecAYA/Ko6KdwJVnkXgOcZDYzxkdP51raXrMVncx3M9mlzPCd8Qlw8ZbjAeNgVZOOVxz61i04rhAc9f0pqTtYFZO5e1bVH1LU5b429rbtIVJht49sQIAHC89cZPqSajm1O9mu0upbu4e6TbtmaVi67RhcHPGABj0qmaSpeu43Jt36nd6b8WfHenFzbeLNWJZQp8+cz4AORjfnB9xyRx0rsPD/wC0T4w09Hi1GPSdXifAzc2oiZV7qDFtGD15BrxWkrF4el/KilUktmfV3hr9pDTpUkbWZNS0+4c4SJbdLq2h567lKSEEcYIbB557d7p/x78E3Sbv+EnELs+0R3FhIpHv02gD3bP8j8K0u49MnFYvBQt7ra9GavESfxJfcv8AI/R/RvGttraouhXukavKEDsLG9RyF4+ZkzuXkgcjjvWi3iKRDIr6Vfb0xkIm8c98jt79PSvzRR2U5U4PqOKes0mfvtkgL949Ow61m8JW+zVf4MpVaf2qa+9o/Se48baHZ3CQanew6fcOQFivJUhZh/eUMRuX3GR+Rq2uvaVew4WRJwwGYiAT0zgj1x2r85NM8V6/pdsbbTtZ1K1tjwYorlgn025x2Feh+BfjTqmktaWniO3XVtNif/Wp+5u4gQQSsi4EmASdsgOemR1qK9PGKHuyT+X9I0g8K37ya9NT7rt0iYRPHHtVVwvoBxxiuc8ZW13NPbNEEaM/u4mflYZW4DlcHcT90dgGP48boPjizbQ7fU7W/jewCrKLh5Ag8rcASy8jAzhhnKHrjBr0OHU/PjfzYQQMrJEeSxA6KPU+nf1rk+txr0vZVE09Pv8Alb7v1Oj2FTC1VUVpL+v6/wCAO0jV7KXUbrR45o/tlgqB4gcEKVBHHsCM4yORzzgaxGSDk8VT09YGh+02bLOso4kPLEDou7GTjpzyKuIyyxhlIZWHBFenRd4cknruvS+ln1tpr6XPPr8vPeKa7379fx6HmX7RKW0vwc8T/bVQxpArLgniTeuw8f7WP85r4Ek+8a+7/wBqGGaT4PaqLNmUl0aQIMmRFySD7ADP4V8Hy/eNLCQlBz5nd3/T/Iqa/dxfe/8AX9dxkv3B9ahqWT7g+tRV2GDCiiigQUtJRTAKKWkoAKKc2Cx25C54BOTim0gCilP1zQOtACUueMUMckk9TSUwClopKQC0lFFAC5ozSUUAOpc0yigdywnleQ5Z2EoYBU25BHOTnPGOOMHOe2OWBhUeTjHajNKwXO08GeOL/wAOxyWMsNtqmhTyCS50y9UPG5xtZkbrE5Ukb1x2znAFfVfhzx/pviLRW1nSJW/s+2dVuYZmVZ7UlWRfNHIUf3X+6R3BBx8Rq2OlX9J1G407UILyxmeC5iOUkQ4IyMEH1BBII6EEiuDGYKOIV1oztwmLdGSUtY9V+dj9E9G1pFvNyxMtvclCccgswHzqcncBlQ2PUMcfNXXV4/8ACfxnZeKdFjvmkgSWcvK1tHOXeAgKHDKPuJnLdeA2MDGT69G4dAw71hlcpR5qUnt/TKzCnGM04r/gnkf7Ul7HafCyaOVJG+03KwjY+0gbHZvrlVYY96+EHPPPWv0Q+OXht/FXwu1zToE33Kxi5hUKGLPGQ+B7kAjj1/CvzzuVUTOIyWTcdp9RmvSgkpy7u3+X6GEm3Sh2VyGT7oqKpZB8o+tRVqc7CiiigQUtJS0AKPSkII6ikp4chcZ4pgMopc9qSkAU8MBEy7FJJB3c5HXj07/pTKKACiiigAooooAWikooAKKKKACilpKAF7daSlBxngH+lFABTgaZSg0DTPbf2f8AxC9ne/ZWMu0usWPMG2TcxKJtyCuCbhi/zfeVflyGr7c01le0VkcSDJG8EHdjjqOp7fhX5m+HdSvdO1BW067NrJNiFmMpjRlLA4cgj5QQrc9CoPav0G+F+rHVdLkklgS1nz80KIyqAPlwobDAbg3UD881wTj7LExn0lp8z0JS9thvOH5PY7Y9K/O/40+E5vC/xF8RWkUBXT47sSROikxokwMkaZ9cBxj/AGGx0r9EK+Xf2wja6bdWjy2i3DazapFuyFa3e2m3q6kg53JPMhHHY9sHsekkzig/dcfn/XybPlKUYX8aiqaX7oz61DVkMKKKKBBS0lO5GaaASkpaSkAUUUUAFFFFAC0lFFABRRRQAUUUUAFFFLQAqttDcA5GOe1NoooAKWkooAKWiigCaQItw6wuZIwxCsRtLDscdq+w/wBmrW5Yb+TRboyu72VtfLNIJV80TRpIxCyE8iSRsspCscsBya+Nx1r1D4Aa/Hovjq1+1Mq2zh5AVISUSojFBG5IwW5UqSVcHBVjtxhiIc0L9mn9x2YWXvOD+0rf5fjY/QKvnL9tXTfN8JeHdT34+z3z2xQd/MjLZ/Dyf1r6JtpUuLeOaJg8cih1YHIIIyDXgv7Z7qPhnpMZVizavGykHGMQzdfXrWqakk1scqvF+Z8YTfdH1qCp5vuD61BVCYUUUUCClpKceppoBOtJRUiOyLIoCYddpyoJxkHgnoeOo+nQmgCOiiikAUUUUAFFFFABRS0lABRS0vGPemA2iiikAtJRS4oASiiigAopaSgBwq3p809rdQXNq+2eORXiZT8wdSCCB9cVTFTW0jxTxyRttdCGVjzgg5B/OgqLsz9IPhhrMms+EbGW5KC6WMBgrs25cnZJ84D/ADrhssBnORkcnzv9sKMP8KIGMXmGPU4HDEgbPlkGevPUj8am/Z/1ayvBLFpWqDUrCSMXCPNII7iEsWAgmjAw0iBSuQQuwIQuCK6n9oDTbbU/g74pivJBEkVoblH4/wBZERIg59WUL/wKubDycoWfR/1+H9dDqxMYqrdbSV/v/wCCfnpN9wfWoKsXIwPxqvXScjCiiigQUppKeSp/hx06frTAZRS0lIBaSlBI6HFFACUUUUAFFFLQAlFFFABRS0lABRRS44zQAlFFFABRS9sUlACjrzSUUvagAFKOopKUUDR6R8JvG8/hKa6nEnmw2oS+hs3kCrNOsiIQMqwyYmkHTIxuBBFe3/GT42aL4i+E1zZaNHNDqOrk27W12EWSCJSGkdhlgMgBVBIJL5HK18oWsskMqSQu0ciEMjKxBBByCCOhzVi/uJbu4mmmlmmeR2kMkz73YkkksT1Jzknuc1PLC99U/wA/w/Kxcqk5JReqW3kVJjlfqagqaX7g+tQ1RDCiiigQUUUUAFFFFABRRRQAUtFFABSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALRRRQMAxHQml3t/eP50UUgEJJ6k0lFFMQUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse section of an extrapleural pneumonectomy surgical specimen with the entire right lung, parietal and visceral pleurae, portions of pericardium and the majority of the right hemidiaphragm. Note the thick rind of tumor along the pleural surface encasing the lung, interlobar fissures, and invading the diaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5377=[""].join("\n");
var outline_f5_16_5377=null;
var title_f5_16_5378="Congenital lobar emphysema gross pathologic specimen";
var content_f5_16_5378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross pathologic specimen from a two-year-old girl with congenital lobar emphysema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left upper lobe is enlarged and pale with a uniform appearance. The adjacent lingula is unaffected; it has a somewhat darker color and is without airspace enlargement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Claire Langston, MD, and Christopher Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5378=[""].join("\n");
var outline_f5_16_5378=null;
var title_f5_16_5379="Phenylephrine (topical): Pediatric drug information";
var content_f5_16_5379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=see_link\">",
"    see \"Phenylephrine (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=see_link\">",
"    see \"Phenylephrine (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anu-Med [OTC];",
"     </li>",
"     <li>",
"      Formulation R&trade; [OTC];",
"     </li>",
"     <li>",
"      Medicone&reg; Suppositories [OTC];",
"     </li>",
"     <li>",
"      Preparation H&reg; [OTC];",
"     </li>",
"     <li>",
"      Rectacaine [OTC];",
"     </li>",
"     <li>",
"      Tronolane&reg; Suppository [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10513107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hemorrhoidal Treatment Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10513148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=see_link\">",
"      see \"Phenylephrine (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hemorrhoidal symptoms: Children &ge;12 years and Adults: Apply to rectal area or by applicator into rectum up to 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, rectal, as hydrochloride: 0.25% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Formulation R&trade;: 0.25% (30 g, 60 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preparation H&reg;: 0.25% (30 g, 60 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as hydrochloride: 0.25% (1s); 0.25% (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anu-Med: 0.25% (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medicone&reg; Suppositories: 0.25% (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preparation H&reg;: 0.25% (12s, 24s, 48s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectacaine: 0.25% (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tronolane&reg; Suppository: 0.25% (12s, 24s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13307666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10513149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply to clean and dry rectal area at night, in the morning, or after each bowel movement; when using applicator, remove protective cover from applicator and attach to tube. Lubricate applicator well, then gently insert into rectum. Thoroughly cleanse applicator after each use and replace protective cover.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10513144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of hemorrhoidal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9504846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare systemic effects may occur.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10513145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylephrine or any component; severe hypertension, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10513146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease, diabetes, hyperthyroidism, ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9504848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11391519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered intravenously, phenylephrine crosses the placenta. Refer to the Phenylephrine (Systemic) monograph for details. There is limited information available supporting the use of topical agents for the treatment of hemorrhoids. Products containing phenylephrine should be used with caution in pregnant women, especially patients with hypertension or diabetes.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10513147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, direct-acting alpha-adrenergic stimulator with weak beta-adrenergic activity; produces vasoconstriction of arterioles supplying hemorrhoids, temporarily shrinking hemorrhoidal tissue",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16037 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5379=[""].join("\n");
var outline_f5_16_5379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504772\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513107\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513148\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505022\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307666\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513149\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513144\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504846\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513145\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513146\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299871\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504848\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391519\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16037|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_16_5380="Fluocinolone (topical): Patient drug information";
var content_f5_16_5380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluocinolone (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=see_link\">",
"     see \"Fluocinolone (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=see_link\">",
"     see \"Fluocinolone (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Capex&reg;;",
"     </li>",
"     <li>",
"      Derma-Smoothe/FS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8097445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Capex&reg;;",
"     </li>",
"     <li>",
"      Derma-Smoothe/FS&reg;;",
"     </li>",
"     <li>",
"      Synalar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluocinolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use shampoo as you have been told.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11683 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5380=[""].join("\n");
var outline_f5_16_5380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097444\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097445\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031149\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031148\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031153\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031154\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031156\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031151\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031152\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031157\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031158\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/18/29987?source=related_link\">",
"      Fluocinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/32/3587?source=related_link\">",
"      Fluocinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=related_link\">",
"      Fluocinolone (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1220?source=related_link\">",
"      Fluocinolone (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/15/29938?source=related_link\">",
"      Fluocinolone (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=related_link\">",
"      Fluocinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=related_link\">",
"      Fluocinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_16_5381="Early papilledema";
var content_f5_16_5381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72814%7ENEURO%2F64616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72814%7ENEURO%2F64616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early papilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don C Bienfang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fully developed papilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don C Bienfang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5381=[""].join("\n");
var outline_f5_16_5381=null;
var title_f5_16_5382="Pentazocine: Pediatric drug information";
var content_f5_16_5382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentazocine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"    see \"Pentazocine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/29/4564?source=see_link\">",
"    see \"Pentazocine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Talwin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Talwin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Opioid Partial Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12864283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not recommended for use; safety, efficacy, and dose are not established.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"      see \"Pentazocine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: Limited information available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative sedation: Manufacturer recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;1 year: Safety, efficacy, and dose not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-16 years: I.M.: 0.5 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In 300 children (1-14 years) I.M. doses ranging from approximately 0.45-1.5 mg/kg in children &lt;27 kg to 0.65-1.9 mg/kg in children &gt;27 kg were used preoperatively (Rita, 1970)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postoperative pain: I.M.: Doses of 15 mg for children 5-8 years of age and 30 mg for children 9-14 years of age have been used (n=30) (Waterworth, 1974)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intraoperative analgesia: I.V.: Titrating doses of 0.5 mg/kg every 30-45 minutes as needed have been given in 50 children 5-9 years of age; total dose required: 1-1.5 mg/kg (Ray, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analgesia (excluding labor pain):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ: 30-60 mg every 3-4 hours; do",
"     <b>",
"      not",
"     </b>",
"     exceed 60 mg/dose; maximum: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 30 mg every 3-4 hours; do",
"     <b>",
"      not",
"     </b>",
"     exceed 30 mg/dose; maximum: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Labor pain:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 30 mg once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 20 mg every 2-3 hours as needed; maximum total dose: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of normal dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Talwin&reg;: 30 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Talwin&reg;: 30 mg/mL (10 mL) [contains sodium bisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F208072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     SubQ route not advised due to tissue damage; rotate injection site for I.M., SubQ use; avoid intra-arterial injection",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F208078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Nafcillin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, butorphanol, chlorpromazine, cimetidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, hydromorphone, hydroxyzine, meperidine, methotrimeprazine, metoclopramide, morphine, prochlorperazine edisylate, promethazine, ranitidine, scopolamine, trimethobenzamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Glycopyrrolate, heparin, pentobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store injection at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not mix injection with barbiturates, precipitation will occur",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate to severe pain (FDA approved in adults); a sedative prior to surgery (FDA approved in ages &ge;1 year and adults); supplement to surgical anesthesia (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5978067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F208077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Circulatory depression, facial edema, flushing, hyper-/hypotension, shock, syncope, systemic vascular resistance increased, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, CNS depression, confusion, disorientation, dizziness, drowsiness, euphoria, excitement, hallucinations, headache, insomnia, irritability, lightheadedness, malaise, nightmares, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, erythema multiforme, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distress, anorexia, constipation, diarrhea, nausea, taste alteration, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), eosinophilia, WBCs decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (tissue damage and irritation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, miosis, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, respiratory depression (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentazocine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in seizure-prone patients, acute MI, patients undergoing biliary tract surgery, and patients with renal, hepatic, or respiratory dysfunction; decrease dosage in patients with decreased hepatic or renal function. Use with caution in ambulatory patients; pentazocine may cause CNS depression and dizziness, which may impair physical or mental abilities; patients must be cautioned against performing tasks which require mental alertness (eg, operating machinery or driving). Use with alcohol or other CNS depressants may increase CNS depressant effects; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentazocine is a potent opioid analgesic which may cause physical and psychological dependence; abrupt discontinuation after prolonged use may result in withdrawal symptoms or seizures; use with caution in patients with a history of prior opioid dependence or abuse. Pentazocine is also a mild opioid antagonist and may precipitate opiate withdrawal symptoms in patients who have been receiving opiates regularly. Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. Respiratory depression has been reported (rarely); use with caution in patients with respiratory depression, limited respiratory reserve, severe asthma, other obstructive respiratory conditions, or cyanosis; do not use if appropriate rescue respiratory therapy equipment is unavailable. May cause acute CNS manifestations such as hallucinations, disorientation, and confusion; most cases resolve within a few hours without intervention; monitor closely; use caution if drug is reintroduced after these effects subside; CNS effects may recur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe sclerosis of skin, subcutaneous tissue, and underlying muscle have occurred at injection site; avoid SubQ use unless absolutely necessary; rotate injection site to minimize risk. Injection may contain sodium bisulfite which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F208012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentazocine was not found to be teratogenic in animal studies. Pentazocine has been shown to cross the human placenta. Use should be avoided during labor and delivery of premature infants. Abstinence syndromes in the newborn have been reported after long-term use of pentazocine during pregnancy. Other adverse effects in the newborn have been reported following abuse of pentazocine during pregnancy; these effects may be due to pentazocine, other drugs abused, the mother's lifestyle, or a combination of all factors.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status; level of pain relief and sedation; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression; partial agonist antagonist",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., SubQ: Within 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Parenteral: 2-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Children 4-8 years (mean &plusmn; SD): V",
"     <sub>",
"      dss",
"     </sub>",
"     : 4 &plusmn; 1.2 L/kg (Hanunen, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via oxidative and glucuronide conjugation pathways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Increased half-life with decreased hepatic function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 8-12 hours (estimated; Osifo, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-8 years (mean &plusmn; SD): 3 &plusmn; 1.5 hours (Hanunen, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Small amounts excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/29/4564?source=see_link\">",
"      see \"Pentazocine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may be habit-forming; avoid abrupt discontinuation after prolonged use; will cause narcotic withdrawal symptoms in patients currently dependent on narcotics; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use only in patients who are not tolerant to or physically dependent upon narcotics",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A retrospective study assessed the use of pentazocine 0.5 mg/kg every 8 hours in neonates undergoing surgery; pentazocine use was associated with life-threatening morbidity and unacceptable high mortality due to persistent respiratory depression; the authors of the study recommend the use of alternative neonatal analgesics (Osifo, 2008).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hanunen K, Olkkola KT, Seppala T, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Pentazocine in Children,&rdquo;",
"      <i>",
"       Pharmacol Toxicol",
"      </i>",
"      , 1993, 73(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5382/abstract-text/8248007/pubmed\" id=\"8248007\" target=\"_blank\">",
"        8248007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osifo OD and Aghahowa SE, \"Hazards of Pentazocine for Neonatal Analgesia: A Single-Centre Experience Over 10 Years,\"",
"      <i>",
"       Ann Trop Paediatr",
"      </i>",
"      , 2008, 28(3):205-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5382/abstract-text/18727849/pubmed\" id=\"18727849\" target=\"_blank\">",
"        18727849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ray AD and Gupta M, &ldquo;Clinical Trial of Pentazocine as Analgesic in Pediatric Cases,&rdquo;",
"      <i>",
"       J Indian Med Assoc",
"      </i>",
"      , 1994, 92(3):77-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5382/abstract-text/ 8057003 /pubmed\" id=\" 8057003 \" target=\"_blank\">",
"        8057003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rita L, Seleny FL, and Levin RM, &ldquo;A Comparison of Pentazocine and Morphine for Pediatric Premedication,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1970, 49(3):377-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5382/abstract-text/5534413/pubmed\" id=\"5534413\" target=\"_blank\">",
"        5534413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waterworth TA, &ldquo;Pentazocine (Fortal) as Postoperative Analgesic in Children,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1974, 49(6):488-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5382/abstract-text/4604887/pubmed\" id=\"4604887\" target=\"_blank\">",
"        4604887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12692 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5382=[""].join("\n");
var outline_f5_16_5382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208028\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208029\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054792\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864283\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054785\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208001\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207985\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208072\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054797\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208078\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054788\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054796\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5978067\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208077\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054801\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054784\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054783\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299846\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207994\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207996\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208012\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054791\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054782\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054799\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054800\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054790\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054802\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12692|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=related_link\">",
"      Pentazocine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/29/4564?source=related_link\">",
"      Pentazocine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_16_5383="Epidermal basement membrane zone - EM";
var content_f5_16_5383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrastructural view of the epidermal basement membrane zone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marinkovich MP. Inherited epidermolysis bullosa. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, New York 2012. Copyright &copy; 2012 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5383=[""].join("\n");
var outline_f5_16_5383=null;
var title_f5_16_5384="Rivaroxaban: Drug information";
var content_f5_16_5384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rivaroxaban: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=see_link\">",
"    see \"Rivaroxaban: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13135512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13107816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xarelto&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6724104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xarelto&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6724108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Factor Xa Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6724168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Extremes of body weight (&lt;50 kg or &gt;120 kg) did not significantly influence rivaroxaban exposure (Kubitza, 2007). Clinical outcomes in postoperative thromboprophylaxis trials were also not affected by weight (range: 37-190 kg) (Turpie, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Deep vein thrombosis (DVT), pulmonary embolism (PE):",
"     </b>",
"     Oral: Initial: 15 mg twice daily with food for 3 weeks followed by 20 mg once daily with food.",
"     <b>",
"      Note:",
"     </b>",
"     The American College of Chest Physicians (ACCP) recommends anticoagulant treatment for 3 months in patients with provoked DVT or &ge;3 months with unprovoked DVT (duration depends on bleeding risk) (Guyatt, 2012). Canadian labeling recommends continuation of treatment for at least 3 months if first episode of provoked DVT (ie, secondary to transient risk factors) and for at least 6 months if first episode of unprovoked DVT. May continue treatment beyond the recommended treatment period in select patients to reduce the risk of recurrent DVT/PE.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Reduction in the risk of recurrent DVT/PE (in select patients):",
"     </b>",
"     Oral: 20 mg once daily with food; duration of treatment in the EINSTEIN-Extension Study was 6-12 months in addition to the initial treatment duration of 6-12 months (EINSTEIN Investigators, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):",
"     </b>",
"     Oral: 20 mg once daily with the evening meal.",
"     <b>",
"      Note:",
"     </b>",
"     The American Heart Association/American Stroke Association recommends rivaroxaban as a reasonable alternative to warfarin in patients who are at moderate-to-high risk of stroke (prior history of TIA, stroke, or systemic embolism or &ge;2 additional risk factors for stroke) (Furie, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion from warfarin: Discontinue warfarin and initiate rivaroxaban as soon as INR falls to &lt;3.0 (U.S. labeling) or &le;2.5 (Canadian labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion to warfarin:",
"     <b>",
"      Note:",
"     </b>",
"     Rivaroxaban affects INR; therefore, initial INR measurements after initiating warfarin may be unreliable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     U.S. labeling: Initiate warfarin and a parenteral anticoagulant 24 hours after discontinuation of rivaroxaban (other approaches to conversion may be acceptable).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Canadian labeling: Continue rivaroxaban concomitantly with warfarin until INR &ge;2.0 and then discontinue rivaroxaban.",
"     <b>",
"      Note:",
"     </b>",
"     Caution must be employed with this strategy given the lack of an antidote for rivaroxaban reversal. During concomitant therapy, measure INR daily at least 24 hours after previous rivaroxaban dose and just prior to the next scheduled rivaroxaban dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion from continuous infusion unfractionated heparin: Initiate rivaroxaban at the time of heparin discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion to continuous infusion unfractionated heparin: Initiate continuous infusion unfractionated heparin 24 hours after discontinuation of rivaroxaban",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion from anticoagulants (other than warfarin and continuous infusion unfractionated heparin): Discontinue current anticoagulant and initiate rivaroxaban &le;2 hours prior to the next regularly scheduled evening dose of the discontinued anticoagulant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion to other anticoagulants (other than warfarin): Initiate the anticoagulant 24 hours after discontinuation of rivaroxaban",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postoperative thromboprophylaxis:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Initiate therapy after hemostasis has been established, 6-10 hours postoperatively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Knee replacement: 10 mg once daily; recommended total duration of therapy: 12-14 days; ACCP recommendation: Minimum of 10-14 days; extended duration of up to 35 days suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hip replacement: 10 mg once daily; total duration of therapy: 35 days; ACCP recommendation: Minimum of 10-14 days; extended duration of up to 35 days suggested (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6724169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6724170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Clinical trials evaluating safety and efficacy utilized the Cockcroft-Gault formula with the use of actual body weight (data on file;  Janssen Pharmaceuticals Inc, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      DVT, PE, reduction of the risk of recurrent DVT/PE:",
"     </b>",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      DVT treatment:",
"     </b>",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 15 mg twice daily for 3 weeks then 15 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Nonvalvular atrial fibrillation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-50 mL/minute: 15 mg once daily with the evening meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     ESRD requiring hemodialysis: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 15 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Postoperative thromboprophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: No dosage adjustment necessary; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ESRD requiring hemodialysis: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6724171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild hepatic impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling. Limited data indicates pharmacokinetics and pharmacodynamic response were similar to healthy subjects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe hepatic impairment (Child-Pugh class B or C) and patients with any hepatic disease associated with coagulopathy: Avoid use.",
"     <b>",
"      Note:",
"     </b>",
"     The Canadian labeling contraindicates use in these patient populations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13107817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xarelto&reg;: 10 mg, 15 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13376301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6724172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer doses &ge;15 mg/day with food; dose of 10 mg/day may be administered without regard to meals. For patients who cannot swallow whole tablets, the 15 mg and 20 mg tablets (but",
"     <b>",
"      not",
"     </b>",
"     the 10 mg tablet) may be crushed and mixed with applesauce immediately prior to use; immediately follow administration with food.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For nasogastric/gastric feeding tube administration, the 15 mg and 20 mg tablets (but",
"     <b>",
"      not",
"     </b>",
"     the 10 mg tablet) may be crushed and mixed in 50 mL of water; administer the suspension within 4 hours of preparation and follow administration immediately with enteral feeding. Avoid administration distal to the stomach; a decrease in the AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     (29% and 56%, respectively) was observed when rivaroxaban was delivered to the proximal small intestine; further decreases may be seen with delivery to the distal small intestine or ascending colon.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Missed doses: Patients receiving 15 mg twice daily dosing who miss a dose should take a dose immediately to ensure 30 mg of rivaroxaban is administered per day (two 15 mg tablets may be taken together); resume therapy the following day as previously taken. Patients receiving once-daily dosing who miss a dose should take a dose as soon as possible on the same day; resume therapy the following day as previously taken.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6724109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postoperative thromboprophylaxis in patients who have undergone hip or knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce the risk of recurrent DVT and/or PE",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Postoperative thromboprophylaxis in patients who have undergone hip or knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of DVT without symptomatic PE",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14199109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6724118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (&le;6%), headache (3% to 5%), pyrexia (1% to 3%), fatigue (&le;3%), syncope (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (3%), pruritus (&le;2%), rash (2%), blister (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (&le;5%), constipation (&le;3%), abdominal pain (&le;2%), nausea (1% to 3%), dyspepsia (&le;2%), vomiting (&le;2%), oropharyngeal pain (&le;1%), toothache (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Hematuria (&le;4%), urinary tract infection (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Bleeding (atrial fibrillation: 21% [major: 6%]; DVT prophylaxis: 5% to 6% [major: &lt;1%]; DVT treatment: 6% to 10% [major: 1%]), thrombocytopenia (&lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or &lt;50% baseline: 3%), hematoma (&le;3%), anemia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Wound secretion (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Extremity pain (&le;5%), back pain (&le;4%), osteoarthritis (&le;2%), muscle spasm (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (4% to 10%), hemoptysis (&le;1%), sinusitis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alkaline phosphatase increased, allergic dermatitis, amylase increased, anaphylactic reaction, anaphylactic shock, anaphylaxis, angioedema, BUN increased, cholestasis, cytolytic hepatitis, creatinine increased, dysuria, ecchymosis, fatal bleeding, GI hemorrhage, hematoma (epidural/subdural), hemiparesis, hemoglobin decrease (&ge;2 g/dL), hemorrhage (cerebral/retroperitoneal), hypersensitivity, hypotension, intracranial bleeding, intraocular bleeding, jaundice, LDH increased, lipase increased, menorrhagia, pain, pulmonary hemorrhage (with and without bronchiectasis), retroperitoneal bleeding, Stevens-Johnson syndrome, tachycardia, thrombocythemia, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6724113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity to rivaroxaban or any component of the formulation; active pathological bleeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hepatic disease (including Child-Pugh classes B and C) associated with coagulopathy and clinically relevant bleeding risk; clinically significant active bleeding, including hemorrhagic manifestations and bleeding diathesis; lesions at increased risk of clinically significant bleeding (eg, hemorrhagic or ischemic cerebral infarction) within previous 6 months; spontaneous hemostasis impairment; concomitant systemic treatment with strong CYP3A4 and P-glycoprotein (P-gp) inhibitors; pregnancy; lactation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6724114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding: The most common complication is bleeding; major hemorrhages (eg, intracranial, GI, retinal, epidural hematoma, adrenal bleeding) have been reported. Certain patients are at increased risk of bleeding; risk factors include bacterial endocarditis, congenital or acquired bleeding disorders, vascular retinopathy, thrombocytopenia, recent puncture of large vessels or organ biopsy, stroke, intracerebral surgery, or other neuraxial procedure, severe uncontrolled hypertension, renal impairment, recent major surgery, recent major bleeding (intracranial, GI, intraocular, or pulmonary), concomitant use of drugs that affect hemostasis, and advanced age. Monitor for signs and symptoms of bleeding (weakness, dizziness, unexplained edema). Prompt clinical evaluation is warranted with any unexplained decrease in hemoglobin or blood pressure.",
"     <b>",
"      Note:",
"     </b>",
"     No specific antidote exists for rivaroxaban reversal; not dialyzable. Therapy for severe hemorrhage may include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC), or recombinant factor VIIa; however, efficacy has not been adequately evaluated in human clinical trials. Notably, the use of a four-factor PCC (Cofact&reg;, not available in the U.S.) has been shown to reverse the anticoagulant effect of rivaroxaban (Eerenberg, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Avoid use in patients with moderate-to-severe hepatic impairment (Child-Pugh classes B and C) or in patients with any hepatic disease associated with coagulopathy; use in this patient population is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute) when used for postoperative thromboprophylaxis, including patients receiving concomitant drug therapy that may increase rivaroxaban systemic exposure and those with deteriorating renal function. Monitor for any signs or symptoms of blood loss. Avoid use in severe renal impairment (DVT/PE, postoperative thromboprophylaxis: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute; nonvalvular atrial fibrillation: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute) since rivaroxaban exposure is expected to increase and is not recommended; discontinue use in patients who develop acute renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticoagulants and antiplatelet agents: Due to an increased risk of bleeding, avoid use with direct thrombin inhibitors (eg, bivalirudin), unfractionated heparin or heparin derivatives, low molecular weight heparins (eg, enoxaparin), aspirin, coumarin derivatives, and sulfinpyrazone. NSAIDs and other platelet aggregation inhibitors (eg, clopidogrel) should be used cautiously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP3A4/P-glycoprotein (P-gp) inducers: Avoid concomitant use with combined P-gp and strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin, St John's wort).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP3A4/P-gp inhibitors: Avoid concomitant use with combined P-gp and strong CYP3A4 inhibitors (eg, ketoconazole, indinavir/ritonavir, itraconazole, lopinavir/ritonavir, ritonavir, conivaptan); concurrent use is contraindicated in the Canadian labeling. In patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-50 mL/minute), concomitant use of rivaroxaban with combined P-gp and weak or moderate CYP3A4 inhibitors should only occur if the potential benefit outweighs the risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution in the elderly. Elderly patients exhibit higher rivaroxaban concentrations compared to younger patients due primarily to reduced clearance. Overall, efficacy of rivaroxaban in the elderly (age &ge;65 years) was similar to that of patients &lt;65 years of age. Both thrombotic and bleeding events were higher in the elderly; however, the risk to benefit profile was favorable among all age groups.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactose intolerance: May contains lactose; use is not recommended in patients with lactose or galactose intolerance (eg, Lapp lactase deficiency, glucose-galactose malabsorption).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Discontinuation of therapy:",
"     <b>",
"      [U.S. Boxed Warning]: An increased risk of stroke was noted upon discontinuation of rivaroxaban in clinical trials of patients with atrial fibrillation; consider the addition of alternative anticoagulant therapy when discontinuing rivaroxaban for reasons other than bleeding.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuraxial anesthesia:",
"     <b>",
"      [U.S. Boxed Warning]: Spinal or epidural hematomas, including subsequent paralysis, may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients who are anticoagulated;",
"     </b>",
"     the risk is increased with concomitant administration of other drugs that affect hemostasis (eg, NSAIDS, platelet inhibitors, other anticoagulants), in patients with a history of traumatic or repeated epidural or spinal punctures, or a history of spinal deformity or surgery. In patients who receive both rivaroxaban and neuraxial anesthesia, avoid removal of epidural catheter for at least 18 hours following last rivaroxaban dose; avoid rivaroxaban administration for at least 6 hours following epidural catheter removal; if traumatic puncture occurs, avoid rivaroxaban administration for at least 24 hours. Monitor for signs of neurologic impairment (eg, numbness/weakness of legs, bowel/bladder dysfunction); prompt diagnosis and treatment are necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery and invasive procedures: Discontinue rivaroxaban at least 24 hours prior to procedure; risk of bleeding should be weighed against the urgency of the procedure; reinitiate rivaroxaban when adequate hemostasis has been achieved unless oral therapy cannot be administered then consider administration of a parenteral anticoagulant.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6754126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Rivaroxaban. Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azithromycin (Systemic): May increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6724122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may increase levels/effects of rivaroxaban; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid concomitant use of St John's wort if possible (may decrease levels/effects of rivaroxaban; use with caution and consider dosage adjustment of rivaroxaban if concomitant use cannot be avoided).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13056049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6724110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Data are insufficient to evaluate the safety of oral factor Xa inhibitors during pregnancy; use during pregnancy should be avoided (Guyatt, 2012). Use may increase the risk of pregnancy related hemorrhage. Clinicians should note that the anticoagulant effect cannot be easily monitored or readily reversed. Prompt clinical evaluation is warranted with any unexplained decrease in hemoglobin, hematocrit or blood pressure, or fetal distress. Pregnancy planning should be discussed if use is needed in women of reproductive potential. Use during pregnancy is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6724112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13940522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if rivaroxaban is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother; use of alternative anticoagulants is preferred. Use in breast-feeding mothers is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xarelto Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $300.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (90): $901.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $901.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6724174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine monitoring of coagulation tests not required; in major clinical trials, monitoring of coagulation tests (eg, aPTT, PT/INR, or antifactor Xa activity) did not occur. Prothrombin time (PT) or antifactor Xa activity may be used to detect presence of rivaroxaban (neither is intended to be used for dosage adjustment). However, variability exists among PT assays and even more so when converted to INR. Therefore, antifactor Xa activity measurement is the preferred test (Asmis, 2012; Barrett, 2010; Kubitza, 2005). A therapeutic range has not been defined, and dosage adjustment based on results has not been established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     CBC with differential, renal function, hepatic function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Xarelto (AR, AU, BB, BE, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, KP, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, SE, SG, SR, SV, TH, TT, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6724165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa (FXa) in both the intrinsic and extrinsic coagulation pathways. FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, factor II and phospholipid, catalyzes the conversion of prothrombin to thrombin. Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6724145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : ~50 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~92% to 95% (primarily to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4/5 and CYP2J2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Absolute bioavailability: 10 mg dose: ~80% to 100%; 20 mg dose: ~66% (fasting; increased with food)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: 5-9 hours; Elderly: 11-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (66% primarily via active tubular secretion [36% as unchanged drug; 30% as inactive metabolites]); feces (28% [7% as unchanged drug; 21% as inactive metabolites])",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abrams PJ and Emerson CR, &ldquo;Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(2):167-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/19170587/pubmed\" id=\"19170587\" target=\"_blank\">",
"        19170587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Asmis LM, Alberio L, Angelillo-Scherrer A, et al, &ldquo;Rivaroxaban: Quantification by Anti-FXa Assay and Influence on Coagulation Tests: A Study in 9 Swiss Laboratories,\"",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 2012, 129(4):492-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/21840043/pubmed\" id=\"21840043\" target=\"_blank\">",
"        21840043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrett YC, Wang Z, Frost C, et al, &ldquo;Clinical Laboratory Measurement of Direct Factor Xa Inhibitors: Anti-Xa Assay is Preferable to Prothrombin Time Assay,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2010, 104(6):1263-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/20978714/pubmed\" id=\"20978714\" target=\"_blank\">",
"        20978714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al, &ldquo;Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(14):1573-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/21900088/pubmed\" id=\"21900088\" target=\"_blank\">",
"        21900088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al, &ldquo;Oral Rivaroxaban for Symptomatic Venous Thromboembolism,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(26):2499-510.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/21128814/pubmed\" id=\"21128814\" target=\"_blank\">",
"        21128814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      EINSTEIN-PE Investigators, &ldquo;Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2012, 366(14):1287-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/22449293/pubmed\" id=\"22449293\" target=\"_blank\">",
"        22449293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson BI, Borris LC, Friedman RJ, et al, &ldquo;Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Hip Arthroplasty,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(26):2765-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/18579811/pubmed\" id=\"18579811\" target=\"_blank\">",
"        18579811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furie KL, Goldstein LB, Albers GW, et al, &ldquo;Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals from the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2012, 43(12):3442-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/22858728/pubmed\" id=\"22858728\" target=\"_blank\">",
"        22858728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gulseth MP, Michaud J, Nutescu EA, &ldquo;Rivaroxaban: An Oral Direct Inhibitor of Factor Xa,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2008, 65(16): 1520-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/18693206/pubmed\" id=\"18693206\" target=\"_blank\">",
"        18693206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kubitza D, Becka M, Voith B, et al, &ldquo;Safety, Pharmacodynamics, and Pharmacokinetics of Single Doses of BAY 59-7939, an Oral, Direct Factor Xa Inhibitor,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005, 78(4):412-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/16198660/pubmed\" id=\"16198660\" target=\"_blank\">",
"        16198660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kubitza D, Becka M, Wensing G, et al, &ldquo;Safety, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 -- An Oral, Direct Factor Xa Inhibitor -- After Multiple Dosing in Healthy Male Subjects,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2005, 61(12):873-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/16328318/pubmed\" id=\"16328318\" target=\"_blank\">",
"        16328318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kubitza D, Becka M, Zuehlsdorf M, et al, &ldquo;Body Weight has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban  (BAY 59-7939) in Healthy Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007, 47(2):218-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/17244773/pubmed\" id=\"17244773\" target=\"_blank\">",
"        17244773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lassen MR, Ageno W, Borris LC, et al, &ldquo;Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(26):2776-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/18579812/pubmed\" id=\"18579812\" target=\"_blank\">",
"        18579812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marlu R, Hodaj E, Paris A, et al, &ldquo;Effect of Non-Specific Reversal Agents on Anticoagulant Activity of Dabigatran and Rivaroxaban,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2012, 108(2):217-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/22627883/pubmed\" id=\"22627883\" target=\"_blank\">",
"        22627883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mega JL, Braunwald E, Wiviott SD, et al, &ldquo;Rivaroxaban in Patients With a Recent Acute Coronary Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(1):9-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/22077192/pubmed\" id=\"22077192\" target=\"_blank\">",
"        22077192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel MR, Mahaffey KW, Garg J, et al, &ldquo;Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(10):883-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/21830957/pubmed\" id=\"21830957\" target=\"_blank\">",
"        21830957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turpie AG, &ldquo;New Oral Anticoagulants in Atrial Fibrillation,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2007, 29(2):155-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/18096568/pubmed\" id=\"18096568\" target=\"_blank\">",
"        18096568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turpie AG, Lassen MR, Eriksson BI, et al, &ldquo;Rivaroxaban for the Prevention of Venous Thromboembolism After Hip or Knee Arthroplasty. Pooled Analysis of Four Studies,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2011, 105(3):444-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/16/5384/abstract-text/21136019/pubmed\" id=\"21136019\" target=\"_blank\">",
"        21136019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9498 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5384=[""].join("\n");
var outline_f5_16_5384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135512\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13107816\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724104\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724108\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724168\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724169\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724170\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724171\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13107817\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376301\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724172\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724109\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14199109\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724118\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724113\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724114\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838498\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6754126\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724122\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13056049\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724110\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724112\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13940522\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321848\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724174\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961940\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724165\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6724145\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9498|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=related_link\">",
"      Rivaroxaban: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_16_5385="Acute mastoiditis in children: Clinical features and diagnosis";
var content_f5_16_5385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute mastoiditis in children: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/16/5385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5385/contributors\">",
"     Ellen R Wald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/16/5385/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5385/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5385/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/16/5385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5385/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/16/5385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mastoiditis is the most common suppurative complication of acute otitis media (AOM) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1\">",
"     1",
"    </a>",
"    ]. In many cases, it may be the first evidence of AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of acute mastoiditis in children will be reviewed here. The treatment, outcome, and prevention of acute mastoiditis, as well as issues related to AOM, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16471?source=see_link\">",
"       \"Acute mastoiditis in children: Treatment and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"       \"Acute otitis media in children: Diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"       \"Acute otitis media in children: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link\">",
"       \"Acute otitis media in children: Prevention of recurrence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mastoiditis",
"      </strong>",
"      is a suppurative infection of the mastoid air cells (",
"      <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Acute mastoiditis",
"      </strong>",
"      is a suppurative infection of the mastoid air cells with symptoms of less than one month's duration [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute mastoiditis is subdivided according to the pathologic stage [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Acute mastoiditis with periosteitis",
"      </strong>",
"      (also called incipient mastoiditis) is defined by the presence of purulent material in the mastoid cavities.",
"     </li>",
"     <li>",
"      <strong>",
"       Coalescent mastoiditis",
"      </strong>",
"      (also called \"acute mastoid osteitis\") is defined by destruction of the thin bony septae between air cells. It may be followed by the formation of abscess cavities and the dissection of pus into adjacent areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Masked mastoiditis",
"      </strong>",
"      (also called subacute mastoiditis) refers to low-grade but persistent infection in the middle ear and mastoid with destruction of the bony septae between air cells [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/4\">",
"       4",
"      </a>",
"      ]. It occurs in patients with persistent middle-ear effusion or recurrent episodes of acute otitis media (AOM) without sufficient antimicrobial therapy.",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic mastoiditis",
"      </strong>",
"      is a suppurative infection of the mastoid air cells of long-standing duration (months to years) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74651140\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mastoid is a division of the temporal bone, which forms portions of the side and base of the skull [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/5\">",
"     5",
"    </a>",
"    ]. At birth, the mastoid consists of a single cell, the antrum, which is connected to the middle ear by a narrow channel, the aditus ad antrum (",
"    <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1\">",
"     1",
"    </a>",
"    ]. As the child grows, the mastoid bone becomes pneumatized, resulting in a series of interconnected air cells, lined by modified respiratory epithelium.",
"   </p>",
"   <p>",
"    The relationship between the mastoid, eustachian tube, and middle ear is a central feature of the pathogenesis of mastoiditis. The proximity of the mastoid to the facial nerve, semicircular canals, sternocleidomastoid muscle, jugular vein, internal carotid artery, sigmoid sinus, brain, and meninges is crucial to the development of complications (",
"    <a class=\"graphic graphic_figure graphicRef83204 \" href=\"UTD.htm?27/44/28358\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mastoiditis is a complication of acute otitis media (AOM). The middle ear cavity and mastoid air spaces are continuous [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3\">",
"     3",
"    </a>",
"    ]. During an episode of AOM, the mucosa lining the middle ear, and often that lining the mastoid, becomes inflamed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1\">",
"     1",
"    </a>",
"    ]. In almost all cases, the inflammation resolves as the AOM improves. When inflammation persists, purulent material accumulates within the mastoid cavities (acute mastoiditis with periosteitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. As the pressure increases, the thin bony septae between air cells may be destroyed (coalescent mastoiditis) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Coalescent mastoiditis may be followed by the formation of abscess cavities and ultimately by the dissection of pus into adjacent areas. The direction of dissection determines the clinical presentation and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Through the aditus ad antrum (",
"      <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"       figure 1",
"      </a>",
"      ) &ndash; Resolution (if the eustachian tube is patent) or tympanic membrane perforation with otorrhea (if the eustachian tube is obstructed)",
"     </li>",
"     <li>",
"      Through the lateral cortex of the mastoid &ndash; Subperiosteal abscess (usually above the ear in infants and children &lt;2 years and behind the ear in older children)",
"     </li>",
"     <li>",
"      Inferiorly, through the medial aspect of the mastoid tip (rare) &ndash; Bezold abscess (an abscess in the neck beneath the attachment of the sternocleidomastoid and digastric muscles)",
"     </li>",
"     <li>",
"      Medially to the petrous air cells &ndash; Petrositis; petrositis may be associated with facial nerve palsy or Gradenigo syndrome (otitis media, eye pain, ipsilateral abducens [sixth cranial nerve] palsy, and possibly other cranial nerve deficits)",
"     </li>",
"     <li>",
"      Posteriorly to the occipital bone &ndash; Osteomyelitis of the calvaria (Citelli abscess)",
"     </li>",
"     <li>",
"      Through the oval or round window into the bony labyrinth &ndash; Suppurative labyrinthitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=see_link&amp;anchor=H3#H3\">",
"       \"Vestibular neuritis\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toward the inner cortical bone &ndash; Suppurative central nervous system complications (eg, meningitis; venous sinus thrombosis; epidural, subdural, temporal lobe, or cerebellar abscess) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacterial species most often isolated from children with acute mastoiditis are",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    (including multiply resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , particularly serotype 19A),",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    , and",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/9-26\">",
"     9-26",
"    </a>",
"    ]. Although",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    has been isolated frequently in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/10,23\">",
"     10,23",
"    </a>",
"    ], exaggerated rates of recovery may occur if the sample for culture is taken from the external canal in patients with otorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    should only be considered as a potential pathogen in children with acute mastoiditis who have a history of recurrent acute otitis media and recent antibiotic use, especially if there is a perforation of the tympanic membrane or if the process is potentially non-acute [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, precise delineation of the microbiology of acute mastoiditis is difficult. Most of the case series describing the microbiology are retrospective and specimens for microbiology were not obtained from all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/9-24\">",
"     9-24",
"    </a>",
"    ]. In addition, antibiotic therapy, which may affect the yield of cultures, frequently is administered for acute otitis media before symptoms or signs of mastoiditis are present [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/10,19,20,23\">",
"     10,19,20,23",
"    </a>",
"    ].",
"    <em>",
"    </em>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of acute mastoiditis parallels that of acute otitis media (AOM), with the highest incidence in children younger than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ]. A history of recurrent AOM is a risk factor for acute mastoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Reports describing the incidence of acute mastoiditis during and after the 1990s disagree about whether the incidence is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/11,12,28,30-34\">",
"     11,12,28,30-34",
"    </a>",
"    ]. Few of these reports are population-based; accordingly, it is uncertain whether changes in the incidence in cases of mastoiditis reflect actual increases, a change in referral patterns, or other epiphenomena (eg, antibiotic prescribing patterns, effects of the pneumococcal conjugate vaccine, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of mastoiditis ranges from a lack of symptoms with spontaneous resolution to progressive disease with life-threatening complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The presentation is determined by age, stage of infection, and the path of drainage of purulent material [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,7,26\">",
"     1,7,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute mastoiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic features of acute coalescent mastoiditis include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,35,36\">",
"     1,35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ear pain, which may manifest as irritability in young children",
"     </li>",
"     <li>",
"      Postauricular tenderness, erythema, swelling (with loss of the postauricular crease), fluctuance (or draining fistula), or mass (",
"      <a class=\"graphic graphic_picture graphicRef70910 \" href=\"UTD.htm?23/27/23999\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Displacement of the auricle (usually downward and outward in children younger than two years (",
"      <a class=\"graphic graphic_picture graphicRef83205 \" href=\"UTD.htm?29/29/30174\">",
"       picture 2",
"      </a>",
"      ) and upward and outward in children older than two years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a systematic review of the diagnostic criteria for acute mastoiditis (65 studies published between 1980 and 2007), ear pain was present in an average of 67 percent of patients; the two other characteristic findings were present in an average of 79 to 85 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/36\">",
"     36",
"    </a>",
"    ]. Additional signs included fever (76 percent); sagging or edema (narrowing) of the external auditory canal (71 percent); tympanic membrane perforation (37 percent); and otorrhea (50 percent). Approximately 40 percent of children had a history of previous otitis media, and 50 percent had received antibiotics before admission.",
"   </p>",
"   <p>",
"    Examination of the tympanic membrane usually reveals abnormal findings (eg, bulging, middle-ear effusion, perforation). On average, 80 percent of children in the systematic review had acute otitis media (AOM (",
"    <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"     picture 3",
"    </a>",
"    )) at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the absence of AOM (current or recent) does not exclude a diagnosis of acute mastoiditis. Middle-ear effusion may be absent if there is obstruction of the aditus ad antrum with a patent eustachian tube (",
"    <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Fever is a nonspecific symptom but is sensitive and may be predictive of complications or the need for surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/5,14,36,37\">",
"     5,14,36,37",
"    </a>",
"    ]. High-spiking \"picket-fence\" fevers may be indicative of sigmoid sinus thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/38\">",
"     38",
"    </a>",
"    ]. Other systemic symptoms and signs may include lethargy, malaise, irritability, poor feeding, or diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Masked mastoiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of masked (subacute) mastoiditis include fever, cough, ear pain, and tympanic membrane findings compatible with AOM (",
"    <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"     picture 3",
"    </a>",
"    ). Masked mastoiditis occasionally presents with an extracranial or intracranial complication without signs of AOM or mastoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Masked mastoiditis should be considered in children with AOM that is not responding to antibiotics and in children with signs of intracranial infection without another focus of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Otoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of mastoiditis are related to the spread of infection or inflammation from the middle ear or mastoid to contiguous structures. In some cases, the complication (eg, cranial nerve palsy) is the presenting complaint.",
"   </p>",
"   <p>",
"    In most case series, the rate of complications is approximately 10 to 20 percent (range 7 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/2,9,10,14,15,25,26,29,36\">",
"     2,9,10,14,15,25,26,29,36",
"    </a>",
"    ]. In a multicenter study,",
"    <em>",
"     S. pyogenes",
"    </em>",
"    was associated with the highest rate of complications at presentation (50 percent) and",
"    <em>",
"     S. aureus",
"    </em>",
"    with the highest rate of complications during hospitalization (31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extracranial complications of acute mastoiditis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subperiosteal abscess &ndash; Signs of subperiosteal abscess include erythema, fluctuance, and a tender mass overlying the mastoid bone (",
"      <a class=\"graphic graphic_picture graphicRef70910 \" href=\"UTD.htm?23/27/23999\">",
"       picture 1",
"      </a>",
"      ). In a systematic review of 35 studies, subperiosteal abscess occurred in an average of 58 percent of cases of acute mastoiditis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Facial nerve palsy &ndash; Facial nerve palsy can result from infection or inflammatory compression of the facial nerve as it traverses the narrow canal in the petrous portion of the temporal bone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=see_link\">",
"       \"Facial nerve palsy in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hearing loss &ndash; Acute mastoiditis may result in transient or permanent hearing loss secondary to middle-ear effusion, damage to the ossicles, or suppurative labyrinthitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Labyrinthitis &ndash; Inflammation or infection of the bony labyrinth may cause serous or suppurative labyrinthitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3\">",
"       3",
"      </a>",
"      ]. Clinical features of labyrinthitis include tinnitus, hearing loss, nausea, vomiting, dizziness, vertigo, and nystagmus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=see_link&amp;anchor=H3#H3\">",
"       \"Vestibular neuritis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteomyelitis &ndash; Infection in the mastoid may spread to other parts of the skull, resulting in osteomyelitis. Osteomyelitis of the petrous bone (petrositis) may be associated with facial nerve palsy or Gradenigo syndrome (ie, otorrhea, retroorbital pain, ipsilateral abducens [sixth cranial nerve] palsy, and possibly other cranial nerve deficits). Osteomyelitis of the calvaria is known as Citelli abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bezold abscess &ndash; A Bezold abscess is a neck abscess located beneath the sternocleidomastoid and digastric muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Clinical features of Bezold abscess include swelling and tenderness below the mastoid process and under the sternocleidomastoid muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intracranial complications of mastoiditis, which are discussed separately, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Temporal lobe or cerebellar abscess (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epidural or subdural abscess (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"       \"Epidural abscess\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Venous sinus thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=see_link\">",
"       \"Septic dural sinus thrombosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a systematic review of 42 studies, intracranial complications occurred in a mean of 17 percent of cases of acute mastoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H138024055\">",
"    <span class=\"h1\">",
"     LABORATORY FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral white blood cell count in children with acute mastoiditis may be normal or elevated, often with a left shift [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. The erythrocyte sedimentation rate or C-reactive protein also may be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These laboratory findings are nonspecific. They are not helpful in making the diagnosis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172812\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74653225\">",
"    <span class=\"h2\">",
"     Indications for imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the temporal bone is not necessary to make the diagnosis of acute mastoiditis in children with characteristic clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/39\">",
"     39",
"    </a>",
"    ]. However, it may be necessary to confirm the diagnosis in children without characteristic findings (eg, persistent ear pain or drainage without postauricular findings); determine the stage (acute mastoiditis with periostitis versus coalescent mastoiditis), which affects management; or evaluate suspected complications.",
"   </p>",
"   <p>",
"    Indications for imaging in children with mastoiditis or suspected mastoiditis may include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/2,3,5,15,40,41\">",
"     2,3,5,15,40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical findings suggestive of extracranial complications (eg, postauricular mass, neck mass, cranial nerve deficits, retroorbital pain, hearing loss, tinnitus, vertigo, nystagmus) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Clinical findings suggestive of intracranial complications (eg, meningeal signs, cranial nerve deficits, focal neurologic findings, altered level of consciousness) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Severe illness or toxic appearance",
"     </li>",
"     <li>",
"      Acute otitis media (AOM) that is not responding to antibiotics (a possible indication of masked mastoiditis) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Masked mastoiditis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93287728\">",
"    <span class=\"h2\">",
"     Imaging modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;When imaging is indicated, changes in the temporal bone are best visualized with contrast-enhanced computed tomography (CT). Specific findings that are helpful include an occult abscess, dehiscence of the mastoid cortex or coalescence of the air cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/5\">",
"     5",
"    </a>",
"    ]. Plain radiographs may be performed if CT is not available, but there are reports of cases of acute, and even complicated, mastoiditis in which plain radiographs were normal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Cranial CT with intravenous contrast or cranial magnetic resonance imaging (MRI) with gadolinium is recommended in patients with suspected intracranial complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/8\">",
"     8",
"    </a>",
"    ]. These studies may confirm the diagnosis and delineate the extent of suspected disease. MRI with gadolinium has greater sensitivity than CT for detection of extraaxial fluid collections and associated vascular problems [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/40,44\">",
"     40,44",
"    </a>",
"    ]. (See &nbsp;above and &nbsp;above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93287721\">",
"    <span class=\"h2\">",
"     Findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT findings in children with acute mastoiditis include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,3,5,25,45\">",
"     1,3,5,25,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clouding of the middle ear and mastoid; this is a nonspecific finding that occurs early in the course; it is often seen in children with acute otitis media without mastoiditis",
"     </li>",
"     <li>",
"      Loss of definition of the bony septae that define the mastoid air cells (coalescent mastoiditis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83573 \" href=\"UTD.htm?5/4/5185\">",
"       image 1",
"      </a>",
"      )); this finding is diagnostic of mastoiditis",
"     </li>",
"     <li>",
"      Destruction or irregularity of the mastoid cortex (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83574 \" href=\"UTD.htm?34/62/35811\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Periosteal thickening, disruption of the periosteum, subperiosteal abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plain radiographic findings of acute mastoiditis are similar to CT findings: clouding of the mastoid or coalescence of the mastoid air cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H613782863\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute mastoiditis is usually made clinically in children with characteristic findings. The criteria that are used most frequently to make the diagnosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3,36,46\">",
"     3,36,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Otalgia",
"     </li>",
"     <li>",
"      Postauricular erythema, tenderness, swelling, fluctuance, or mass (",
"      <a class=\"graphic graphic_picture graphicRef70910 \" href=\"UTD.htm?23/27/23999\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Displacement of the auricle (down and out in children &lt;2 years (",
"      <a class=\"graphic graphic_picture graphicRef83205 \" href=\"UTD.htm?29/29/30174\">",
"       picture 2",
"      </a>",
"      ); up and out in children &ge;2 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tympanic membrane findings consistent with acute otitis media (eg, bulging, marked erythema (",
"    <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"     picture 3",
"    </a>",
"    ) or acute perforation with purulent otorrhea in the absence of otitis externa) often are present. A normal-appearing tympanic membrane usually (but not invariably) excludes mastoiditis (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below). In a systematic review of diagnostic features of acute mastoiditis, the characteristic postauricular findings, displacement of the auricle, and AOM were present in 79 to 85 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Acute mastoiditis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H138024437\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is not necessary to make the diagnosis of acute mastoiditis in children with characteristic clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/39\">",
"     39",
"    </a>",
"    ]. However, it may be necessary to confirm the diagnosis in children without characteristic findings (eg, persistent ear pain or drainage without postauricular findings); determine the stage (acute mastoiditis with periostitis versus coalescent mastoiditis), which affects management; or evaluate suspected complications. (See",
"    <a class=\"local\" href=\"#H74653225\">",
"     'Indications for imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When imaging is necessary, computed tomography (CT) of the temporal bone is preferred to plain radiographs. The CT should include the entire cranium and intravenous contrast should be administered if intracranial complications are suspected. (See",
"    <a class=\"local\" href=\"#H93287728\">",
"     'Imaging modality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    CT findings characteristic of coalescent mastoiditis include loss of definition of the bony septae between the mastoid air cells (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83573 \" href=\"UTD.htm?5/4/5185\">",
"     image 1",
"    </a>",
"    ); destruction or irregularity of the mastoid cortex (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83574 \" href=\"UTD.htm?34/62/35811\">",
"     image 2",
"    </a>",
"    ); or periosteal thickening, disruption of the periosteum, or subperiosteal abscess. Mastoiditis can be excluded by the absence of mastoid opacification [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H93287721\">",
"     'Findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Microbiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of obtaining clinical specimens for microbiology cannot be overemphasized. Results from cultures and susceptibility testing are crucial in guiding therapy given the variety of microorganisms that can cause acute mastoiditis (eg,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     S. pyogenes",
"    </em>",
"    , and",
"    <em>",
"     S. aureus",
"    </em>",
"    ) and the potential for antibiotic resistance among isolates of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Microbiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16471?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute mastoiditis in children: Treatment and prevention\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following microbiologic studies be obtained from children with mastoiditis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Middle ear specimens &ndash; Middle ear drainage (eg, tympanocentesis, myringotomy) is indicated in the treatment of acute mastoiditis and should be performed even if there is a subperiosteal abscess (to increase the possibility of recovering an organism). Tympanocentesis can be performed by anyone who is skilled in the procedure. Middle ear specimens generally should be obtained before antimicrobial therapy is administered. However, if consultation is necessary for middle ear drainage, antimicrobial therapy should not be delayed for more than several hours.",
"      <br/>",
"      <br/>",
"      Middle ear specimens should be sent for Gram stain, aerobic and anaerobic culture, and antimicrobial susceptibility testing. Clinical specimens for microbiology should be obtained from the middle ear by tympanocentesis through an intact eardrum or by aspiration through a tympanostomy tube or perforation after sterilization of the surrounding structures. Cultures obtained from the external canal without sterilization may be contaminated with",
"      <em>",
"       P. aeruginosa",
"      </em>",
"      or",
"      <em>",
"       S. aureus",
"      </em>",
"      .",
"     </li>",
"     <li>",
"      Subperiosteal abscess &ndash; If a subperiosteal abscess is present, samples of subperiosteal abscess fluid should be sent for Gram stain, aerobic and anaerobic culture, and antimicrobial susceptibility testing. Subperiosteal abscess should be percutaneously aspirated, particularly if definitive surgery will be delayed.",
"     </li>",
"     <li>",
"      Cerebrospinal fluid &ndash; Cerebrospinal fluid specimens for culture and susceptibility testing should be obtained in children with symptoms or signs of meningeal irritation (eg, stiff neck, headache). Computed tomography should be obtained before lumbar puncture in children with papilledema or findings consistent with intracranial extension (eg, cranial nerve palsy) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood cultures &ndash; Blood cultures rarely are positive but aerobic and anaerobic cultures should be obtained if the patient&rsquo;s temperature is &ge;39&deg;C (102.2&deg;F).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of acute mastoiditis includes other causes of postauricular inflammation or swelling (",
"    <a class=\"graphic graphic_table graphicRef83715 \" href=\"UTD.htm?3/49/3868\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/1,3,8\">",
"     1,3,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphadenopathy &ndash; Postauricular lymphadenopathy (eg, from a scalp infection) may cause postauricular swelling. In contrast to the poorly circumscribed and immobile postauricular mass in acute mastoiditis (",
"      <a class=\"graphic graphic_picture graphicRef70910 \" href=\"UTD.htm?23/27/23999\">",
"       picture 1",
"      </a>",
"      ), lymphadenopathy usually is well circumscribed and freely mobile (",
"      <a class=\"graphic graphic_picture graphicRef53334 \" href=\"UTD.htm?40/34/41505\">",
"       picture 4",
"      </a>",
"      ). Additional features that may distinguish posterior lymphadenopathy from mastoiditis include lack of displacement of the auricle, preservation of the postauricular crease, and normal-appearing tympanic membrane.",
"     </li>",
"     <li>",
"      Periauricular cellulitis &ndash; Periauricular cellulitis (",
"      <a class=\"graphic graphic_picture graphicRef58541 \" href=\"UTD.htm?9/10/9376\">",
"       picture 5",
"      </a>",
"      ) (eg, secondary to severe otitis externa) may be distinguished from mastoiditis by the normal appearance of the tympanic membrane.",
"     </li>",
"     <li>",
"      Perichondritis of the auricle &ndash; Perichondritis of the auricle is characterized by swelling and erythema of the outer ear (",
"      <a class=\"graphic graphic_picture graphicRef67879 \" href=\"UTD.htm?30/46/31457\">",
"       picture 6",
"      </a>",
"      ) and may spread to the periosteum of the postauricular area. In contrast to acute mastoiditis, the postauricular crease is preserved, and the tympanic membrane appears normal.",
"     </li>",
"     <li>",
"      Mumps &ndash; Mumps may cause parotid swelling (",
"      <a class=\"graphic graphic_picture graphicRef53503 \" href=\"UTD.htm?33/38/34415\">",
"       picture 7",
"      </a>",
"      ), which pushes the earlobe upward and outward. However, the swelling is over the parotid gland, rather than the mastoid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology, clinical manifestations, diagnosis and management of mumps\", section on 'Parotitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tumor &ndash; Benign and malignant tumors of the mastoid bone (eg, aneurysmal bone cyst, acute lymphocytic leukemia, Langerhans cell histiocytosis) may have clinical features suggestive of mastoiditis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/47\">",
"       47",
"      </a>",
"      ]. The tympanic membrane examination usually is normal in children with such tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H27#H27\">",
"       \"Overview of benign bone tumors in children and adolescents\", section on 'Aneurysmal bone cyst'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Early signs and symptoms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648804#H452648804\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87140852\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunologic evaluation may be warranted in children with recurrent episodes of acute otitis media leading to mastoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5385/abstract/3,48\">",
"     3,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the child with recurrent infections\", section on 'Infection history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute mastoiditis is a complication of acute otitis media (AOM) in which purulent material accumulates within the mastoid cavities. As the pressure increases, the bony septae between the mastoid air cells may be destroyed (coalescent mastoiditis), abscess cavities may form, and the purulent material may dissect into adjacent areas. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The bacterial species most often implicated as the cause of acute mastoiditis are",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      ,",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      , and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical spectrum of mastoiditis ranges from a lack of symptoms with spontaneous resolution to progressive disease with life-threatening complications. Characteristic features of coalescent mastoiditis include postauricular abnormalities (tenderness, erythema, swelling, fluctuance, mass (",
"      <a class=\"graphic graphic_picture graphicRef70910 \" href=\"UTD.htm?23/27/23999\">",
"       picture 1",
"      </a>",
"      )) and protrusion of the auricle (",
"      <a class=\"graphic graphic_picture graphicRef83205 \" href=\"UTD.htm?29/29/30174\">",
"       picture 2",
"      </a>",
"      ); most patients also have fever and ear pain. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute mastoiditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Masked (subacute) mastoiditis should be considered in children with AOM that is not responding to antibiotics and in children with signs of intracranial disease without another focus of infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Masked mastoiditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of mastoiditis are related to the spread of infection or inflammation from the middle ear or mastoid to contiguous structures (",
"      <a class=\"graphic graphic_figure graphicRef83204 \" href=\"UTD.htm?27/44/28358\">",
"       figure 2",
"      </a>",
"      ). They include subperiosteal abscess, facial nerve palsy, hearing loss, labyrinthitis, osteomyelitis, neck abscess, meningitis, temporal lobe or cerebellar abscess, epidural empyema, subdural empyema, and venous sinus thrombosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute coalescent mastoiditis is usually made clinically in children with characteristic examination findings (fever; ear pain; postauricular erythema, tenderness, swelling; displacement of the auricle (",
"      <a class=\"graphic graphic_picture graphicRef83205 \" href=\"UTD.htm?29/29/30174\">",
"       picture 2",
"      </a>",
"      )). Imaging may be necessary to confirm the diagnosis, determine the stage and extent of infection, or evaluate suspected complications. (See",
"      <a class=\"local\" href=\"#H613782863\">",
"       'Clinical diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35172812\">",
"       'Radiographic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Results from cultures and susceptibility testing are crucial in guiding therapy. Specimens from the middle ear",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abscesses that are obtained through aspiration or surgical drainage should be submitted for Gram stain, aerobic and anaerobic cultures, and antimicrobial susceptibility testing. Cerebrospinal fluid specimens for culture and susceptibility testing should be obtained in children with symptoms or signs of meningeal irritation. Blood cultures are rarely positive, but can help in determining the etiology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16471?source=see_link&amp;anchor=H8#H8\">",
"       \"Acute mastoiditis in children: Treatment and prevention\", section on 'Antimicrobial therapy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H18\">",
"       'Microbiologic studies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H29#H29\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis of acute mastoiditis includes other causes of postauricular inflammation or swelling (",
"      <a class=\"graphic graphic_table graphicRef83715 \" href=\"UTD.htm?3/49/3868\">",
"       table 1",
"      </a>",
"      ): postauricular lymphadenopathy (",
"      <a class=\"graphic graphic_picture graphicRef53334 \" href=\"UTD.htm?40/34/41505\">",
"       picture 4",
"      </a>",
"      ), periauricular cellulitis (",
"      <a class=\"graphic graphic_picture graphicRef58541 \" href=\"UTD.htm?9/10/9376\">",
"       picture 5",
"      </a>",
"      ), perichondritis of the auricle (",
"      <a class=\"graphic graphic_picture graphicRef67879 \" href=\"UTD.htm?30/46/31457\">",
"       picture 6",
"      </a>",
"      ), mumps (",
"      <a class=\"graphic graphic_picture graphicRef53503 \" href=\"UTD.htm?33/38/34415\">",
"       picture 7",
"      </a>",
"      ), and benign and malignant tumors of the mastoid bone. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bluestone CD, Klein JO. Intratemporal complications and sequelae of otitis media. In: Pediatric otolaryngology, 4th ed, Bluestone CD, Casselbrant ML, Stool SE, et al (Eds), Saunders, Philadelphia 2003. p.687.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/2\">",
"      Pang LH, Barakate MS, Havas TE. Mastoiditis in a paediatric population: a review of 11 years experience in management. Int J Pediatr Otorhinolaryngol 2009; 73:1520.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis K, Shapiro NL, Cherry JD.. Mastoiditis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.238.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/4\">",
"      Holt GR, Gates GA. Masked mastoiditis. Laryngoscope 1983; 93:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/5\">",
"      Lin HW, Shargorodsky J, Gopen Q. Clinical strategies for the management of acute mastoiditis in the pediatric population. Clin Pediatr (Phila) 2010; 49:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/6\">",
"      Anderson KJ. Mastoiditis. Pediatr Rev 2009; 30:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/7\">",
"      Leskinen K. Complications of acute otitis media in children. Curr Allergy Asthma Rep 2005; 5:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/8\">",
"      Bluestone CD. Clinical course, complications and sequelae of acute otitis media. Pediatr Infect Dis J 2000; 19:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/9\">",
"      Geva A, Oestreicher-Kedem Y, Fishman G, et al. Conservative management of acute mastoiditis in children. Int J Pediatr Otorhinolaryngol 2008; 72:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/10\">",
"      Luntz M, Brodsky A, Nusem S, et al. Acute mastoiditis--the antibiotic era: a multicenter study. Int J Pediatr Otorhinolaryngol 2001; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/11\">",
"      Katz A, Leibovitz E, Greenberg D, et al. Acute mastoiditis in Southern Israel: a twelve year retrospective study (1990 through 2001). Pediatr Infect Dis J 2003; 22:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/12\">",
"      Thorne MC, Chewaproug L, Elden LM. Suppurative complications of acute otitis media: changes in frequency over time. Arch Otolaryngol Head Neck Surg 2009; 135:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/13\">",
"      Benito MB, Gorricho BP. Acute mastoiditis: increase in the incidence and complications. Int J Pediatr Otorhinolaryngol 2007; 71:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/14\">",
"      Bilavsky E, Yarden-Bilavsky H, Samra Z, et al. Clinical, laboratory, and microbiological differences between children with simple or complicated mastoiditis. Int J Pediatr Otorhinolaryngol 2009; 73:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/15\">",
"      Oestreicher-Kedem Y, Raveh E, Kornreich L, et al. Complications of mastoiditis in children at the onset of a new millennium. Ann Otol Rhinol Laryngol 2005; 114:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/16\">",
"      Palma S, Fiumana E, Borgonzoni M, et al. Acute mastoiditis in children: the \"Ferrara\" experience. Int J Pediatr Otorhinolaryngol 2007; 71:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/17\">",
"      Ruiz D&iacute;az AI, del Castillo Mart&iacute;n F, Bilbao Garitagoitia A, et al. [Acute mastoiditis: an increasing entity]. An Esp Pediatr 2002; 57:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/18\">",
"      Roddy MG, Glazier SS, Agrawal D. Pediatric mastoiditis in the pneumococcal conjugate vaccine era: symptom duration guides empiric antimicrobial therapy. Pediatr Emerg Care 2007; 23:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/19\">",
"      Ho D, Rotenberg BW, Berkowitz RG. The relationship between acute mastoiditis and antibiotic use for acute otitis media in children. Arch Otolaryngol Head Neck Surg 2008; 134:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/20\">",
"      Mustafa A, Debry Ch, Wiorowski M, et al. Treatment of acute mastoiditis: report of 31 cases over a ten year period. Rev Laryngol Otol Rhinol (Bord) 2004; 125:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/21\">",
"      Baljosevic I, Mircetic N, Subarevic V, Markovic G. Acute mastoiditis in infants. Eur Arch Otorhinolaryngol 2006; 263:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/22\">",
"      Heslop A, Ovesen T. Severe acute middle ear infections: microbiology and treatment. Int J Pediatr Otorhinolaryngol 2006; 70:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/23\">",
"      Nussinovitch M, Yoeli R, Elishkevitz K, Varsano I. Acute mastoiditis in children: epidemiologic, clinical, microbiologic, and therapeutic aspects over past years. Clin Pediatr (Phila) 2004; 43:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/24\">",
"      Ongkasuwan J, Valdez TA, Hulten KG, et al. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008; 122:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/25\">",
"      St&auml;helin-Massik J, Podvinec M, Jakscha J, et al. Mastoiditis in children: a prospective, observational study comparing clinical presentation, microbiology, computed tomography, surgical findings and histology. Eur J Pediatr 2008; 167:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/26\">",
"      Groth A, Enoksson F, Hultcrantz M, et al. Acute mastoiditis in children aged 0-16 years--a national study of 678 cases in Sweden comparing different age groups. Int J Pediatr Otorhinolaryngol 2012; 76:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/27\">",
"      Chien JH, Chen YS, Hung IF, et al. Mastoiditis diagnosed by clinical symptoms and imaging studies in children: disease spectrum and evolving diagnostic challenges. J Microbiol Immunol Infect 2012; 45:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/28\">",
"      Thompson PL, Gilbert RE, Long PF, et al. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort study using the United kingdom general practice research database. Pediatrics 2009; 123:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/29\">",
"      Ghaffar FA, W&ouml;rdemann M, McCracken GH Jr. Acute mastoiditis in children: a seventeen-year experience in Dallas, Texas. Pediatr Infect Dis J 2001; 20:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/30\">",
"      Kvaerner KJ, Bentdal Y, Karevold G. Acute mastoiditis in Norway: no evidence for an increase. Int J Pediatr Otorhinolaryngol 2007; 71:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/31\">",
"      Choi SS, Lander L. Pediatric acute mastoiditis in the post-pneumococcal conjugate vaccine era. Laryngoscope 2011; 121:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/32\">",
"      Groth A, Enoksson F, Hermansson A, et al. Acute mastoiditis in children in Sweden 1993-2007--no increase after new guidelines. Int J Pediatr Otorhinolaryngol 2011; 75:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/33\">",
"      Finnbogad&oacute;ttir AF, Petersen H, Laxdal T, et al. An increasing incidence of mastoiditis in children in Iceland. Scand J Infect Dis 2009; 41:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/34\">",
"      Pritchett CV, Thorne MC. Incidence of pediatric acute mastoiditis: 1997-2006. Arch Otolaryngol Head Neck Surg 2012; 138:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/35\">",
"      Ginsburg CM, Rudoy R, Nelson JD. Acute mastoiditis in infants and children. Clin Pediatr (Phila) 1980; 19:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/36\">",
"      van den Aardweg MT, Rovers MM, de Ru JA, et al. A systematic review of diagnostic criteria for acute mastoiditis in children. Otol Neurotol 2008; 29:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/37\">",
"      Gliklich RE, Eavey RD, Iannuzzi RA, Camacho AE. A contemporary analysis of acute mastoiditis. Arch Otolaryngol Head Neck Surg 1996; 122:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/38\">",
"      Davison SP, Facer GW, McGough PF, et al. Use of magnetic resonance imaging and magnetic resonance angiography in diagnosis of sigmoid sinus thrombosis. Ear Nose Throat J 1997; 76:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/39\">",
"      Tamir S, Schwartz Y, Peleg U, et al. Acute mastoiditis in children: is computed tomography always necessary? Ann Otol Rhinol Laryngol 2009; 118:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/40\">",
"      Vazquez E, Castellote A, Piqueras J, et al. Imaging of complications of acute mastoiditis in children. Radiographics 2003; 23:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/41\">",
"      Luntz M, Bartal K, Brodsky A, Shihada R. Acute mastoiditis: the role of imaging for identifying intracranial complications. Laryngoscope 2012; 122:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/42\">",
"      Ogle JW, Lauer BA. Acute mastoiditis. Diagnosis and complications. Am J Dis Child 1986; 140:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/43\">",
"      Venezio FR, Naidich TP, Shulman ST. Complications of mastoiditis with special emphasis on venous sinus thrombosis. J Pediatr 1982; 101:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/44\">",
"      Fritsch MH, Miyamoto RT, Wood TL. Sigmoid sinus thrombosis diagnosis by contrasted MRI scanning. Otolaryngol Head Neck Surg 1990; 103:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/45\">",
"      Bluestone CD. Acute and chronic mastoiditis and chronic suppurative otitis media. Semin Pediatr Infect Dis 1998; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     Wald ER, Conway JH. Mastoiditis. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.222.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/47\">",
"      Kontorinis G, Psarommatis I, Karabinos C, et al. Incidence of non-infectious 'acute mastoiditis' in children. J Laryngol Otol 2012; 126:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5385/abstract/48\">",
"      Schiffenbauer AI, Wahl C, Pittaluga S, et al. IgG4-related disease presenting as recurrent mastoiditis. Laryngoscope 2012; 122:681.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6062 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5385=[""].join("\n");
var outline_f5_16_5385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74651140\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Masked mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H138024055\">",
"      LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35172812\">",
"      RADIOGRAPHIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74653225\">",
"      Indications for imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93287728\">",
"      Imaging modality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93287721\">",
"      Findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H613782863\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H138024437\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Microbiologic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87140852\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6062|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/4/5185\" title=\"diagnostic image 1\">",
"      Coalescent mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/62/35811\" title=\"diagnostic image 2\">",
"      Coalescent mastoiditis with cortical disruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6062|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/51/17204\" title=\"figure 1\">",
"      Mastoid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/44/28358\" title=\"figure 2\">",
"      Complications of acute mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6062|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/27/23999\" title=\"picture 1\">",
"      Mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/29/30174\" title=\"picture 2\">",
"      Mastoiditis infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/54/1891\" title=\"picture 3\">",
"      Acute otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/34/41505\" title=\"picture 4\">",
"      Postauricular lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/10/9376\" title=\"picture 5\">",
"      Auricular cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/46/31457\" title=\"picture 6\">",
"      Perichondritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/38/34415\" title=\"picture 7\">",
"      Parotid gland swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/49/3868\" title=\"table 1\">",
"      Differential diagnosis mastoiditis children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16471?source=related_link\">",
"      Acute mastoiditis in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=related_link\">",
"      Septic dural sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=related_link\">",
"      Vestibular neuritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_16_5386="Management of heart failure in infants and children";
var content_f5_16_5386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of heart failure in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/16/5386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5386/contributors\">",
"     Rakesh K Singh, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5386/contributors\">",
"     TP Singh, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/16/5386/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5386/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5386/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/16/5386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/16/5386/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/16/5386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10100827\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure is estimated to affect 12,000 to 35,000 children below the age of 19 years in the United States each year [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/1\">",
"     1",
"    </a>",
"    ]. It results from any structural or functional cardiac disorder that impairs the ability of the ventricle(s) to fill with or eject blood.",
"   </p>",
"   <p>",
"    The management of children with heart failure will be presented here. The etiology, presentation, diagnosis, and initial evaluation of the pediatric patient with heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link\">",
"     \"Etiology and diagnosis of heart failure in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5420163\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because heart failure is a common clinical condition in adults, there is a substantial amount of evidence-based data based on large, placebo-controlled clinical trials that guide management. Over the past 20 years, management of heart failure in adults has shifted based on observations that heart failure and left ventricular (LV) systolic dysfunction activate sympathetic nervous and renin-angiotensin systems. This response is initially physiologic (and compensatory), but persistent activation is maladaptive and contributes to progressive LV dilation and dysfunction (remodeling) and worsening heart failure. Data from clinical trials have shown that drugs targeted to block the effects of neuro-hormonal activation not only reverse LV remodeling but also improve survival in patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Pharmacologic therapy of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the ability to conduct similar trials in children is not possible because the much lower prevalence rate of pediatric heart failure does not allow for a sufficient number of patients to replicate these studies. As a result, treatment of heart failure in children is based on results provided by adult studies. This approach is justifiable because children in heart failure have neuro-hormonal changes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] and systemic ventricular remodeling similar to that described in adults with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2004, the International Society of Heart and Lung Transplantation (ISHLT) published guidelines for the treatment of heart failure in children primarily based on the adult literature [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/6\">",
"     6",
"    </a>",
"    ]. Modifications for specific pediatric diagnoses were recommended based on expert consensus that was largely informed by clinical experience, small case series, and physiological studies. The management approach for this review is based on these guidelines and advances in heart failure therapy since the publication of these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5420264\">",
"    <span class=\"h2\">",
"     Goals of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic goals for children with heart failure are to relieve symptoms, decrease morbidity (including the risk of hospitalization), slow the progression of heart failure, and improve patient survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5420285\">",
"    <span class=\"h2\">",
"     Management approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pediatric heart failure is dependent on its etiology and severity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5421295\">",
"    <span class=\"h3\">",
"     Etiology and pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management begins with a thorough assessment of the underlying cause of heart failure. The causes of pediatric heart failure can be divided into pathophysiologic categories (",
"    <a class=\"graphic graphic_table graphicRef79989 \" href=\"UTD.htm?6/33/6685\">",
"     table 1",
"    </a>",
"    ). This categorization helps guide the approach to management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H23884815#H23884815\">",
"     \"Etiology and diagnosis of heart failure in infants and children\", section on 'Pathophysiology and etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure due to ventricular pump dysfunction &ndash; Ventricular pump dysfunction and reduced ventricular contractility lead to impaired ejection of blood from the ventricle. Ventricular systolic dysfunction may occur in children with structurally normal hearts or in those with congenital heart disease. Medical pharmacologic therapy is generally the primary intervention. Drug choice is dependent on the severity of heart failure and may include angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), diuretics, aldosterone antagonists,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      , and beta-blockers. In patients with advanced heart failure refractory to pharmacologic therapy, interventions such as positive pressure ventilation, mechanical circulatory support, and heart transplantation may be considered. (See",
"      <a class=\"local\" href=\"#H10100864\">",
"       'Pharmacologic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Heart failure due to volume overload with preserved ventricular pump",
"      <strong>",
"      </strong>",
"      function &ndash; Volume overload (increased preload) may occur due to a significant left-to-right shunt from the systemic to the pulmonary circulation (eg, ventricular septal defect or atrioventricular canal defects) or, less commonly, due to valvular insufficiency. Surgical or catheter-based interventions to correct these defects lead to resolution of heart failure. Medical therapy may be needed for stabilization or symptom relief while awaiting a more definitive intervention.",
"     </li>",
"     <li>",
"      Heart failure due to pressure overload with preserved ventricular pump function &ndash; Pressure overload (increased afterload) may lead to heart failure if severe ventricular outflow obstruction impedes ejection of blood from the heart resulting in inadequate cardiac output (eg, aortic stenosis), or if ventricular hypertrophy due to prolonged pressure overload results in high filling pressures and congestion (eg, hypertrophic cardiomyopathy). Surgical or catheter-based interventions to correct these defects lead to resolution of heart failure. Medical therapy may be needed for stabilization or symptom relief while awaiting a more definitive intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81356725\">",
"    <span class=\"h3\">",
"     Severity of heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pediatric heart failure is dependent on the severity of heart failure, which is defined by a staging system (stages A to D) developed by a writing committee on behalf of the American College of Cardiology (ACC) and the American Heart Association (AHA), and modified for children by the ISHLT (",
"    <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/6\">",
"     6",
"    </a>",
"    ]. This schema identifies asymptomatic patients in the early stages of heart failure (ie, stage B) in whom early intervention, such as ACE inhibitors, may prolong the symptom-free state, as well as determine which patients require more aggressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H180717674#H180717674\">",
"     \"Etiology and diagnosis of heart failure in infants and children\", section on 'Staging of the progression of HF'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H105075394\">",
"     'Our approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5421324\">",
"    <span class=\"h1\">",
"     COMPONENTS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of therapy for children with heart failure include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification and correction of noncardiac factors that contribute to cardiac dysfunction. In the acute setting, these may include acidosis and sepsis. Other factors that may be associated with either acute or chronic heart failure include anemia, hypertension, and renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link\">",
"       \"Impact of anemia in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=see_link\">",
"       \"Treatment of hypertension in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H3449497#H3449497\">",
"       \"Etiology and diagnosis of heart failure in infants and children\", section on 'Noncardiac causes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H180717491#H180717491\">",
"       \"Etiology and diagnosis of heart failure in infants and children\", section on 'Structurally normal heart'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical or catheter-based interventions to correct the underlying structural defect (eg, significant left-to-right shunt or ventricular outflow obstruction)",
"     </li>",
"     <li>",
"      Pharmacologic therapy to relieve symptoms, slow the progression of ventricular dysfunction, and improve patient survival",
"     </li>",
"     <li>",
"      Additional therapeutic interventions for patients with advanced heart failure refractory to pharmacologic therapy include positive pressure ventilation, mechanical circulatory support, and heart transplantation",
"     </li>",
"     <li>",
"      Nonpharmacologic therapy for chronic heart failure includes optimal nutrition and exercise rehabilitation",
"     </li>",
"     <li>",
"      Therapeutic interventions to reduce the risk of",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treat associated complications (eg, thromboembolism, arrhythmias, and ventricular dyssynchrony).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81357520\">",
"    <span class=\"h2\">",
"     Surgical or catheter-based intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical or catheter-based intervention can lead to resolution of heart failure in patients with either volume or pressure overload, and preserved ventricular function (",
"    <a class=\"graphic graphic_table graphicRef79989 \" href=\"UTD.htm?6/33/6685\">",
"     table 1",
"    </a>",
"    ). Volume overload is associated with lesions with significant left-to-right shunting (eg, large ventricular septal defects and atrioventricular canal defects), whereas pressure overload is seen in patients with ventricular outlet obstruction (eg, critical aortic stenosis and coarctation of the aorta). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H23884808#H23884808\">",
"     \"Etiology and diagnosis of heart failure in infants and children\", section on 'Preserved ventricular pump function with volume overload'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H23884801#H23884801\">",
"     \"Etiology and diagnosis of heart failure in infants and children\", section on 'Preserved ventricular pump function with pressure overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100864\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81357124\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy is primarily used in patients with ventricular pump dysfunction. Drug therapy is also used initially to stabilize and relieve symptoms in patients with preserved ventricular function who are awaiting correction of the underlying defect that results in either volume or pressure overload.",
"   </p>",
"   <p>",
"    Data from adults with heart failure have shown that a number of drugs provide symptom relief, and improvement in patient outcome and cardiac functions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Pharmacologic therapy of HF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in symptoms can be achieved by diuretics,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      , angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs).",
"     </li>",
"     <li>",
"      Prolongation of patient survival has been documented with beta-blockers, ACE inhibitors, ARBs, and aldosterone antagonists.",
"     </li>",
"     <li>",
"      Improvement in left ventricular (LV) function and reversal of LV dilation, described as reversal of LV remodeling, is seen with the chronic use of ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists.",
"     </li>",
"     <li>",
"      Hospitalized patients with end-stage heart failure awaiting heart transplant may require intravenous inotropic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diuretics because they are refractory to oral medical therapy. (See",
"      <a class=\"local\" href=\"#H105074919\">",
"       'Drug therapy for advanced heart failure'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on this evidence in adults, these drugs are used in children with heart failure, if no contraindications to their use are identified. These drugs are discussed in detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100871\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics decrease preload by promoting natriuresis and provide relief of volume overload symptoms such as pulmonary and peripheral edema. Diuretics are used to treat children with stage C or D heart failure (",
"    <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loop diuretics &ndash; Loop diuretics inhibit sodium and chloride reabsorption in the thick ascending limb of the loop of Henle.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       Furosemide",
"      </a>",
"      is the most commonly used loop diuretic. A study of 62 hospitalized children with heart failure and fluid overload demonstrated the efficacy and safety of furosemide [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/15/40182?source=see_link\">",
"       Bumetanide",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/17/9494?source=see_link\">",
"       torsemide",
"      </a>",
"      are more potent drugs, which are used less frequently and reserved for more severe or furosemide-resistant fluid overload. Side effects of loop diuretics include electrolyte abnormalities (hyponatremia, hypochloremia, and hypokalemia), metabolic alkalosis, and renal insufficiency. Long-term therapy can lead to nephrocalcinosis and ototoxicity (usually with high intravenous dosages) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thiazide diuretics &ndash; Thiazide diuretics inhibit reabsorption of sodium and chloride ions from the distal convoluted tubules of kidneys. They generally are used as second-line agents and often in combination with a loop diuretic. Commonly used thiazide diuretics are",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/27/20919?source=see_link\">",
"       chlorothiazide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/50/30501?source=see_link\">",
"       metolazone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Aldosterone antagonists &ndash; Aldosterone antagonists decrease sodium reabsorption and potassium excretion in the collecting ducts of kidneys. Their potassium-sparing diuretic effect makes them particularly suitable for use in conjunction with loop diuretics and thiazides. Both",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"       spironolactone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      have been shown to reduce mortality in adults with heart failure when added to standard therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. This effect is independent of their diuretic effect and is mediated by inhibition of myocardial fibrosis, an important component of LV remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/13\">",
"       13",
"      </a>",
"      ]. Side effects include hyperkalemia (with both) and gynecomastia (with spironolactone).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100878\">",
"    <span class=\"h3\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     Digoxin",
"    </a>",
"    has a positive inotropic effect (mediated by",
"    <span class=\"nowrap\">",
"     Na+/K+",
"    </span>",
"    ATPase inhibition and increase in intracellular Ca+), a negative chronotropic effect that slows atrial conduction, and vagotonic properties that counter symptoms and signs mediated by the activation of sympathetic nervous system in heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/14\">",
"     14",
"    </a>",
"    ]. Digoxin used to be the mainstay of heart failure management before the 1990s, but its role became controversial after it was found not to reduce mortality in adults with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Although digoxin is no longer used in children with asymptomatic ventricular dysfunction, it continues to be used in the treatment of infants and children with stage C heart failure because of its physiologic benefit and symptom relief. These benefits are generally seen with a smaller dose (trough level 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    than was used in the past. Potential adverse effects (arrhythmias) are rare with this lower level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105074464\">",
"    <span class=\"h3\">",
"     Renin-angiotensin-aldosterone system inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure leads to activation of the renin-angiotensin-aldosterone system (RAAS) and increased sympathetic tone. ACE inhibitors and ARBs inhibit the RAAS, thereby decreasing afterload and promoting reversal of ventricular remodeling with long-term use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100885\">",
"    <span class=\"h4\">",
"     Angiotensin-converting enzyme inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors inhibit the formation of angiotensin II: a potent vasoconstrictor that also promotes myocyte hypertrophy, fibrosis, and aldosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, ACE inhibitors benefit patients in heart failure first by reducing afterload, improving cardiac output and, on chronic use, by mediating reversal of LV remodeling. Clinical trials in adults have shown that ACE inhibitors improve survival in patients with symptomatic heart failure and reduce the rate at which asymptomatic patients with severe LV dysfunction develop symptomatic heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H3#H3\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'General efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prospective studies with survival (or mortality) as their endpoint have not been possible in children with heart failure. Nevertheless, ACE inhibitors are accepted as an important component of heart failure therapy in children. The mixed results in the following pediatric studies discussed should be cautiously interpreted because of limitations in study design including small sample size (power), length of follow-up, and surrogate endpoints.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one small study of 16 patients, ACE inhibitors improved cardiac function in children with systemic ventricular pump dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of 81 children with dilated cardiomyopathy showed that treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=see_link\">",
"       captopril",
"      </a>",
"      was associated with better survival during the first year of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized, controlled study of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"       enalapril",
"      </a>",
"      in 230 infants with single ventricle anatomy and predominantly normal systemic ventricular function did not show any difference between the enalapril and placebo groups in somatic growth, ventricular function, heart failure severity, or death after one year of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with mitral or aortic regurgitation treated with ACE inhibitors have shown inconsistent improvement in LV function, dilatation, and hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 17 children treated with anthracycline chemotherapy,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"       enalapril",
"      </a>",
"      was associated only with transient early benefits on LV function [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/22\">",
"       22",
"      </a>",
"      ]. Despite continued enalapril therapy, deterioration in LV function and fra",
"      <em>",
"       c",
"      </em>",
"      tional shortening occurred between 6 and 10 years.",
"     </li>",
"     <li>",
"      In a randomized, double-blinded trial in children with Duchenne muscular dystrophy (DMD), although groups treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"       perindopril",
"      </a>",
"      and placebo had similar LV function after three years (when the trial stopped), those treated with perindopril had late beneficial effects on LV function at 5 and 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on current evidence from adult trials and pediatric studies, most pediatric heart failure experts use ACE inhibitor therapy in children with ventricular pump dysfunction (stage B or C heart failure) (",
"    <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"     table 2",
"    </a>",
"    ). Blood pressure and renal function should be closely monitored, especially in neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100892\">",
"    <span class=\"h4\">",
"     Angiotensin receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with heart failure, there is a paucity of data in the use of ARBs, which block the angiotensin receptor. Thus, ACE inhibitors are the preferred class of drugs for inhibition of the RAAS. ARBs are usually reserved for patients unable to tolerate ACE inhibitors due to cough or angioedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100899\">",
"    <span class=\"h3\">",
"     Beta-blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-blockers counteract the maladaptive effects of chronic sympathic activation of the myocardium. In adults with heart failure, they improve patient survival, reverse LV remodeling, and decrease myocardial fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although mixed results have been reported in the following pediatric studies, most experts in the field use beta-blockers for children with stage C heart failure (",
"    <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"     table 2",
"    </a>",
"    ). Results need to be cautiously interpreted because of limitations in study design including small sample size (power), length of follow-up, and surrogate endpoints.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective multicenter study of 15 children with chronic heart failure,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=see_link\">",
"       metoprolol",
"      </a>",
"      was associated with a significant increase in ejection fraction from 27 to 41 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In several small observational studies,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=see_link\">",
"       carvedilol",
"      </a>",
"      therapy has been associated with improved symptoms, improvement in ventricular function, and delay in time to transplant or death in children with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]. Carvedilol therapy has also been shown to preserve LV function after exposure to anthracyclines at six months follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/30\">",
"       30",
"      </a>",
"      ], and to improve LV function when added to ACE inhibitor therapy to patients with DMD and dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multicenter trial of 161 children with heart failure and ventricular pump dysfunction, there was no difference in the composite endpoint between groups treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=see_link\">",
"       carvedilol",
"      </a>",
"      and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/32\">",
"       32",
"      </a>",
"      ]. However, the study was thought to be underpowered as the clinical course of all children enrolled was better than expected. There was a trend towards clinical improvement in children with a systemic LV but not in those with a systemic right ventricle (RV), suggesting that the response to carvedilol may be affected by the morphology of the child&rsquo;s systemic ventricle [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2009 Cochrane review of beta-blockers in children with heart failure concluded there were not enough data to recommend or discourage its use [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the current evidence in adult and pediatric patients, most pediatric heart failure experts use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=see_link\">",
"     carvedilol",
"    </a>",
"    in children with a systemic LV and systolic dysfunction in stage C heart failure who are stable on other heart failure medications (",
"    <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"     table 2",
"    </a>",
"    ). Beta-blockers are usually added to an established regimen of diuretics,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    , and an ACE inhibitor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=see_link\">",
"     Carvedilol",
"    </a>",
"    dosing is initiated at a low dose (approximately one-eighth of the eventual target dose, usually an oral dose of 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose given twice a day) and increased every two weeks to minimize side effects. In general, the dose is doubled after observing the response to the new higher test dose in clinic to a maximum oral dose of 0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given twice a day. Side effects that may preclude dose increase include dizziness, fatigue, hypotension, bradycardia, bronchospasm, and hypoglycemia. Beta-blockers are",
"    <strong>",
"     discontinued",
"    </strong>",
"    in patients with decompensated heart failure (stage D). &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100906\">",
"    <span class=\"h3\">",
"     Pulmonary vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     Sildenafil",
"    </a>",
"    , a phosphodiesterase-5 inhibitor, is a pulmonary vasodilator. Its use has been associated with improved LV function, functional capacity, and quality of life in adults with systolic LV dysfunction and secondary pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/35\">",
"     35",
"    </a>",
"    ]. Larger, controlled studies are underway in adults with heart failure and secondary pulmonary hypertension to assess the effect of these drugs on patient survival. Although sildenafil was shown to improve symptoms of heart failure in 13 children with failing Fontan physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/36\">",
"     36",
"    </a>",
"    ], it remains an investigational drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105074919\">",
"    <span class=\"h3\">",
"     Drug therapy for advanced heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous diuretics and inotropic agents are generally used in hospitalized patients with stage D heart failure (",
"    <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100966\">",
"    <span class=\"h4\">",
"     Inotropes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inotropic agents are used during acute exacerbations of heart failure to improve cardiac output and to stabilize patients awaiting heart transplantation. Their effect is mediated through higher intracellular cyclic adenylate monophosphate (cAMP) levels, either by increased production (catecholamines) or by decreased degradation (phosphodiesterase III inhibition).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100973\">",
"    <span class=\"h5\">",
"     Catecholamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathomimetic stimulation by catecholamine agents improves myocardial contractility and may have an additional beneficial effect on peripheral vascular beds [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     Dopamine",
"    </a>",
"    is the preferred drug during decompensated heart failure (usually in combination with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"     milrinone",
"    </a>",
"    ), although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    has the additive effect of reducing afterload. Invasive monitoring of arterial blood pressure and central venous pressure may allow dose titration for optimal end-organ perfusion, as measured by urine output, serum lactate, and mixed venous saturations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H20#H20\">",
"     \"Use of vasopressors and inotropes\", section on 'Dopamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H21#H21\">",
"     \"Use of vasopressors and inotropes\", section on 'Dobutamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100980\">",
"    <span class=\"h5\">",
"     Milrinone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"     milrinone",
"    </a>",
"    , a phosphodiesterase III inhibitor, is the preferred drug in decompensated heart failure, as it increases contractility and reduces afterload without a significant increase in myocardial oxygen consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/38\">",
"     38",
"    </a>",
"    ]. A randomized, double-blind, placebo-controlled trial in pediatric postoperative cardiac surgery patients demonstrated that children treated with high-dose milrinone infusion (0.75",
"    <span class=\"nowrap\">",
"     mcg/kg/min)",
"    </span>",
"    were at a lower risk for the development of low cardiac output syndrome (LCOS) compared with children treated with placebo (12 versus 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To avoid hypotension,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"     milrinone",
"    </a>",
"    is initially administered as an infusion starting at a dose of 0.25",
"    <span class=\"nowrap\">",
"     mcg/kg/min",
"    </span>",
"    (without a pre-infusion bolus) and titrated upwards slowly as needed to a maximum dose of 1.0",
"    <span class=\"nowrap\">",
"     mcg/kg/min.",
"    </span>",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"     milrinone",
"    </a>",
"    is usually used in hospitalized children with heart failure refractory to oral drug therapy awaiting heart transplantation, a small study of 14 patients reported the safe administration of intravenous at home in children awaiting heart transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/40\">",
"     40",
"    </a>",
"    ]. Several centers (including ours) use home milrinone in selected children awaiting heart transplantation. In our practice, home milrinone infusion therapy is used in children who are clinically stable without end-organ dysfunction, no history of arrhythmias, generally are on a milrinone dose &le;0.5",
"    <span class=\"nowrap\">",
"     mcg/kg/min",
"    </span>",
"    and a stable regimen of oral diuretic therapy, and are under continuous adult supervision. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100987\">",
"    <span class=\"h4\">",
"     Nesiritide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    is a recombinant B-type natriuretic peptide that reduces preload and afterload by promoting diuresis, natriuresis, and arterial- and veno-dilation, thereby improving cardiac output without a direct inotropic effect on the myocardium. It has been reported to be well tolerated and efficacious in children as illustrated in a prospective, open-label study in 63 children with refractory heart failure that showed nesiritide was associated with improved urine output, serum creatinine, and cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, trials in adults with acute decompensated heart failure have failed to show that nesiritide is associated with lower mortality or re-hospitalization rate, or that it improves dyspnea. In addition, there is an associated increased risk of hypotension. As a result, nesiritide is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for general use in acute heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=see_link\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105075139\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions for advanced heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic interventions for selected patients with advanced heart failure refractory to pharmacologic therapy (stage D) may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive pressure ventilation",
"     </li>",
"     <li>",
"      Mechanical circulatory support in patients with end-stage heart failure",
"     </li>",
"     <li>",
"      Heart transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100994\">",
"    <span class=\"h3\">",
"     Positive pressure ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV), such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) ventilation, is effective in alleviating respiratory distress from cardiogenic pulmonary edema. It promotes alveolar recruitment, improves lung compliance, and leads to decreased left ventricular preload and afterload [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/43\">",
"     43",
"    </a>",
"    ]. Although there is high quality evidence of the benefit of NPPV in adult patients with cardiogenic pulmonary edema, there are no pediatric studies evaluating its use in heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10101015\">",
"    <span class=\"h3\">",
"     Mechanical circulatory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a child with decompensated heart failure, with low cardiac output syndrome unresponsive to medical therapy, mechanical circulatory support (MCS) can be life-saving. MCS maintains end-organ function and reduces myocardial oxygen requirements. It is used as a bridge to recovery (extracorporeal membrane oxygenation [ECMO]) in patients with secondary cardiomyopathy or to heart transplantation (ECMO or ventricular assist device [VAD]). In a report from the International Society for Heart and Lung Transplantation (ISHLT), 25 percent of pediatric heart transplant recipients received mechanical circulatory support as a bridge to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The options include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extracorporeal membrane oxygenation (ECMO) is a total heart-lung bypass device and is used in the setting of imminent or actual cardiac arrest, such as postcardiotomy shock following cardiac surgery and acute myocarditis. Cannulation can be performed percutaneously, and ECMO can provide full cardiopulmonary support for days to weeks. A multicenter registry review of 3416 neonatal and 4181 pediatric cardiac ECMO cases showed a survival to discharge rate of 38 and 45 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/45\">",
"       45",
"      </a>",
"      ]. If myocardial recovery does not occur or is not expected to occur within two to three weeks, ECMO may be used as a bridge to a more durable ventricular assist device placement and subsequent heart transplantation.",
"     </li>",
"     <li>",
"      Ventricular assist device (VAD), a cardiac-only support device, can offer either univentricular or biventricular support. Multiple devices currently exist and differ by flow design (pulsatile, centrifugal, or axial), pump location relative to patient (implantable, paracorporeal, or extracorporeal), and delivery system (percutaneous or central) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/46\">",
"       46",
"      </a>",
"      ]. They are primarily used in patients awaiting heart transplantation and have yielded favorable results. A retrospective, multicenter analysis of 99 children supported by VAD as a bridge to transplantation showed a 77 percent survival to transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/47\">",
"       47",
"      </a>",
"      ]. VAD options are limited in small children awaiting heart transplantation due to body size and anatomic considerations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of device depends on the etiology of heart failure, patient&rsquo;s cardiac anatomy, expected length of support, the availability of devices, and the expertise of the center&rsquo;s physicians. Serious complications associated with ECMO and VAD include bleeding (eg, gastrointestinal and intracranial hemorrhage), thromboembolism (eg, stroke), and infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10101036\">",
"    <span class=\"h3\">",
"     Heart transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart transplantation is recommended for end-stage heart failure refractory to medical therapy (stage D). It may also be considered for less severe heart failure (stage C) associated with severe limitation of activity, significant growth failure, intractable arrhythmias, or restrictive cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/48\">",
"     48",
"    </a>",
"    ]. The current survival in pediatric recipients 1, 5, and 10 years after transplantation is approximately 90, 80, and 60 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/44\">",
"     44",
"    </a>",
"    ]. Early referral to a pediatric heart failure and transplant center should be considered to optimize medical therapy and the timing of listing for heart transplant. Decision to pursue heart transplantation is based upon the expected survival with medical therapy, quality of life, alternative options for treatment, and estimation of survival post-transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190772857\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy for chronic heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapy for chronic heart failure includes optimal nutrition and exercise rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190772882\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure is common in infants and children with heart failure. Nearly one-third of children with cardiomyopathy manifest growth failure during the course of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/49\">",
"     49",
"    </a>",
"    ]. A retrospective analysis of 165 children with idiopathic dilated cardiomyopathy showed that nutritional status positively and independently correlated with survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caloric intake and growth should be carefully assessed in infants and children with heart failure. Some children may need a daily intake greater than 120",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    for optimal growth because of increased metabolic demands of heart failure. In order to provide adequate caloric intake, intermittent or continuous nasogastric or gastrostomy tube feeds may be required.",
"   </p>",
"   <p>",
"    In addition, salt and fluid restriction is recommended in children with severe heart failure to reduce volume overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190772889\">",
"    <span class=\"h3\">",
"     Exercise rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiovascular rehabilitation programs have been shown to improve exercise performance, physical activity, and quality of life in adults with chronic heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/51\">",
"     51",
"    </a>",
"    ], data in children are limited. In a single center study, 15 of 16 children with complex congenital heart disease demonstrated improved exercise performance after participation in a cardiac rehabilitation program [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/52\">",
"     52",
"    </a>",
"    ]. Furthermore, a study of 20 hospitalized children awaiting heart transplantation demonstrated that even those on inotropic support can safely participate in exercise training programs with relatively moderate to high compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/53\">",
"     53",
"    </a>",
"    ]. Further studies are needed to evaluate the long-term benefits of exercise rehabilitation in children with heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105074814\">",
"    <span class=\"h2\">",
"     Therapy to reduce complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heart failure are at-risk for complications, which increase morbidity and mortality. Complications include thromboembolism, arrhythmias, and ventricular dyssynchrony.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105074822\">",
"    <span class=\"h3\">",
"     Thrombi formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with heart failure due to systemic ventricular dysfunction are at risk for the formation of intracardiac thrombi, which may result in pulmonary embolus, cerebral embolic strokes, and, in some cases, death.",
"   </p>",
"   <p>",
"    Although there are no controlled trials in children, most experts recommend using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    in children with moderate LV dysfunction, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"     enoxaparin",
"    </a>",
"    for children with severe LV dysfunction. Anticoagulation with aspirin should also be considered in the presence of marked atrial dilation in children with restrictive cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link&amp;anchor=H9#H9\">",
"     \"Indications for antithrombotic therapy in heart failure\", section on 'Role of antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105074829\">",
"    <span class=\"h3\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with decreased ventricular function, sustained atrial and ventricular tachyarrhythmias can rapidly impair hemodynamics. In these patients, cardioversion or defibrillation may be needed along with antiarrhythmic therapy. Ablation therapy also has a potential role in the setting of chronic atrial tachyarrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link\">",
"     \"Management and evaluation of wide QRS complex tachycardia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17226?source=see_link\">",
"     \"Atrial arrhythmias (including AV block) in congenital heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of supraventricular tachycardia in children\", section on 'Radiofrequency ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Implantable cardioverter defibrillatory (ICD) therapy is used in select patients who are at risk for sudden cardiac death due to ventricular tachycardia and fibrillation. The indications for ICD placement are aborted sudden cardiac death, unexplained syncope, and recurrent, sustained ventricular dysrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the risk of sudden death in children with end-stage heart failure awaiting transplantation is only about 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/55\">",
"     55",
"    </a>",
"    ]. Unlike adults, there are no data to support when an ICD should be placed in children with ventricular dysfunction. Risk stratification for sudden cardiac death (SCD) in children with dilated cardiomyopathy may be useful in identifying children who may benefit from this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H14#H14\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Role of an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105075684\">",
"    <span class=\"h3\">",
"     Ventricular dyssynchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraventricular conduction delay or left bundle branch block (LBBB) may worsen heart failure by causing ventricular dyssynchrony. Cardiac resynchronization therapy (CRT) uses biventricular pacing to minimize ventricular dyssynchrony seen in patients with heart failure who usually have a prolonged QRS on electrocardiogram. In adult patients with LV dysfunction, heart failure, and LBBB, CRT has been shown to improve hemodynamics and symptoms. Pediatric data are limited and include a multicenter, retrospective analysis of 103 children and young adults with congenital heart disease and prolonged QRS on electrocardiogram that showed CRT was associated with improvement of ventricular ejection fraction from 26 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/57\">",
"     57",
"    </a>",
"    ]. When CRT is considered for a pediatric patient, guidelines for use of CRT in adults are a useful reference [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105075394\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our management approach for treating pediatric heart failure is consistent with the 2004 International Society of Heart and Lung Transplantation (ISHLT) published guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/16/5386/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5420163\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is based on the etiology of the heart failure and the severity of heart disease, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with structural heart disease with preserved ventricular pump function, surgical or catheter-based interventions are used to correct the underlying defects causing heart failure (ie, left-to-right heart shunts or ventricular outflow obstruction). (See",
"      <a class=\"local\" href=\"#H5421295\">",
"       'Etiology and pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H81357520\">",
"       'Surgical or catheter-based intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ventricular pump dysfunction or those who require stabilization before surgical or catheter-based correction, therapy is provided based on the severity of heart failure (",
"      <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage A &ndash; Patients at-risk for heart failure with normal cardiac function and size: No therapeutic intervention.",
"     </li>",
"     <li>",
"      Stage B &ndash; Asymptomatic patients with abnormal systemic ventricular function: Angiotensin converting enzyme (ACE) inhibitors. (See",
"      <a class=\"local\" href=\"#H10100885\">",
"       'Angiotensin-converting enzyme inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stage C &ndash; Patients with current or past symptoms and structural or functional heart disease: ACE inhibitors, aldosterone antagonists, beta-blockers, low dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      , and oral diuretic therapy. (See",
"      <a class=\"local\" href=\"#H10100864\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stage D &ndash; Patients with end-stage heart failure who are refractory to oral medical therapy: Intravenous administration of inotropes and diuretics. In addition, nonpharmacologic interventions include positive pressure ventilation, mechanical circulatory support, and subsequent heart transplantation. (See",
"      <a class=\"local\" href=\"#H105074919\">",
"       'Drug therapy for advanced heart failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H105075139\">",
"       'Nonpharmacologic interventions for advanced heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification and correction of noncardiac factors that contribute to cardiac dysfunction. These include anemia, hypertension, acidosis, renal failure, and sepsis.",
"     </li>",
"     <li>",
"      For children with chronic heart failure, nonpharmacologic interventions include provision of adequate caloric intake for growth (which may entail nasogastric or gastrostomy tube feedings), and an exercise program to improve physical activity level. (See",
"      <a class=\"local\" href=\"#H190772857\">",
"       'Nonpharmacologic therapy for chronic heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with heart failure are at risk for thromboembolic disease, arrhythmia, and ventricular dyssynchrony.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      To decrease the risk of intracardiac thrombi, we administer prophylactic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      to children with moderate left ventricular (LV) dysfunction, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"       enoxaparin",
"      </a>",
"      for children with severe LV dysfunction. (See",
"      <a class=\"local\" href=\"#H105074822\">",
"       'Thrombi formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with sustained atrial or ventricular tachyarrhythmias, interventions include cardioversion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antiarrhythmic therapy followed by ablation therapy in patients deemed suitable. Implantable cardioverter defibrillatory therapy may be considered in patients who remain at risk for sudden cardiac death (SCD) due to ventricular arrhythmias. (See",
"      <a class=\"local\" href=\"#H105074829\">",
"       'Arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with ventricular dyssynchrony, cardiac resynchronization therapy may be used to improve ventricular function. (See",
"      <a class=\"local\" href=\"#H105075684\">",
"       'Ventricular dyssynchrony'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10101043\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of limited pediatric data, the management of children with heart failure is primarily based on evidence from clinical trials of adults with heart failure. (See",
"      <a class=\"local\" href=\"#H5420163\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of therapeutic interventions for children with heart failure are to relieve symptoms, decrease morbidity (including the risk of hospitalization), slow the progression of heart failure, and improve patient survival. (See",
"      <a class=\"local\" href=\"#H5420264\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our management approach is based on the etiology and severity of heart failure, and is consistent with the 2004 International Society of Heart and Lung Transplantation (ISHLT) published guidelines. (See",
"      <a class=\"local\" href=\"#H5420285\">",
"       'Management approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H105075394\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with structural heart disease and preserved ventricular pump function, we recommend surgical or catheter-based interventions to correct the underlying defects responsible for heart failure (ie, left-to-right heart shunts or ventricular outflow obstruction) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5421295\">",
"       'Etiology and pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H81357520\">",
"       'Surgical or catheter-based intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ventricular pump dysfunction or those who require stabilization before surgical or catheter-based intervention are treated with a combination of medications that alter afterload, preload, and myocardial contractility, and may be effective with chronic use in reverse-remodeling of the systemic ventricle. For these patients, we suggest the following approach based on the severity of heart failure (",
"      <a class=\"graphic graphic_table graphicRef60553 \" href=\"UTD.htm?6/37/6748\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage A &ndash; Patients at risk for heart failure with normal cardiac function and size: No therapeutic intervention.",
"     </li>",
"     <li>",
"      Stage B &ndash; Asymptomatic patients with abnormal systemic ventricular function: Angiotensin converting enzyme (ACE) inhibitors, which decrease afterload by blocking formation of angiotensin II and promote reversal of ventricular remodeling on long-term use. (See",
"      <a class=\"local\" href=\"#H105074464\">",
"       'Renin-angiotensin-aldosterone system inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stage C &ndash; Patients with current or past symptoms and structural or functional heart disease: ACE inhibitors, aldosterone antagonists, beta-blockers (counteract the maladaptive effects of chronic sympathic activation on the myocardium), low dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      (improves symptoms with its positive inotropic effect and vagotonic properties), and oral diuretic therapy (decreases preload by promoting natriuresis). (See",
"      <a class=\"local\" href=\"#H105074464\">",
"       'Renin-angiotensin-aldosterone system inhibition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10100899\">",
"       'Beta-blockers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10100878\">",
"       'Digoxin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10100871\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stage D &ndash; Patients with end-stage heart failure who are refractory to medical therapy: Intravenous administration of inotropes (improve myocardial contractility) and diuretics. In addition, nonpharmacologic interventions include positive pressure ventilation, mechanical circulatory support, and subsequent heart transplantation. (See",
"      <a class=\"local\" href=\"#H105074919\">",
"       'Drug therapy for advanced heart failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H105075139\">",
"       'Nonpharmacologic interventions for advanced heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition, medical care for children with heart failure includes identification and correction of noncardiac factors that contribute to cardiac dysfunction such as anemia, hypertension, renal failure, and sepsis. (See",
"      <a class=\"local\" href=\"#H5421324\">",
"       'Components of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with chronic heart failure, we recommend provision of adequate caloric intake for growth (which may entail nasogastric feedings) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also suggest an exercise program to improve physical activity level (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H190772857\">",
"       'Nonpharmacologic therapy for chronic heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional therapeutic interventions are used to prevent or treat complications associated with heart failure such as intracardiac thrombi, arrhythmias, and ventricular dyssynchrony. (See",
"      <a class=\"local\" href=\"#H105074814\">",
"       'Therapy to reduce complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/1\">",
"      Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and pathophysiology. Circ Heart Fail 2009; 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/2\">",
"      Baylen BG, Johnson G, Tsang R, et al. The occurrence of hyperaldosteronism in infants with congestive heart failure. Am J Cardiol 1980; 45:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/3\">",
"      Ross RD, Daniels SR, Schwartz DC, et al. Plasma norepinephrine levels in infants and children with congestive heart failure. Am J Cardiol 1987; 59:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/4\">",
"      Auerbach SR, Richmond ME, Lamour JM, et al. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial. Circ Heart Fail 2010; 3:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/5\">",
"      Singh TP, Sleeper LA, Lipshultz S, et al. Association of left ventricular dilation at listing for heart transplant with postlisting and early posttransplant mortality in children with dilated cardiomyopathy. Circ Heart Fail 2009; 2:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/6\">",
"      Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004; 23:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/7\">",
"      Hsu DT, Pearson GD. Heart failure in children: part II: diagnosis, treatment, and future directions. Circ Heart Fail 2009; 2:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/8\">",
"      Simpson KE, Canter CE. Can adult heart failure regimens be applied to children: what works and what does not? Curr Opin Cardiol 2012; 27:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/9\">",
"      Engle MA, Lewy JE, Lewy PR, Metcoff J. The use of furosemide in the treatment of edema in infants and children. Pediatrics 1978; 62:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/10\">",
"      Kantor PF, Mertens LL. Clinical practice: heart failure in children. Part II: current maintenance therapy and new therapeutic approaches. Eur J Pediatr 2010; 169:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/11\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/12\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/13\">",
"      Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/14\">",
"      Shaddy RE. Optimizing treatment for chronic congestive heart failure in children. Crit Care Med 2001; 29:S237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/15\">",
"      Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/16\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/17\">",
"      Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 1991; 83:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/18\">",
"      Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/19\">",
"      Hsu DT, Zak V, Mahony L, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation 2010; 122:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/20\">",
"      Mori Y, Nakazawa M, Tomimatsu H, Momma K. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J Am Coll Cardiol 2000; 36:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/21\">",
"      Gisler F, Knirsch W, Harpes P, Bauersfeld U. Effectiveness of angiotensin-converting enzyme inhibitors in pediatric patients with mid to severe aortic valve regurgitation. Pediatr Cardiol 2008; 29:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/22\">",
"      Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20:4517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/23\">",
"      Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/24\">",
"      Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007; 154:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/25\">",
"      Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/26\">",
"      Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001; 138:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/27\">",
"      Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002; 40:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/28\">",
"      Rusconi P, G&oacute;mez-Mar&iacute;n O, Rossique-Gonz&aacute;lez M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004; 23:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/29\">",
"      Blume ED, Canter CE, Spicer R, et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/30\">",
"      Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/31\">",
"      Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006; 70:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/32\">",
"      Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/33\">",
"      O'Connor MJ, Rosenthal DN, Shaddy RE. Outpatient management of pediatric heart failure. Heart Fail Clin 2010; 6:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/34\">",
"      Frobel AK, Hulpke-Wette M, Schmidt KG, L&auml;er S. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev 2009; :CD007037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/35\">",
"      Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/36\">",
"      Reinhardt Z, Uzun O, Bhole V, et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010; 20:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/37\">",
"      Schweigmann U, Meierhofer C. Strategies for the treatment of acute heart failure in children. Minerva Cardioangiol 2008; 56:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/38\">",
"      Wessel DL. Managing low cardiac output syndrome after congenital heart surgery. Crit Care Med 2001; 29:S220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/39\">",
"      Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/40\">",
"      Berg AM, Snell L, Mahle WT. Home inotropic therapy in children. J Heart Lung Transplant 2007; 26:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/41\">",
"      Mahle WT, Cuadrado AR, Kirshbom PM, et al. Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 2005; 6:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/42\">",
"      Jefferies JL, Price JF, Denfield SW, et al. Safety and efficacy of nesiritide in pediatric heart failure. J Card Fail 2007; 13:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/43\">",
"      Tkacova R, Rankin F, Fitzgerald FS, et al. Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Circulation 1998; 98:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/44\">",
"      Kirk R, Dipchand AI, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: fifteenth pediatric heart transplantation report--2012. J Heart Lung Transplant 2012; 31:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/45\">",
"      Haines NM, Rycus PT, Zwischenberger JB, et al. Extracorporeal Life Support Registry Report 2008: neonatal and pediatric cardiac cases. ASAIO J 2009; 55:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/46\">",
"      Adachi I, Fraser CD Jr. Mechanical circulatory support for infants and small children. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2011; 14:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/47\">",
"      Blume ED, Naftel DC, Bastardi HJ, et al. Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study. Circulation 2006; 113:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/48\">",
"      Canter CE, Shaddy RE, Bernstein D, et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/49\">",
"      Miller TL, Neri D, Extein J, et al. Nutrition in Pediatric Cardiomyopathy. Prog Pediatr Cardiol 2007; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/50\">",
"      Azevedo VM, Albanesi Filho FM, Santos MA, et al. [The impact of malnutrition on idiopathic dilated cardiomyopathy in children]. J Pediatr (Rio J) 2004; 80:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/51\">",
"      Pi&ntilde;a IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003; 107:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/52\">",
"      Rhodes J, Curran TJ, Camil L, et al. Impact of cardiac rehabilitation on the exercise function of children with serious congenital heart disease. Pediatrics 2005; 116:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/53\">",
"      McBride MG, Binder TJ, Paridon SM. Safety and feasibility of inpatient exercise training in pediatric heart failure: a preliminary report. J Cardiopulm Rehabil Prev 2007; 27:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/54\">",
"      Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm 2008; 5:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/55\">",
"      Rhee EK, Canter CE, Basile S, et al. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome? J Heart Lung Transplant 2007; 26:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/56\">",
"      Pahl E, Sleeper LA, Canter CE, et al. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. J Am Coll Cardiol 2012; 59:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/16/5386/abstract/57\">",
"      Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol 2005; 46:2277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14520 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5386=[""].join("\n");
var outline_f5_16_5386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10101043\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10100827\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5420163\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5420264\">",
"      Goals of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5420285\">",
"      Management approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5421295\">",
"      - Etiology and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81356725\">",
"      - Severity of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5421324\">",
"      COMPONENTS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81357520\">",
"      Surgical or catheter-based intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10100864\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81357124\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10100871\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10100878\">",
"      - Digoxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105074464\">",
"      - Renin-angiotensin-aldosterone system inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10100885\">",
"      Angiotensin-converting enzyme inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10100892\">",
"      Angiotensin receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10100899\">",
"      - Beta-blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10100906\">",
"      - Pulmonary vasodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105074919\">",
"      - Drug therapy for advanced heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10100966\">",
"      Inotropes",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H10100973\">",
"      - Catecholamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H10100980\">",
"      - Milrinone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10100987\">",
"      Nesiritide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105075139\">",
"      Nonpharmacologic interventions for advanced heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10100994\">",
"      - Positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10101015\">",
"      - Mechanical circulatory support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10101036\">",
"      - Heart transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190772857\">",
"      Nonpharmacologic therapy for chronic heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190772882\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190772889\">",
"      - Exercise rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105074814\">",
"      Therapy to reduce complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105074822\">",
"      - Thrombi formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105074829\">",
"      - Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105075684\">",
"      - Ventricular dyssynchrony",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105075394\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10101043\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/33/6685\" title=\"table 1\">",
"      Pediatric causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/37/6748\" title=\"table 2\">",
"      Stages of pediatric heart failure and therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17226?source=related_link\">",
"      Atrial arrhythmias (including AV block) in congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=related_link\">",
"      Etiology and diagnosis of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=related_link\">",
"      Nesiritide in the treatment of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=related_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_16_5387="Low purine diet";
var content_f5_16_5387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Low purine diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        The following should be AVOIDED:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animal-based proteins",
"       </td>",
"       <td>",
"        Meats, poultry, seafood, liver, kidney, heart, gizzard, sweetbreads, meat extracts, yeast extract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beverages",
"       </td>",
"       <td>",
"        Alcohol, beer, and beer products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetables",
"       </td>",
"       <td>",
"        Peas, beans, spinach, lentils*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    On a strict low purine diet, protein is derived principally from eggs and cheese. Grains, most vegetables, fruits and nuts are acceptable.",
"    <div class=\"footnotes\">",
"     * Not confirmed in study as risk factor for gout [Choi, HK, Atkinson, K, Karlson, EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093].",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5387=[""].join("\n");
var outline_f5_16_5387=null;
var title_f5_16_5388="UVB phototherapy indications";
var content_f5_16_5388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical indications for UVB phototherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Broadband",
"       </td>",
"       <td class=\"subtitle1\">",
"        Narrowband",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atopic dermatitis",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pruritus, prurigo",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parapsoriasis en plaques",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycosis fungoides (patch stage)",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymorphous light eruption (prophylaxis)",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitiligo",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pityriasis lichenoides",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphomatoid papulosis",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seborrheic dermatitis",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV-associated pruritic eruptions",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    +: recommendable; ++: superior; &ndash;: low efficacy; X: no experience.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5388=[""].join("\n");
var outline_f5_16_5388=null;
var title_f5_16_5389="Varicella vaccine";
var content_f5_16_5389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of Oka/Merck vaccine use in adults*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Storage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Before reconstitution, the vaccine should be stored",
"in a freezer with an average temperature of -15&deg;C",
"(+5&deg;F) or colder. Any freezer that reliably maintains",
"-15&deg;C and has a separate freezer door is acceptable (including frost free models).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. The vaccine should be protected from light. The",
"reconstituted vaccine should not be refrozen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. The diluent should be stored separately at room",
"temperature, or in the refrigerator.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Adult dose: 0.5 mL with a second dose 4 to 8 week later.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Administer subcutaneously in the",
"outer aspect of the upper arm (deltoid). Administer immediately after reconstitution, to minimize",
"loss of potency, discard if reconstituted vaccine is not used within 30 minutes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Do not administer IG including VZIG concurrently with",
"the vaccine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. The vaccine may be stored at",
"refrigerator temperature (2-8&deg;C) for up to 72 continuous hours",
"prior to reconstitution. Vaccine not used within 72 hours",
"should be discarded.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Hypersensitivity to any component of the vaccine,",
"including gelatin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. A history of anaphylactoid reaction to neomycin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Blood dyscrasias, leukemia,",
"lymphomas of any other type, or other malignant neoplasms of the bone marrow or lymphatic systems.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Immunosuppressant therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Primary and acquired immunodeficiency states or a",
"family history of congenital or hereditary immunodeficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Active untreated tuberculosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Any febrile respiratory or other active febrile",
"infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Pregnancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Precautions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Vaccination should be deferred for at least 5 months",
"following blood or plasma transfusions, or administration of immune globulin (including VZIG).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Following administration of vaccine,",
"immune globulin should be not be given for 2 months unless its use outweighs the benefits of immunization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Vaccine recipients should avoid use of salicylates for",
"6 weeks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. The safety and efficacy of vaccine have not been",
"established in persons infected with HIV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Pregnancy should be avoided for 3 months following",
"immunization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug Interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Vaccine may be administered concomitantly with MMR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Limited data suggest that vaccine",
"can be administered concomitantly with DTaP and hepatitis B vaccine using separate sites and syringes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. There are no data regarding simultaneous administration",
"of vaccine with DTP or OPV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Informed consent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. As with all immunizations, written",
"informed consent should be obtained which details the risks and benefits of varicella vaccine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Adopted from Package Insert (Merck 1996). Providers should read and be familiar with the entire package insert.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5389=[""].join("\n");
var outline_f5_16_5389=null;
var title_f5_16_5390="Resident rating simulated pts";
var content_f5_16_5390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resident interviewing skills with simulated patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Data",
"gathering skills",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Informing",
"and motivating skills",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Managing",
"somatization skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        U (n=19)",
"       </td>",
"       <td class=\"subtitle2\">",
"        T (n=22)",
"       </td>",
"       <td class=\"subtitle2\">",
"        p",
"       </td>",
"       <td class=\"subtitle2\">",
"        U (n=14)",
"       </td>",
"       <td class=\"subtitle2\">",
"        T (n=13)",
"       </td>",
"       <td class=\"subtitle2\">",
"        p",
"       </td>",
"       <td class=\"subtitle2\">",
"        U (n=18)",
"       </td>",
"       <td class=\"subtitle2\">",
"        T (n=15)",
"       </td>",
"       <td class=\"subtitle2\">",
"        p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourages responses",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        0.045",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        0.007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allows talking",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        0.004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Responds to emotions*",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pursues biomedical",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pursues psychosocial",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dominates interview",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        .0004",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        0.039",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Builds rapport",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"       <td>",
"        0.034",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        0.002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracks patient",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        0.027",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manages interview",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        0.066",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient-centered",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        0.094",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        0.003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall rating",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        0.004",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        .0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Informs patient&bull;",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        0.018",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motivates patient&bull;",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Willing to help&bull;",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        0.002",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manages somatization",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     U: untrained residents; T: trained residents.",
"     <br>",
"      * n reduced because it is rated only when patients mention an emotion. On this item, n=39 for data gathering skills, n=17 for informing and motivating skills, and n=32 for managing somatization skills.",
"      <br>",
"       &bull; n reduced to 26 due to missing data.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from Smith, RC, Lyles, JS, Mettler, J, et al, Ann Intern Med 1998; 128:139.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5390=[""].join("\n");
var outline_f5_16_5390=null;
var title_f5_16_5391="Foreign body fragmentation";
var content_f5_16_5391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Potential complication of foreign body extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 206px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADOAQ4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDE8dhv+E28QOCM/wBo3Axn/pq1Y8ZCyr3Ocmtbx4+PG3iAKP8AmJXJ/wDIrVl7FLK2MADJruS0Pjqvxv1LLMA3JX5ueKmhIOxhjrgn2qvCobaJBkei1YH+t3DbtwRgfSkzElRxJgINpB/BqlVGVQVyvrUMC7Qdzc+lWlGxdpBIPTFSImjz5exyNzA8+lRoimJsMQRjnFKm9mO1lGD3qSJMq+GBGOtICIISTuO7Jp0ajdgduD70oUEjC4GQadGSVLAYXkc0xEyqqgsSGHXHpVRtWsjOY1niMgOCM8/SqPid3h0eVo2IcgdOuCah/sGyOk8wL5gj3eZ/Fuxmg0jBWvJ7m4fv+ZheaivL6yRxDNdRIQM4/wAao+HJTPokJlYlmBTceSMGq93DpulwhbkpLKW3DeuXf8KYlBXcWa8MiTFXidXQcZB4NKzZlCDjnt3rJ8No6G5l8hoIZGzHG3UD6dqtR6iHuzGqTJg7f9XwffNApQs2kXbmeOMZllRCmAwY8getSNJDNCGhbcEABw2a5URC11W6Oq200xlO5GALLtpmjS58S3EUEbxW7D/Vt2wOuKRo6Ojaex1DSWsLAySqn8RVmANEV1aYEiSxMp4B3jOap3ej2t7qa3N0S4CbQh6fWsPTLO3n8ST/AGYKtpBngfd3UyYwi03fY6eWMqPMC85xgdvemsnyZXHvipJCgBCsG4ySF6+1RK38HVaDIXnyxggjmk+dWUEEEjA2HnmnBjyoCDtiokDMd2VXCnGf5UxkqwFYypwFx90nFVdwKAqMEcj8KsSSlk2yH94Bwc1VQsqFQwwT29qARI244DHqcnJ9ajZHAJJGFHTsamcuYmKYypHJ71EGYA5POSRxQMZIuzqw6A4xTIwE+8Dzz1puGLbgfm4IyKJg4O7eMn0FMY2RQJkft25qCRjIOT+NPTasf3ixHIGKglJUEbsKf1pjQqRny13soyM4Nen/ALO7E+OL7IIUac+Ce/7yKvLCCYy+7I6V6f8As55Pji+PP/IPk/8ARkVTU+FnXgv48fU4jx2F/wCEy8QnIyNSuP1lasncMKVYHnkVp+O0B8ceIjnGdRuP/RrVk28ZU7ivHY1S2RhV+N+paUbWDqcZ55pQ+x+eATk4phO1hjIOMGmLuEh3YwfUUmZGlG8e8nqTyM1PFIfmZhkZ5HtWcDhl2nqBxVqHzNxwGI6HHpUtAW7YZDHoDz61JCqqzbUJz6/zqrEsm7IUgA4xnmrgX98oG4qDjJGDj1qGwsSkKrKCRzjOe1MMZkHyMOvrirYtxLghSDjnjNS/ZCBK2z5gOMip5gsY99p6XdvJavJ8rDg9/rWMNP1wwGza5g+z7dnm4+bbXU+QQVG3leS3+FLlCIhIx2jOSOtXccZuKsZlpaLY2iWyHOF4OO9c3BpuqW2rSXckcVwJCRlmzt+npXXzEpIATkEHBx0pZFXAKtjanX3ppjjNxv5lGxe7kTddxom08bDmrjyhgSwJOQAMdqZDLgscjkcVBPOQ2FI680XM3qynfS6wZgsAtyijCFj0qLTrG6GpyX19IjTldoCDgVpvIX3bSvOOlKkiglVbODg46CmVzu1kiRmd9zDGccD3rH0LTpLK0uBOm2WRyxwc962I9ys2cLxwc1VnkIIBY5z2oQlJpOKJ02gYCkDHWo3Ytj5duB3piMzDB5w1PMjFhnGQMUCsMdmZCAnzE8kUqFdipl92efT8KjRn4Bwcnnio5Nok7hc4zTQWJ2TJB3YIyOT2qLgFiCd3t/OnO469cAZ45piyK7OmMtjtxzQMXkeYWGPxpHlKZ2L/AFqAy4DA43E9jSoSy5JHAOSD15oHYWZ2G09MDgdKYwJ3AnA68HrSsd3X7vTNVpX2TY6KR1681QIV0fywQoKg89jUQCfMZOucYqXOIWCNnPX2qGXjowznPNBSEfcGbGMZHavT/wBnNs+Ob8dhp78f9tIq8sdyu4Ht+deofs3k/wDCb32ev9nSH/yLFU1PhZ2YJfv4+pxvj1ivjjXzhVU6hOB9fMbmsWFTsI3AIOcVqePefGviHjJGo3B/8itWUMbkVueKpbHNV+N+pZYZ2sr5U/zpIio2q+cknj3qAKY3UHrnOKazsZSw4AyRmmZ2LhKtHkHinLOxVFBwG7Zqh56gsWzzzVaS4O5cHpxmpaGo3NgXLB3y3J6ZNbFhcebIgZ1CkYwTnPSuOiuV+csd2fT1q3bakVljHReOlRJF8h6JblREoJCju3Tj61qC2eWPaCOmAcdqwfD19HdeWjfM54I9Oa9BSwW1jVrslXf+AdQPU15uJxdPDLmqOx3YLAVcZLkpRuzlLvTnVVKBgCOWxWUYdjfPjcOox1HrXpcVhb3MbneysR8ofkE1yniDR5LFyzoVB6NjIx/WjDY+jiP4crixmWYjCP8AexscfdLslLMx2ryMVQeXaCVJKEc1JrNywklG/Kgd+K5y4vm8slTwOuK7ou5wqmzYW6DOedo6dKUzqQcHBB+9XMrqG8tk8djUkd+qbyD26GtLA6bOieTKhgx3jr6U4yDAZjjA5x3rnptRJQfOM5x+FLJfdRvGdvPPanYXs2b5l2jcXG3ioWnTeNzE96wDf46njrxUf28Ic469MGnYapM31uwy4Y7TnP1psl1kghxuY1z8t/u+7gECmNejIIYAmnYfsmb32uQAkSEZ4A9RTkmByXkxjmueN9kAZ460f2htOQwxinZD9kzo3mJLB3x3DU3zxufaD16isCXUwy9RkDn3qCTVyM7fUEUAqLN8zBGyuN33uaVpjvVt33ic57VzY1RAxJbI9KRtV3MoY8LyDRoV7BnSPc52YbgHPHao1n+bfu7jGea506rgYA4PPNRyamdyn0HSi6KVBnSfaVBds/xZqB5g+SHBBOetYY1NcEkDJHftUP8AaQBPzKPwouhqgzcE45y2R0616x+zO+7x3fc9dNkP/kWKvCjqQPUj16V7B+ypdef8RdRAYH/iVSH/AMjQ1NRrlZ1YSk1WizH8cbW8b+IQDk/2jcg57fvWrGAZXXaQSD61teOhjxv4ibn/AJCNxwB/00aseNFZmBYKNudzd6qOxwVfjfqI+WcNubBPJ9Khy2X+b1wSetWGG1GAIYDGfeoJFBUF14B7GmQitO4CEkcFfWsqSfa3yk1fmUkgYwcfnWXdR52nB6UG8EhguN54Pep1kk3KU9aijiJDHj5sfzrufhdokGp+J4ftaFoYAZypH3ivQfnisMRWjRpyqS2SOqjS9rUjTju3Y7jwDoy6Fp6a3rUe24dcwQEcRr/fYep7CoNd8Q681/NJ/ZrRxxymMySyBQSACQPXgiu51S3+02V2bmQLHIhQgjr9PevMdbXUfEfiGeOxRooztMokYlS4UKWHdc4GR618H9ZWMnKrW+V9l9x+mYHARwVOMKK/xNWv+Pmdd4H8U315fRi6t18lW2swG5fpkV6/rtm+oeH7qAWscvmJmFF4KnHB5714T4W0PXNEuEAt4JbcHO1Lgqc9zytd/rnxUk8OmOC90C8eYw7o2WZChPbce3I5rpwEV7d8treT/wCCcOdKDinrbbX+rHgusm4udWWxTPmtL5YQDBBzjms4Jo4JE8l+hyVO3Yc/Tmuh8Wa5ol54nl1Szm1WznkGZVtoYXTeR8+x2IOOSORXD+Km0yS+urvTY7uPTI4h5dpOQ0jynjGV429z37V9XTcrXasfFxw9JPl5ky5eS+HLWzeZbnUS+MqjImCfrmsSDxdpdvKQ+ltKo/vS4JPeuMuHvJz+8jlI9NpwKrm2uCeIZP8Avk1UnJ6XOqGGpR3PR18eaOfvaCh/7bGlHjnRgW/4kac9P3p4rzf7FdH/AJd5c/7pp40+8Y4FvL/3zUez9TTkpeR6N/wnWijltEQn2lNKfHmg7SB4dXOOvnn+VedjSr45ItZMfSl/sjUOv2WT8qfI/MXJR8jsZ/GenyH91paRj/fJqE+KLA9bQg+xrkW0q+BwbZx+FL/Zl6QP9Gb8qOR+Y+Wl5HZeIdTj01LJo0gma6t1uMRyZ8sNnCsf73HI7VhjxOTkNaj8GrI/s6+IwYHx9KVdMvj/AMu7ZxRyMdqXWx1Wo6pBaLalvLlE8KzAxODtBz8rDswx0rOfWrRjkI/PvWR/ZWof88Gpp0m/Az5DUvZsa9n5fgaz6rb4BAYA9s1p6PPbahFfuJY4BZ2zXBEr4MmCAEQdySfyya5Q6beqBmFhTfsF2uP3LU+UGqb6o05NdKnm1GP+umataZqaXjzLJ5UHlxNKDJIQGwPuj3PasE2N1xmI0LYXRPETU7MfLT8jYbWIO8L/APfVQyapC4+WJh+NURp14cfuzz6mj+zbz/nmTRZi/drqiZ9RQjG1gPTNe5/sa3Il+J2qKoIxo8p6/wDTaCvBzpN7jmIj8a94/Y1sLi1+J2pvMuFOjyjr386CjlaKjKnfRlrx2FHjTxCSDzfz/wDoxqwTuDxqp4A5yOK3vHqg+NtdB3Afb7g/+RGrDQZcFjlR8o967Vsj5Wr8b9WARihPGeKRo2Zvlbnv71bt8AbWAyG5/wAKkmiVZOGAGeoFFzO5ly27mVcAc5qjNbryRgkcVuujBgTzjP8AkVDHAM5IHXHI4NFylOxlRW3XgA123wzu00zxNb+e4EMo8p2I6BuM/nisIWyl8pux6Vctk2XCupA24IzWFemqsHCWzNaWIlSqKpHdanvWoeHrO5hJuXnWWEho9jkD6iuS0W1+zTSNtBXnEj8DOe9c9aeJtUSHyI7tioHy7jnb7Cq11qN1eRMz3DOBjgt3PtXyy4fm3ZySR9nHjCMKbSg233eiO31fxVZWEJSzQ3VyO4GEH+NeWeItVutYu3luny7cewHoBV6WSR/lfBJH41Ua38whgqgnP1Ne5hMuo4XWC17ny+NzfEYx/vHp26HKz2Z8wjaM55NItgwiJKk5PQCujFrkDoMk54p8dsrDaSQwycV6COD2rOcj04M2CmT1qV9KjUAmM885roobZSZDIxB25A29T6UeVsCludvVRTJdWXc5n+zRk4TIxU0mljcMRqBjrXSW8a7mLqQDnipnhik+Yp97OR6U7i9qzljpsflgBMtnmn/2ZEGO4HG3IOK6NbVUIwCB6CllhAj37AWI4+n0oTZPtGc0umI6Z2j8qe2lxjpGCfpW5HCkagtkd8dxUkkTFQ0QBOPwNUHtGc22kx/NlQ2R6U06VGcnZgDrxXQtArMgAxgdSetPFuFTONzHPToBQP2j7nOvpUW1cqCT74ptzpsauCEUsV6V0bQxqQxGcngelNniViWZAG7kCgFUZzs2mAn7iAAelEmmRhIyIwTjk46mt4QhUGRlDgbu4qMxt8oySg9O/wBKY/aMwX0yLgELnGTx0qNtMTC7VQZ46V0Bh3Pk9SeucE1DsJDHblvr0xxQP2jMVLBMgeWpA9qatghGCoHfmtcKBGuMkjv6e1MZVKksCOBgUx87Ml7FShGFxng4616r+zTbLD47vmVcD+zHH/kWKvPdokV8noeDXqf7PC7fGt7zk/2e/wD6MiqKnwM6sFN+3ivM4bxyo/4TXxAxP/MQuP8A0Y1YojbzVCt8mc4rtPGXhfX5/FmuzW+iapLDJfTyJIlpIwcGRiCCByDmskeFPEishTQNXx3zZSdfypKSsZVKc3N6MyFOZGJOSSOcU6UE425YN+HStuHwz4hUlf8AhHNWKk97OUfj0ofwr4jxxoWr/wDgHJz/AOO07oy9lP8AlZihC7KdpAPGM0+OJ4TkEf7PcVsL4W8RGMf8U/q/Qf8ALpJn+VSHwv4jCFRoWrbe3+hydf8AvmlzIXsp9mZAbIUlQCTnPqakCbSpzxjuK018LeIdvOg6r0/59JP8KsReFteBBbQdU2/9ecmf5UroPZT/AJWZMg2yEHI44I70ryAuPkAIA4rVk8M+IGZT/YWqkn/p0k/wofwx4hMg/wCJHqgGMZFpJ/hU6B7KfZlFAzEhAo285PFJbM4XHUAk9PWtMeGfELPk6Jqaj0+ySf4U/wD4RfxCBxo+pgA44tXyf0p6B7Kf8rM07GYLkbPQDFI6L5q87dvTnrWvH4Z1xhn+xNTBz0NrJ/8AE0h8La4G40bVM5z/AMej/wCFO6F7Kp2ZkxJ+98xlyo6DPGaXb5mS+cjqTWlD4a8QiQB9E1PywcAC0k4/Spz4c11d23RdT9B/ojn+lF0T7Kf8r+4xgwU5U/KRu5HSpomAVNqqMc7hV4eGNdzn+xNT4GAPssmM569KkPhjXOG/sbUQR/CLSQ/0ouh+yn/K/uMguVY45PXNOVWbBMhAA6Y61pP4Y1/aGj0bUx2x9kkyf0p8PhvX+S2i6kDjGPssn+FO6F7Kf8r+4wjvUOc5IIGKm3BCxyTjGB0xWl/wjeu7z/xI9VIPBzaSf4Ui+Ftc5J0XVOR/z6yZ/lTTQeyn/K/uMeef93wQGJ7ChDJIgGcJzgitlvC+uNGwXQdTBAAXNtJx+lMj8Ma+EAOian15H2SQflxRdD9lP+VmQ6t5cYHJA547Uil2DFsdcc962U8LeICcjR9TQDj/AI9JOf0pF8MeIGZt+iantB4/0WT/AOJougVKfZ/cYo/hY7QQOFphH7obAcDsOlbf/CMeIADu0PVCx4GLR+P0qF/C2vrjboOqMp6/6JJx+lF0V7KfZmGzFZAZASQO54FQSEL9z5GJ6ZroJfCviCQZGg6ore9nJ/hVM+EfEW9s6Bq5zn/lzk/wp3Q1Sn2ZkyZ8kMATz1/Go2IySgyAPXvWyPCXiPbt/sHWMdCPscmMflTv+ES8Qsu3+wNYB6/8eUmP/QaLofsp/wArMZVXySkh5J3Yr039nvnxtekY/wCQfJ0/66x1wz+EfEYVdvh/V847WUmR/wCO16L8BdD1bS/Fl1JqWk39nCbF0ElxbvGCxkjOMkDJ4P5VNRrlZ1YOnJV4trqYx+OvicDP2HReP+mUv/xypo/jj4kYE/YdH/CGTr/38ryCNwGO0HOe9WImKxkgnHHaocI9hPGV/wCZnryfGzxCwx9i0nd0H7qTGf8Av5SJ8a/EjA5stIBHX91J/wDHK8sjO2VXXG3OcZ7VLE3mlxls9eaXIuxH13Efzs9Vj+M/iFosmy0rfntFJjH/AH8qaL4x6877TZ6WM9P3cn/xdeUwB9pLEAGrMUYWMMGLNn5QOMUuWIvr2I/nZ6nH8XtbKgy22loDkZ8qQ5P/AH3T0+LWvFgptNLByf8AlnJg/wDj9eYOGIjwMkjBHpzVhNwIzzjjA6UcsSfr2I/nZ6TD8WNedwpstNz3Ijk/+LqZvinrobP2XTdhGQTFJn/0OvNw5XcVOd3XacU873jBZWAXvRyxF9exH87PQn+KmvqxAtNMPOAdj/r89KPirrh62umAHpmN+v8A33XAy4DndlQ3OAKVFHyhiGOTgU+WPYPr2I/nZ6CvxR11tu2000+v7t+B/wB91KPihq+0loNNBH+w/wD8XXnhyzcYGBXMGKbXdWvIpriSO3tSFCRtgk+po5I9io4zES1c2kj2U/FTWCPktdPJ/wCub/8AxdPT4oa2VJNpp2B/0zf/AOLrx3Smn0/XJNOa4eaJo/MQucsPxrQ1KylvrlVaZ1ssEsFfDM3v7U+SPYHjMQnZ1Gemt8U9cUHNrpmcZGEfn/x+g/FXWRErNa6dk/8ATJ//AIuvF5Fi0+8s0s7qVrkyBXiL7wVPc+ldFd3dtCi+dIiluFVmxk0ckewSxmJVrTep6OPilrrICtpppbrgRv0/77oh+KWtyLzBpatjgeXIc/8Aj9eReJNSljtrRbSYQQPJh5ozkKPrWTq90unpHc2WptLcPINybshvU47UuWPYuGJxMre+9T3BPiprrthbfS+uCDFJn/0Onf8AC0deABNtph4yQsUhPX/fry3UEuL7RybR/LuJgrq27BGawdbtbzR7WK4TUrt7lsJgt8rcU+RdhQxeInp7TU9vk+KuuYHlWumk4zzFJ/8AF1Cnxa1xwxW10zA7+VJ/8XXnWlRTwaenmyOzn5mYnJyecU/cEkZjgDP3c8ZxRyR7Gbx2ITtzs9BX4ta8dxNnpmB6RSf/ABdL/wALb1vp9k03p/zykwD/AN9154rLksWbJxj0qK5ZiXC7weOT060ckewfX8R/Oz0cfFnXy/y2mlsuO0cn/wAXSN8WtfDsv2XSsjoPKkz/AOh1wUbhG2+XtcEHJHNUpXzc5cFl6HHoPSnyR7B9exH87PSP+FueIAcGy0zI6/upOfTHz0h+LuvgA/ZNLORkDypP/i68+iYMMngEnAwck1GJAcABgOeo6mn7OPYPr+I/nZ6Efi/4g25Flph5xxFJ1/77pq/GDxCZMfZNJC4zkxyf/F15zMzglFXHIzkjrTC2IjtRtxPzH39qPZx7DWOxH87PSLj4weIY0yLTSSfTypP/AI5TT8ZteBwbPSgcc/u5P/i681DschVwjDBFQOQjdsjIOfWj2cew1jcR/OzAGcoT6cj1qdAxU4PBwCPSmAEydRxjn0FSwxna2exBFNmbehbiXcVBxgcfhmpootjuCuc9M1WCsowCc/3qc2/O4NyR2qTMtqWbdt45xzVhGKInykEHr61BENqrj7xGcmnlyi7lHIFITLikOhIIBzg5ParanyyFX5ieMjpWdEAyHBIJX86sRvxwOhA+lIksts/d44bPK1PICNh34I7Z7VW8wOVJHzH5eKsxHehZiufuHjvjNJgShQ+4qSeBkn0p7q3mB0Hzclc0QfPARu5I70LAcjk8dDmlzBYh/fNGcr8p4KnvWDIdQ0XUbqeGza6tbnD/ALv7yt/hXSyhklKljtUYBI60kR4YMeApxnrmquOMuXzOd0+G9udVl1S+g+zhY9kSE8hT61V8W3GoRwLDpySeXJzIyDnHcA9q6mTPk5Yq+V5GckVGAvlM6kBdoC/jVXGqlpczRzeiS2kHlJb2M4aT7zMuTn3NdEYIp40W4hikfopYZxUeBFIoAAPHIqxK6gDavIP50XJlK7uihfzRWli6LZG4hbjaq5CkHrXO6hGdQtktrbR2gbeD5zKAAK62OQPFkJjnnnimqHOdwAXOOelBUKnLqtxI8pbxwhcsgC5xjPGKwNat3vPEWmxsrmGNdx4OM10ZdTsO3I74ply7KxxgLjgnvTJhNxdxB80jiVu+F4priNQ/qQCCBUSSlpRnBB4OKeJECElTuPGcUiRofB2nIUHINJE3mvneqpggbqa74cZU47470kpygcMB6DH8qYEr5kBy4Oc4welQMGYrtBDNwPeno2Yjuzj2IFRyNGSfTOOTTAUOysPL+U78cDjinOQXJYYwOgpjyYk2Z+VTnPrURO/cC3HY46n0pgOkaIhygOCAOvSm+bwTySOG96ViPmUAZ7j396gkJgTOcKTn1pDQjNjdv6DuKrs54CgE9+KsrI/n7+SuPmx9KrO24llxjJFNFIzoQNvzHrU9vHubBJAJqnHMolUMvPp61et98nzDgAnFTc0aZNCqsHLE8ZwR3NKWIGVU5Byc/wAqjM6wfdbnOTjselQxzBpTycYzg0ibM0QS27KgZGdppEYb0yMZP3TUug2a6olxI19Ba+QhdBMdvmYzwPyrJa/KRhnXDk8g9qlSTdkV7N2ubcSL8pDDLcYzUsGFfcRlc5ArN8PRXWtahDaWnyux3bz0Ve5NdvqfhlLe2McUzlymN6nLMfp0FedjM0oYSShUerPVy/IsVmCcqKVl3Oda5KopXaPm4GOgq0lwrj5V3Y56eteZXmvXFtdy2zuXWNyob1wa2NK1kMwJYnjsc13Rlzq6PPqYWdJtS6Ho1ttIGRgMvrwDV6Bdy8oGB6eo965jR9QEsaj5cEdz0rsLABo1KkFSOOKzk7GSjdlWW2dndjhRjis6WJt4DjkjAI7fWuvltnj3F0KMo+5ty34CsrW7MLvKkbSOo704VL6BOk1qYEy7I8RqOeGBNUnyigLIpIHP51YvZjHGflTqOCeaw5r3bOx7+lapmfKXnnBkJP3zjjOMU4uvylyME9jWFcX/AMwPG4nqaT7aQ6lXxjnFUPkZvI3BQbBwSGNLHMZFOeo6fWsdL9d+1AMnOTnoagj1Asjt0yaA5Gb5uWRQFcNnn6UySZm6sMe/JFYEuoMGL8jnn8qhOoZwpfvzjoKY1TZ0KzKsgBcKOoPoabJMxQDcMg9c9qxHvo2VsNntkHrVZr0lW5/Oiw1TZtreMX4C9eCefxpWvWdgAqgZxjHArnBflQCevoT2o+2nYTnkZ6GnYfs2dL5pjUA9+pBpsjD5fMODuPPrWDBqKGJlfGRg8HrSNqigkng7vyph7Jm9LMWxls4wODTTOAp8s4I4JJ5rnm1XfjkYz6+9K2qKFOWByMZ7gmmHspHQifcpY5yRk5FV5J9/ytg7vrWEuorkBm4A5ANQPqShWZSSccHPSjQpUWdGJgvlbMAZO7JzUM05JAiC47/WuaN+qyCRGIzgMPf1p7XwV2CsdvqKaK9izT0vStQ1zVxa2MYDhdzOxwqKO5r0/wDsHw9p3g2/trnUIRq+0FJpHxtOf4R6V51a3MtvdCe1cxOv8SnFF8Ev5lnuFMsqjAPTNeRjcNiq1ReyqcsfxPYwGLwFGm1iaTlLptY565kuhfvCZIpVRseZEdyt+Pete037ef4R1PpVk2MQyAmOMjHanCPasmPlA4PNelFNJJnk1akZv3VZEkDkxOFxg/yqndxSMnRcZx9Ktg7FRmBKt74zVqHy55tiKSxI+UDPNJuxkrp6I7f4H6dprTzi/ukgupiI1UsAxXrwT712l5ZeR4gktGk8yJCVD9OMfzrxiZhp5JdmSQMeCMFcdPpUtz4v1SazaA3kmwoRnPOPr1r5zMcmeLqe1hLV9+3kfV5RxD9SpulUg2raW7+Z594o05bbWr2OCTzYlncI394ZPNR6QHQgE/lV+7Tzs8FmznI9K7bwL4TVYU1q9QPbiQiG3I5kYdz6AH869bEYiGCo89R7ficGGo1MwreyprV/gZsyz6TYQTXsTwpMN0ZbuP6V3GhSlPCkWt3N0EhmnNtbwBGZ5WAydoFZN/ZzaneyC+jaSJjgqecfT0rr9Js5tF8IWtnZyJPf2V5JNa2zfelhlTa6j0bnIPtXjQzhVocsvdke9iuFVhKkZX5ovfyf+RY0rxHBfTrGYL0ShRktCc12+o+FzfaUZfMKNszHHs5Y44A968/8O6lqGl3Bml8PXwXI3stv5jj9a7bUNdsdcNjcGe5svszB1MtrMvIPoBg1NDEYqrO/LZeqt+pljcuwOGXJF835/doeL+KUudMvGgureSGQDcElG0getc/HE106yNd21uxGVErFSR0yOORmvY/jQuj+KreG+0/VLOG6tD5BN45gWcEBsKSOcZ59OleReM0ii8OWlzaatp1zqMO21TTrAvJ8n9/cQBkk5I969+NW+x4H1BQk03oQ3GmF2Df2npWepHn/AP1qxr+70+yujDdahESpALQfOOff2rlfEN9Lpd69kLpZ7mMBZih+WN+6g98dM1y8kzOxYsTmrc5PZm9PAQ3Z60uo+Fx11m4yepEJHNI1/wCGRgJq1yVJ5/d15FvPYmje2OprO0v5jp+qUv5T1w3/AIbZ8f2lOB1zsp0dx4XcsH1uWMcf8sSc15CWb3pNzD1p2n/MH1Sl/KesXl54ejJEGrPKv/XMis5rzTZOl7x6mvN2ZvehWODndR7/APMNYSkuh6QBBJbzz28ryxWyh5WQErGucZJ7c8VkHWrDcR9oP61zNpql5aWN3ZwTyJbXezz4weJNpyufoapk55Oc0e93GsLS/lO9t7qGe2luIXZoUIV5MHauemT2qJ7uJgdlwnXn5q5G21C6tbO6tYJpEt7oKJ4weJApyufoeagViR3yafv9w+rUl9k61rlckidM/WkSdWODMgz0+auTDsucHqKSGeSKVJI2KujBlI7Ecg07y7j+r0+x1+oTLp1y9veMYbhMbo5AQwyO47cVWXULZyFFwp3duawtX1S71bUbm+1CUzXdw5klkIGWY9TVHj3o5pdxLCw7HYTOEJSSUKw6hjgj8KgabPSdOP8Aarn76/uL+6kubyR5rh8bnY8nAwP0AqBWwe9HNLuNYaHY9ihdlJ3k+hNXY3HykHGMDNVwqZO5iRjcBjv6Va0WC1utdsbfUJGt7KaURySqM7AT15rpm7Js+ajHndkXItr7jnJwRzVK9IiBOR05Fe32nwg0dnWQandSwtyDEVwR9a85+Mvhmw8LWdsNNlmaeWQgrI4Py464ry6Wa0qtRU4p3Z6c8lrU4Oo5Ky8zza41Is5Qbh2r3j4LaBaW3h641rVYi93c/Lbbv4VH8Q9ye/tXz7bWkrskrjkMCQelfSPhvV7TX7GE2UggeNFV7U8eXxjAHpXJn9atToJU1o92enkGGw9WvapKzWxnfE/w7Yz6FqGt3pMLKPkZOGdz0HvXgWmzyE7GBwOOK9h+O2q3DS6focTfu4YxPKo7u3QH6D+deXWWnMApbI5rTIqM6eGTm3r+Bln2Jp1MQ1FLTTTqX7W1DDJBBzjgV6P4d8T/ANnaNbafd6Wt1FbsSr+ZtODzgjv161x1ra4h4bDZxyeprShTMWD8x6Yr0cVhaWKhyVVdHhYfH1sJU9pRlZnspHh+Sxgv7eW18th86yNtde54ryvxdrM2t3sBtofsq2rkwurEO3uT26Uke5oY15ypJPuKlWMMzL5ed33c968/C5NQw1T2kdX08j0MZxFisXS9lN6dfMvWniDWFQefqV0+AP8AlqTx6Gn3+v3tyxT7XMIwM53HJNZinYWUx4HSnBUlwACeMjHpXqKlFdDxXXm92UL21N1J5lwHbcSck5z/APXqgdLXeP3Yx97Oa6NU2yBWQhApOM96EAVwNqgMpA5zWqVjL2jPO5/B9k0jMIo+DycU4eDbIKCY0Axz8td7NBjCssee9Olt2SR4zg4XAwQRVJI1+t1f5jz1vCdkn/LFD24WgeF7MKSIBwcfdru3gjO0A5bqxxnmpfscRG2JuepH4UWD61U7nBx+GLVsloVUf7tH/CNW5AYRIB74rtGs8ElSxBwMGnraK42EjJxnaM4xRYX1ip3OFfwva7seUh+gFJ/wilpgHyR154/+tXZm1Q3DbOi43D0qXyBg4wSB2707D+s1O5wf/CKWrZKwDAIHNI/hKzH3Y1OTxmu4MA7HGOgA70LasxUkYPqe3vRYf1mp/McMvhK1bd+7TI445qRfClqqM3lKSOfu125tQc+XwC3THamrboItmXwec9qdkH1qp/McO/hayZW/c5xjnGBUH/CIWbiT90VCgY967tIjuYHBUH+E5wfWlNu0e51IcMBgUcq7DWKqr7R5+PCFmVyEOfrTH8I2wDnymwOmK7x4wEBIwOuf6VEUAI+6ucZPXA6Ucq7FLF1f5jgx4WtQOYzz04pp8L2ufunbj0HWu4MKl+vygYz6Y71C6JltxXk5xmhRj2KWKq9zPSPMinHGM5NTww7jsYnaSeo4prIsccThvmcZ2DsM1PbwHEh8zZnAx1oaMXI6rwz4w1nw1bC30+4U27ZYRSLuVD7Vh+Kry68R6g17qMnmTgAcLgKBnAxVRsq2Q/yqcZ9KXJDP0z169RWEcPTjNzS1NHiasoqDk7FOK1UQltvBPT0rTtGe1bzIWZG/vA4IqIFXVWwyrnBB71a2RgKYjntyOhrRxurMy52iLUbl7+7e4vJGlnfG535zjjrVcLjHy52npirKLknf29qeuVZm6qD0xQo2VkJybepJEibAG4IOc/WrAUsuBg7Rznv9KrRsuSoJUnmrUXBb5iB0+lOxBKqlfnyQegNSodoHzsH4wR2ph43LvDLjJ74pVYCJgDkeuO9KwiVSXzudz61JE+2dMLlVUj0zVdXCoVAwxx09Ksw4O4zht5XCBem73/CnYTZcj2ld20HA2gE+1NdV2jOMnoPQ1GhLnkc44FSsrFAA2FGCQeM0WJIZydq5xvIGQB1FSPs2qilScct6moDK0LqNu7IAHHH1qcElI2yDkcdqaEMMZQhuDg88AdaWMJvPmZUbccdzRMOTt4zjgnO6ozv3t5Sln/iGaYx0r+Wq4wOM9DyaYrkBhEOSu0D1pZC5ToWYDoOeaihfeT8uxjzgUWAJ0cNs2ruJ+YqKZGp+8m3BbaSe1TXHGG+6RycH2quwfaAjcEhsY5ppATBYy5Vxk9zjH1qKO4UHJQ7WyMCm+UCDulGT90fzNRRoEuWCnIHGex96QyzvY+YCvRcioopFKqpUAZ4yKQuwBAO7Ixg9c0FwhUyRCNgcimA9CE3FMiQ9MdqdIDu5PQYIPQZ60vJZVOcnqw7CoZchywbOO+M96aAgnI8twQoYdyaguPmK7XBwvOasuFdCocHuB061QnZgePXmgpCBtzElVX1I71CAGXOU4OPWpEZg7FQCpGRk00E72IUEegOKEWZG8Z8wHpwM1oQg+XuJHzrk+9Z7KRwcHaPSrcAyFLYIwMe1DKaJogdoGFJzwKGJ3SGQYdu/rT1yjB+MdsdakUbmJbqTmkRchRQCq/wjknPAq3G6tj5fxFQLGI9xyWLetPkby5sEA46+9ICTaE/e/wARBUD0ob5SWPIYdQe9JGnmsxJxzxgdDTiNuMYO4d6BCxuNzKE3EjqR0qcAopCjIP8AOo4l8sgkA7hx7VOxKqrHBGeRRYVx2CVyq42jHXqKW3MRYrITyOi1H5QkUHLehye1EYVHBI654zxSETAncNrEjJxntVpZGEbBXYS5GBiqk0ZijRw33gGxUhyVUbiCRkkd6Yi4u59zFhnGRgVJMCIk+diowcAVFPAIrGCVHcecCGA9sc/rUTnEaAk555oEWXMaBT1cn7vtUinCDHyhTzkdKqBAu2TJ3MePaptpeMs7Z5AI9aBDSrBshuD3x0qfDPG2ABjkk/zqIyb02r3JAyOlMDEg5OP72O9A0RO6Akx7kbPX1FKM+aMZwecjt9aSVw8CnBOCVOTUSFwPvfKR0oAfdnvg7sdarlnQKVPJIyasSFlk2KQMjd09qrMMAgknaPzoGPIcRs24YzgHrQS5AlYLIgbBIHf0FNicsygE8ZIB6ZqIvt3Zzwex656UDsTuVLBtxDcjk8CmZKnBbdt/OmHdkgnPGeTT4sFWLZ3DAyPSgCTzc/KcNnnOecUJKrvgcKMEdO3rUEhBG4DBUY+tV5M7DIQDyoxVBYfLtLOdi9zhqgu3TJEagJ2HrUqLExZpEJJXAwe/rVebY7FWB69u9BSGSbGbcSNoH8I9uKYMyE7AzEelR9QVHAwT9B6Utu7RruQ7SeOB/n1oLP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Half peanut grasped and fragmented by an optical forceps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_16_5391=[""].join("\n");
var outline_f5_16_5391=null;
